

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
9 September 2011 (09.09.2011)

(10) International Publication Number  
**WO 2011/107480 A1**

(51) International Patent Classification:  
*A61K 39/395* (2006.01)    *C07K 16/18* (2006.01)  
*A61P 25/28* (2006.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:  
PCT/EP2011/053038

(22) International Filing Date:  
1 March 2011 (01.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/309,957                    3 March 2010 (03.03.2010)                    US

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BHINDER, Tejinder, Kaur** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **FORD, Susannah, Karen** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **GERMASCHEWSKI, Volker** [DE/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **LEWIS, Alan, Peter** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **PEPYS, Mark, Brian** [GB/GB]; Pentraxin Therapeutics Ltd, UCL Business PLC, Network Building, 97 Tottenham Court Road, London W1T 4TP (GB).

(74) Agent: **REDDISH, Anna**; GlaxoSmithKline, Global Patents (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))



**WO 2011/107480 A1**

(54) Title: ANTIGEN BINDING PROTEINS SPECIFIC FOR SERUM AMYLOID P COMPONENT

(57) Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.

**FIELD OF INVENTION**

The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins,

5 pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.

**10 BACKGROUND OF THE INVENTION**

Amyloidosis is a serious and usually fatal disease caused by the extracellular accumulation in the tissues of abnormal insoluble protein fibres known as amyloid fibrils. These are derived from more than 20 different proteins in different forms of the disease but all amyloid fibrils

15 share a common cross- $\beta$  core structure and all are derived by misfolding of normally soluble precursor proteins (Pepys, M.B. (2006) *Annu. Rev. Med.*, 57: 223-241). A normal non-fibrillar plasma protein, serum amyloid P component (SAP), is also always present in amyloid deposits by virtue of its avid specific calcium dependent binding to all types of amyloid fibrils (Pepys et al. (1979) *Clin. Exp. Immunol.*, 38: 284-293; Pepys et al. (1997) *Amyloid: Int. J. Exp. Clin. Invest.*, 4: 274-295).

20

Human SAP is a constitutive protein in the plasma, at a concentration of around 20-40 mg/l (Nelson et al. (1991) *Clin. Chim. Acta*, 200:191-200) and with a total of about 50-100 mg of SAP in the combined plasma and extravascular compartments both of normal individuals

25 and patients with diseases other than amyloidosis (Hawkins et al. (1990) *J. Clin. Invest.*, 86: 1862-1869).

In patients with amyloidosis, SAP is also specifically concentrated in the amyloid deposits and in an individual with extensive systemic amyloidosis there may be as much as 20,000 mg of SAP in the amyloid (Pepys et al. (1994) *PNAS*, 91: 5602-5606),

reversibly bound to the fibrils and in equilibrium with the fluid phase SAP pool. The normal physiological function of circulating SAP is poorly understood, but animal experiments and

30 *in vitro* studies suggest a role in host defence (Noursadeghi et al. (2000) *PNAS*, 97: 14584-14589)). SAP is also a normal tissue matrix constituent associated with elastic fibres and the glomerular basement membrane although its function there is not known.

In amyloidosis, the extracellular amyloid deposits cause disease by progressive accumulation until they damage the structure and thus the function of whatever tissue they occupy (Pepys, M.B. (2006) *Annu. Rev. Med.*, 57: 223-241). There is very rarely any 5 inflammatory or 'foreign body' response to amyloid deposition, either seen locally in the tissues or suggested by systemic markers of inflammation. Systemic amyloidosis can involve any organ, is usually fatal and causes ~1 per thousand deaths in developed countries. Localised amyloid, confined to a single anatomical location or tissue type, can also be very 10 serious, for example cerebral amyloid angiopathy is an important cause of haemorrhagic stroke. The clinical presentations of amyloidosis are extremely diverse and the diagnosis is rarely made before significant organ damage is present. Over 20 different amyloid fibril proteins are responsible for different forms of amyloidosis, but treatments that substantially 15 reduce the abundance of the respective amyloid fibril precursor protein do halt amyloid accumulation and the deposits may regress. Unfortunately effective measures are not always available and, when they do exist, are toxic or hazardous and slow to act (Pepys, M.B (2006) *Annu. Rev. Med.*, 57: 223-241). There is therefore a major unmet medical need for 20 therapy which safely promotes the clearance of established amyloid deposits. Furthermore, there are other conditions in which amyloid deposits are always present, most importantly Alzheimer's disease (AD) and type 2 diabetes mellitus, in which the contribution of amyloid deposition to the pathogenesis of disease, specifically loss of cognitive and pancreatic islet function, respectively, is not known (Pepys, M.B. (2006) *Annu. Rev. Med.*, 57: 223-241). 25 However, amyloid deposits anywhere else in the body are demonstrably pathogenic and it is likely that the cerebral deposits of AD and the islet amyloid deposits of type 2 diabetes are also harmful. Since treatment which clears amyloid deposits in systemic amyloidosis will certainly be therapeutic (Pepys, M.B. (2006) *Annu. Rev. Med.*, 57: 223-241), removal of the amyloid deposits in AD and type 2 diabetes should also be clinically beneficial.

Binding of SAP stabilises amyloid fibrils, protects them from proteolysis *in vitro* (Tennent et al., (1995) *PNAS*, 92: 4299-4303), can enhance amyloid fibrillogenesis *in vitro* (Myers et al., 30 (2006), *Biochemistry*, 45: 2311-2321) and contributes to pathogenesis of systemic amyloidosis *in vivo* (Botto et al., (1997) *Nature Med.*, 3: 855-859). Coupled with its universal

presence in all amyloid deposits, these properties of SAP make it an attractive therapeutic target.

European patent application EP 0915088 discloses D-proline derivative compounds that are 5 competitive inhibitors of binding of SAP to amyloid fibrils, as well as methods for their manufacture. A preferred compound disclosed in EP 0915088 is (R)-1-[6-[(R)-2-Carboxy-pyrrolidin-1-yl]-6-oxo oxohexanoyl] pyrrolidine-2-carboxylic acid (CPHPC).

International patent application WO 03/051836 discloses prodrugs for D-proline derivative 10 compounds.

International patent application WO 2004/099173 discloses glycerol cyclic pyruvate derivatives that are competitive inhibitors of binding of SAP to amyloid fibrils.

15 International patent application WO 04/059318 describes methods which are asserted to enhance fibrocyte formation which comprise the provision of compositions which bind SAP. Such compositions include anti-SAP antibodies and CPHPC. WO 04/059318 does not disclose the treatment of disease associated with amyloid deposition. Furthermore, there is compelling clinical and *in vivo* evidence that neither SAP nor its depletion have any effect on 20 fibrosis in humans (Tennent et al., (2007) *Arthritis Rheum.*, 56: 2013-2017; Pepys, M.B., Tennent, G.A. and Denton, C.P. (2007) *Reply to Letter from Pilling, D., Buckley, C.D., Salmon, M. and Gomer, R.G., Serum amyloid P and fibrosis in systemic sclerosis: comment on the article by Tennent et al.* *Arthritis Rheum.*, 56: 4229-4230).

25 The bis-D-proline compound, CPHPC, disclosed in the patents listed above, is bound with high affinity by human SAP and was intended as a drug to remove SAP from amyloid deposits *in vivo* and thereby facilitate their clearance. Binding of CPHPC by SAP triggers rapid clearance of the complex by the liver, depletes almost all circulating SAP for as long as the drug is administered, and removes much but not all amyloid bound SAP (Pepys et al., 30 (2002) *Nature*, 417: 254-259). In initial clinical studies (Gillmore et al., (2010) *Brit. J. Haematol.*, doi:10.1111/j.1365-2141.2009.08036.x), administration of CPHPC seemed to

arrest amyloid accumulation but it did not produce amyloid regression and since CPHPC does not completely remove all SAP from amyloid deposits, another approach is needed.

International patent application WO 2009/000926 discloses the use of compounds which 5 deplete SAP from the circulation, such as D-proline derivatives, in particular CPHPC, in combination with an antibody specific for SAP for the treatment or prophylaxis of amyloidosis.

Related International patent application PCT/EP2008/011135 concerns various mouse 10 monoclonal antibodies which may be used in combination with compounds which deplete SAP from the circulation, such as D-proline derivatives, in particular CPHPC, for the treatment or prophylaxis of amyloidosis.

Accordingly, there is a need in the art for antibodies, particularly humanised or human 15 antibodies, which specifically target SAP and provide improved therapeutic efficacy in patients, particularly human patients, with diseases associated with amyloid deposition in order to preserve organ function and prolong life.

## **SUMMARY OF THE INVENTION**

20 The present invention provides, in a first aspect, an antigen binding protein which specifically binds to SAP and competes for binding to SAP with a reference antibody which comprises a heavy chain variable region sequence of SEQ ID NO:7, and a light chain variable region sequence of SEQ ID NO:9.

25 In a second aspect of the invention, there is provided an antigen binding protein which binds to SAP and comprises CDRH3 set forth in SEQ ID NO: 3 or a functional variant of CDRH3.

30 In a third aspect of the invention, there is provided an antigen binding protein which specifically binds to SAP, wherein the antigen binding protein is a chimeric or a humanised antibody comprising the corresponding CDRH3 of the variable domain sequence of SEQ ID NO:7, or a functional variant of CDRH3.

In a fourth aspect of the invention, there is provided an antigen binding protein which specifically binds to SAP, and comprises a binding unit H3 comprising Kabat residues 95-101 of SEQ ID NO:7, or a functional variant of binding unit H3.

5

In a fifth aspect of the invention, there is provided an antigen binding protein which specifically binds to SAP and comprises a heavy chain variable region selected from SEQ ID NO:27-31; and/or a light chain variable region selected from SEQ ID NO:34-36; or a variant heavy chain variable region or light chain variable region with 75% or greater sequence identity.

10

In a sixth aspect of the invention, there is provided an antigen binding protein which specifically binds to SAP and comprises a heavy chain of SEQ ID NO:62; and/or a light chain of SEQ ID NO:64; or a variant heavy chain or light chain with 75% or greater sequence identity.

15

The present invention also provides a nucleic acid molecule encoding an antigen binding protein of the invention, expression vectors comprising the same, and host cells capable of producing antigen binding proteins of the invention.

20

In a further aspect of the invention a pharmaceutical composition comprising an antigen binding protein as defined herein is provided. The present invention also provides methods of preventing and/or treating a subject susceptible to or afflicted with a disease associated with amyloid deposition, which method comprises the step of administering a prophylactically or therapeutically effective amount of an antigen binding protein to said subject. The use of an antigen binding protein as defined herein for preventing and/or treating a subject susceptible to or afflicted with a disease associated with amyloid deposition is provided. The use of an antigen binding protein as defined herein for the manufacture of a medicament for preventing and/or treating a subject susceptible to or afflicted with a disease associated with amyloid deposition is also provided.

**BRIEF DESCRIPTION OF THE FIGURES**

Figure 1 shows the binding curves for murine antibodies SAP-E and SAP-K at a 1 µg/mL coating concentration of human SAP.

5

Figure 2 shows the binding curves for murine antibodies SAP-E and SAP-K at a 5 µg/mL coating concentration of human SAP.

Figure 3 shows the binding curves for chimeric antibodies cSAP-E and cSAP-K. The profile of 10 the curves for the chimeric antibodies is the same as that of the equivalent hybridomas.

Figure 4 shows the binding curves for SAP-K HOLO, SAP-K H1L0, SAP-K H2L0 and SAP-K H3L0 compared to the SAP-K chimera and the SAP-E H1L1 compared to the SAP-E chimera. An irrelevant human IgG1 kappa antibody was also tested as a negative control.

15

Figure 5 shows purified SAP-K and SAP-E murine monoclonal antibodies in a competition ELISA with the SAP-E chimera.

Figure 6 shows purified SAP-K and SAP-E murine monoclonal antibodies in a competition 20 ELISA with the SAP-K chimera.

Figure 7 shows an immunoradiometric assay for binding of monoclonal mouse antibodies SAP-E and SAP-K to human SAP captured by immobilised sheep polyclonal anti-human SAP antibody.

25

Figure 8 shows epitope mapping for monoclonal anti-human SAP antibody SAP-E.

Figure 9 shows the location of the epitopes on human SAP recognised by SAP-K (A, highlighted in black) and SAP-E (B, shown in white).

30

Figure 10 shows C3 activation by humanised monoclonal anti-human SAP antibodies in whole human serum.

Figure 11 shows C3 activation by low dose humanised monoclonal anti-human SAP antibodies in whole human serum.

5 Figure 12 shows C3 activation by humanised monoclonal anti-human SAP antibodies in whole mouse serum supplemented with pure human SAP.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention provides an antigen binding protein which binds to serum amyloid P component (SAP), for example human SAP, as its specific antigen (i.e. a SAP binding protein). In therapeutic applications of the invention, the antigen binding protein activates the body's potent mechanisms for clearance of abnormal debris from tissues. The antigen binding protein may be an antibody, for example a monoclonal antibody. An antigen binding protein of the invention is not a murine antibody. In an embodiment, an antigen binding protein of the invention is not a murine antigen binding protein. In particular, an antigen binding protein of the invention is a chimeric, humanised or human antigen binding protein.

“Serum amyloid P component” or “SAP” refers to a homopentameric plasma glycoprotein of the pentraxin family. Each molecule is composed of 5 identical protomers, each with a flattened β-jelly roll fold and single alpha helix, non-covalently associated in a disc-like ring with cyclic pentameric symmetry (Hutchinson et al., (2000) Mol. Med., 6: 482-493); Pepys et al., (2002) Nature, 417: 254-259). The term “SAP” as used herein also includes the individual subunit encoded by the human gene APCS (chromosome: 1; Location: 1q21-q23) or homologous genes in other organisms, for example the human SAP polypeptide subunit having the sequence as set forth in SEQ ID NO:43 as well as the native pentameric form of SAP, and any fragments and variants of SAP that retain the biological activity of binding to amyloid fibrils *in vivo*.

The SAP binding protein of the invention can bind to any one or any combination of the above described different forms of SAP. In a particular embodiment, the antigen binding protein of the invention binds human SAP. The SAP binding protein of the invention can bind to SAP when the SAP is bound to amyloid fibrils of any type and in any extracellular



$-C(R^2)=CH-$ ;  $-CH_2CH(OH)-$ ; or thiazol-2,5-diyl;  $-O-$ ;  
 Y is  $-S-S-$ ;  $-(CH_2)n-$ ;  $-O-$ ;  $-NH-$ ;  $-N(R^2)-$ ;  $-CH=CH-$ ;  $-NHC(O)NH-$ ;  
 $N(R^2)C(O)N(R^2)-$ ;  $-N[CH_2C_6H_3(OCH_3)_2]-$ ;  $-N(CH_2C_6H_5)-$ ;  
 $-N(CH_2C_6H_5)C(O)N(CH_2C_6H_5)-$ ;  $-N(alkoxyalkyl)-$ ;  
 5  $N(cycloalkyl-methyl)-$ ; 2,6-pyridyl; 2,5-furanyl; 2,5-thienyl; 1,2-cyclohexyl; 1,3-cyclohexyl; 1,4-cyclohexyl; 1,2-naphthyl; 1,4-naphthyl; 1,5-naphthyl; 1,6-naphthyl; or 1,2-phenylene, 1,3-phenylene and 1,4-phenylene, wherein the phenylene groups are optionally substituted by 1-4 substituents, selected  
 10 from halogen, lower alkyl, lower alkoxy, hydroxyl, carboxy,  $-COO$ -lower alkyl, nitrilo, 5-tetrazol, (2-carboxylic acid pyrrolidin-1-yl)-2-oxo-ethoxy, N-hydroxycarbamimidyl, 5-oxo[1,2,4]oxadiazolyl, 2-oxo [1,2,3,5] oxathiadiazolyl, 5-thioxo[1,2,4]oxadiazolyl and 5-tert-butylsulfanyl-  
 15 [1,2,4]oxadiazolyl;  
 X' is  $-(CH_2)n-$ ;  $-(CH_2)_nCH(R_2)-$ ;  $-(CH_2)_nOCH_2-$ ;  $-NHCH_2-$ ;  
 $-CH=C(R^2)-$ ;  $CH(OH)CH_2$ ; or thiazol-2,5-diyl;  $-O-$ ;  
 R<sup>2</sup> is lower alkyl, lower alkoxy or benzyl,  
 n is 0-3 and wherein  
 20 alkyl or lower alkyl is C<sub>1-6</sub> alkyl; alkoxy or lower alkoxy is C<sub>1-6</sub> alkoxy; cycloalkyl is C<sub>3-6</sub> cycloalkyl; halogen is F, Cl or Br; and the location where the dotted line appears in the formula is either a single or double bond;

or a pharmaceutically acceptable salt or mono- or diester thereof.

25 D-prolines of formula I-A above can be written as Ligand - linker - Ligand, wherein the X-Y-X' moiety of formal I-A forms the linker. The linker (X-Y-X') can be from 4 to 20 linear carbon atoms in length, including from 4-15 linear carbon atoms, 5-10 linear carbon atoms, and 6-8 linear carbon atoms in length. The linker can be a straight or branched chain, or can  
 30 optionally form one or more ring structures, with the proviso that at least 4 linear or straight-chain carbon atoms are present in the linker. At least one of the linear or straight-

chain C atoms can be optionally substituted by at least one hetero atom selected from N, O, or S, advantageously O or S, advantageously O.

Thus, an “optionally substituted linker” can have one or more substitutions that lead to 5 branching and/or one or more substitutions of carbon atom(s) of the linear or straight chain carbon atoms of the linker, e.g. the linker can be an ether or a substituted ether.

(R)-1-[6-[(R)-2-Carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid(CPHPC) is a specific D-proline contemplated by the invention. In a particular embodiment, CPHPC is 10 to be administered to a human patient.

Glycerol cyclic pyruvate derivatives are disclosed in WO 2004/099173, which is incorporated herein by reference in its entirety.

15 The term “antigen binding protein” as used herein refers to antibodies, antibody fragments and other protein constructs, such as domains, which are capable of binding to SAP.

The term “antibody” is used herein in the broadest sense to refer to molecules with an immunoglobulin-like domain and includes monoclonal, recombinant, polyclonal, chimeric, 20 humanised, bispecific and heteroconjugate antibodies; a single variable domain, a domain antibody, antigen binding fragments, immunologically effective fragments, single chain Fv, diabodies, Tandabs™, etc. (for a summary of alternative “antibody” formats see Holliger and Hudson, Nature Biotechnology, 2005, Vol 23, No. 9, 1126-1136).

25 The phrase “single variable domain” refers to an antigen binding protein variable domain (for example, VH, VHH, VL) that specifically binds an antigen or epitope independently of a different variable region or domain.

30 A “domain antibody” or “dAb” may be considered the same as a “single variable domain” which is capable of binding to an antigen. A single variable domain may be a human antibody variable domain, but also includes single antibody variable domains from other species such as rodent (for example, as disclosed in WO 00/29004), nurse shark and Camelid

VHH dAbs. Camelid VHH are immunoglobulin single variable domain polypeptides that are derived from species including camel, llama, alpaca, dromedary, and guanaco, which produce heavy chain antibodies naturally devoid of light chains. Such VHH domains may be humanised according to standard techniques available in the art, and such domains are 5 considered to be “domain antibodies”. As used herein VH includes camelid VHH domains.

As used herein the term “domain” refers to a folded protein structure which has tertiary structure independent of the rest of the protein. Generally, domains are responsible for discrete functional properties of proteins, and in many cases may be added, removed or 10 transferred to other proteins without loss of function of the remainder of the protein and/or of the domain. A “single variable domain” is a folded polypeptide domain comprising sequences characteristic of antibody variable domains. It therefore includes complete antibody variable domains and modified variable domains, for example, in which one or more loops have been replaced by sequences which are not characteristic of antibody 15 variable domains, or antibody variable domains which have been truncated or comprise N- or C-terminal extensions, as well as folded fragments of variable domains which retain at least the binding activity and specificity of the full-length domain. A domain can bind an antigen or epitope independently of a different variable region or domain.

20 An antigen binding fragment may be provided by means of arrangement of one or more CDRs on non-antibody protein scaffolds such as a domain. The domain may be a domain antibody or may be a domain which is a derivative of a scaffold selected from the group consisting of CTLA-4, lipocalin, SpA, an Affibody, an avimer, GroEl, transferrin, GroES and fibronectin/adnectin, which has been subjected to protein engineering in order to obtain 25 binding to an antigen, such as SAP, other than the natural ligand.

An antigen binding fragment or an immunologically effective fragment may comprise partial heavy or light chain variable sequences. Fragments are at least 5, 6, 7, 8, 9 or 10 amino acids in length. Alternatively the fragments are at least 15, at least 20, at least 50, at least 75, or 30 at least 100 amino acids in length.

The term "specifically binds" as used throughout the present specification in relation to antigen binding proteins means that the antigen binding protein binds to SAP with no or insignificant binding to any other proteins, including closely related molecules such as C-reactive protein (CRP) which, in humans, shares 55% of strict residue for residue amino acid sequence homology and has essentially the same protein fold.

The equilibrium dissociation constant (KD) of the antigen binding protein-SAP interaction may be 1 mM or less, 100 nM or less, 10 nM or less, 2 nM or less or 1 nM or less. Alternatively the KD may be between 5 and 10 nM; or between 1 and 2 nM. The KD may be between 1 pM and 500 pM; or between 500 pM and 1 nM.

The binding affinity may be measured by BIACore<sup>TM</sup>, for example by antigen capture with SAP coupled onto a carboxymethyldextran chip by primary amine coupling and antibody capture onto this surface. Alternatively, the binding affinity can be measured by BIACore<sup>TM</sup> by binding of anti-SAP antibodies to human SAP captured by O-phosphoethanolamine immobilised on a CM5 chip. The BIACore<sup>TM</sup> methods described in Example 8 may be used to measure binding affinity.

The dissociation rate constant (kd) may be  $1 \times 10^{-3} \text{ s}^{-1}$  or less,  $1 \times 10^{-4} \text{ s}^{-1}$  or less, or  $1 \times 10^{-5} \text{ s}^{-1}$  or less. The kd may be between  $1 \times 10^{-5} \text{ s}^{-1}$  and  $1 \times 10^{-4} \text{ s}^{-1}$ ; or between  $1 \times 10^{-4} \text{ s}^{-1}$  and  $1 \times 10^{-3} \text{ s}^{-1}$ . A small kd may result in a slow dissociation of the antigen binding protein-ligand complex and improved clearance of complexes of SAP bound to amyloid.

It will be apparent to those skilled in the art that the term "derived" is intended to define not only the source in the sense of it being the physical origin for the material but also to define material which is structurally identical to the material but which does not originate from the reference source. Thus "residues found in the donor antibody" need not necessarily have been purified from the donor antibody.

By "isolated" it is intended that the molecule, such as an antigen binding protein, is removed from the environment in which it may be found in nature. For example, the

molecule may be purified away from substances with which it would normally exist in nature. For example, the mass of the molecule in a sample may be 95% of the total mass.

A “chimeric antibody” refers to a type of engineered antibody which contains a naturally-  
5 occurring variable region (light chain and heavy chains) derived from a donor antibody in association with light and heavy chain constant regions derived from an acceptor antibody.

A “humanised antibody” refers to a type of engineered antibody having its CDRs derived from a non-human donor immunoglobulin, the remaining immunoglobulin-derived parts of  
10 the molecule being derived from one or more human immunoglobulin(s). In addition, framework support residues may be altered to preserve binding affinity (see, e.g., Queen et al. Proc. Natl Acad Sci USA, 86:10029-10032 (1989), Hodgson et al. Bio/Technology, 9:421 (1991)). A suitable human acceptor antibody may be one selected from a conventional database, e.g., the KABAT® database, Los Alamos database, and Swiss Protein database, by  
15 homology to the nucleotide and amino acid sequences of the donor antibody. A human antibody characterized by a homology to the framework regions of the donor antibody (on an amino acid basis) may be suitable to provide a heavy chain constant region and/or a heavy chain variable framework region for insertion of the donor CDRs. A suitable acceptor antibody capable of donating light chain constant or variable framework regions may be  
20 selected in a similar manner. It should be noted that the acceptor antibody heavy and light chains are not required to originate from the same acceptor antibody. The prior art describes several ways of producing such humanised antibodies – see for example EP-A-0239400 and EP-A-054951.

25 The term “donor antibody” refers to an antibody which contributes the amino acid sequences of its variable regions, CDRs, or other functional fragments or analogs thereof to a first immunoglobulin partner. The donor therefore provides the altered immunoglobulin coding region and resulting expressed altered antibody with the antigenic specificity and neutralising activity characteristic of the donor antibody.

30

The term “acceptor antibody” refers to an antibody which is heterologous to the donor antibody, which contributes all (or any portion) of the amino acid sequences encoding its

heavy and/or light chain framework regions and/or its heavy and/or light chain constant regions to the first immunoglobulin partner. A human antibody may be the acceptor antibody.

5 The term "human antibody" refers to an antibody derived from human immunoglobulin gene sequences. These fully human antibodies provide an alternative to re-engineered, or de-immunized, rodent monoclonal antibodies (e.g. humanised antibodies) as a source of low immunogenicity therapeutic antibodies and they are normally generated using either phage display or transgenic mouse platforms. In an embodiment, an antibody of the  
10 invention is a human antibody.

The terms "VH" and "VL" are used herein to refer to the heavy chain variable region and light chain variable region respectively of an antigen binding protein.

15 "CDRs" are defined as the complementarity determining region amino acid sequences of an antigen binding protein. These are the hypervariable regions of immunoglobulin heavy and light chains. There are three heavy chain and three light chain CDRs (or CDR regions) in the variable portion of an immunoglobulin. Thus, "CDRs" as used herein refers to all three heavy chain CDRs, all three light chain CDRs, all heavy and light chain CDRs, or at least two CDRs.

20

Throughout this specification, amino acid residues in variable domain sequences and full length antibody sequences are numbered according to the Kabat numbering convention. Similarly, the terms "CDR", "CDRL1", "CDRL2", "CDRL3", "CDRH1", "CDRH2", "CDRH3" used in the Examples follow the Kabat numbering convention. For further information, see Kabat  
25 et al., Sequences of Proteins of Immunological Interest, 4th Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987).

30 However, although we use the Kabat numbering convention for amino acid residues in variable domain sequences and full length antibody sequences throughout this specification, it will be apparent to those skilled in the art that there are alternative numbering conventions for amino acid residues in variable domain sequences and full length antibody sequences. There are also alternative numbering conventions for CDR

sequences, for example those set out in Chothia et al. (1989) *Nature* 342: 877-883. The structure and protein folding of the antibody may mean that other residues are considered part of the CDR sequence and would be understood to be so by a skilled person.

5 Other numbering conventions for CDR sequences available to a skilled person include "AbM" (University of Bath) and "contact" (University College London) methods. The minimum overlapping region using at least two of the Kabat, Chothia, AbM and contact methods can be determined to provide the "minimum binding unit". The minimum binding unit may be a sub-portion of a CDR.

10

Table 1 below represents one definition using each numbering convention for each CDR or binding unit. The Kabat numbering scheme is used in Table 1 to number the variable domain amino acid sequence. It should be noted that some of the CDR definitions may vary depending on the individual publication used.

15

Table 1

|    | Kabat CDR     | Chothia CDR | AbM CDR       | Contact CDR   | Minimum binding unit |
|----|---------------|-------------|---------------|---------------|----------------------|
| H1 | 31-35/35A/35B | 26-32/33/34 | 26-35/35A/35B | 30-35/35A/35B | 31-32                |
| H2 | 50-65         | 52-56       | 50-58         | 47-58         | 52-56                |
| H3 | 95-102        | 95-102      | 95-102        | 93-101        | 95-101               |
| L1 | 24-34         | 24-34       | 24-34         | 30-36         | 30-34                |
| L2 | 50-56         | 50-56       | 50-56         | 46-55         | 50-55                |
| L3 | 89-97         | 89-97       | 89-97         | 89-96         | 89-96                |

As used herein, the term "antigen binding site" refers to a site on an antigen binding protein which is capable of specifically binding to an antigen. This may be a single domain (for example, an epitope-binding domain), or single-chain Fv (ScFv) domains or it may be paired VH/VL domains as can be found on a standard antibody.

The term "epitope" as used herein refers to that portion of the antigen that makes contact with a particular binding domain of the antigen binding protein. An epitope may be linear, comprising an essentially linear amino acid sequence from the antigen. Alternatively, an

epitope may be conformational or discontinuous. For example, a conformational epitope comprises amino acid residues which require an element of structural constraint. In the case of a conformational epitope, although the residues may be from different regions of the peptide chain, they may be in close proximity in the three dimensional structure of the antigen. In the case of multimeric antigens, such as SAP, a conformational epitope may include residues from different peptide chains that may be in close proximity in the three dimensional structure of the antigen. Such structurally neighbouring residues can be determined through computer modelling programs or via three-dimensional structures obtained through methods known in the art, such as X-ray crystallography.

10

A discontinuous epitope comprises amino acid residues that are separated by other sequences, i.e. not in a continuous sequence in the antigen's primary sequence. In the context of the antigen's tertiary and quaternary structure, the residues of a discontinuous epitope are near enough to each other to be bound by an antigen binding protein.

15

In an embodiment, an antigen binding protein of the invention binds to an epitope within residues 140-158 of human SAP.

For nucleotide and amino acid sequences, the term "identical" or "sequence identity" indicates the degree of identity between two nucleic acid or two amino acid sequences when optimally aligned and compared with appropriate insertions or deletions.

The percent identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions/total number of positions multiplied by 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described below.

30 The percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package, using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. The percent identity between

two nucleotide or amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino

5 acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package, using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

10 By way of example, a polynucleotide sequence may be identical to a reference polynucleotide sequence as described herein (see for example SEQ ID NO:8, 10, 18, 20, 45-48, 51-61, 63, 65-73), that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence, such as at least 50, 60, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identical. Such alterations are selected from  
15 at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is  
20 determined by multiplying the total number of nucleotides in the reference polynucleotide sequence as described herein (see for example SEQ ID NO:8, 10, 18, 20, 45-48, 51-61, 63, 65-73), by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from said total number of nucleotides in the reference polynucleotide sequence as described herein (see for example SEQ ID NO:8, 10, 18, 20, 45-48, 51-61, 63, 65-73), or:

$$n_n \leq x_n - (x_n \bullet y),$$

wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides in the reference polynucleotide sequence as described herein (see for example SEQ ID NO:8, 10, 18, 20, 45-48, 51-61, 63, 65-73), and  $y$  is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.75 for 75%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.98 for 98%, 0.99 for 99% or 1.00 for 100%, • is the symbol for the multiplication operator, and wherein any non-

integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ .

Similarly, a polypeptide sequence may be identical to a polypeptide reference sequence as described herein (see for example SEQ ID NO:1-7, 9, 11-17, 19, 21-24, 27-31, 34-42, 62, 64, 74), that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%, such as at least 50, 60, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identical. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in the polypeptide sequence encoded by the polypeptide reference sequence as described herein (see for example SEQ ID NO:1-7, 9, 11-17, 19, 21-24, 27-31, 34-42, 62, 64, 74) by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in the polypeptide reference sequence as described herein (see for example SEQ ID NO:1-7, 9, 11-17, 19, 21-24, 27-31, 34-42, 62, 64, 74), or:

$$n_a \leq x_a - (x_a \bullet y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in the reference polypeptide sequence as described herein (see for example SEQ ID NO:1-7, 9, 11-17, 19, 21-24, 27-31, 34-42, 62, 64, 74), and  $y$  is, 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.75 for 75%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.98 for 98%, 0.99 for 99%, or 1.00 for 100%,  $\bullet$  is the symbol for the multiplication operator, and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

30

The % identity may be determined across the length of the sequence.

The terms "peptide", "polypeptide" and "protein" each refers to a molecule comprising two or more amino acid residues. A peptide may be monomeric or polymeric.

It is well recognised in the art that certain amino acid substitutions are regarded as being

5 "conservative". Amino acids are divided into groups based on common side-chain properties and substitutions within groups that maintain all or substantially all of the binding affinity of the antigen binding protein are regarded as conservative substitutions, see Table 2 below:

Table 2

| Side chain                                | Members                 |
|---|-------------------------|
| Hydrophobic                               | Met, Ala, Val, Leu, Ile |
| Neutral hydrophilic                       | Cys, Ser, Thr           |
| Acidic                                    | Aap, Glu                |
| Basic                                     | Asn, Gln, His, Lys, Arg |
| Residues that influence chain orientation | Gly, Pro                |
| Aromatic                                  | Trp, Tyr, Phe           |

10

The antigen binding protein may compete for binding to SAP with a reference antibody comprising a heavy chain variable region sequence of SEQ ID NO: 7, and a light chain variable region sequence of SEQ ID NO: 9. Alternatively, the antigen binding protein may

15 compete for binding to SAP with a reference antibody comprising a heavy chain variable region sequence of SEQ ID NO: 17, and a light chain variable region sequence of SEQ ID NO: 19.

Competition between the antigen binding protein and the reference antibody may be

20 determined by competition ELISA, FMAT or BIACore. A competing antigen binding protein may bind to the same epitope, an overlapping epitope, or an epitope in close proximity of the epitope to which the reference antibody binds.

The present invention also provides an antigen binding protein which specifically binds to

25 SAP and comprises CDRH3 of SEQ ID NO:3 or a variant CDR thereof. The antigen binding protein may further comprise one or more CDRs, or all CDRs, in any combination, selected

from: CDRH1 (SEQ ID NO:1), CDRH2 (SEQ ID NO:2), CDRL1 (SEQ ID NO:4), CDRL2 (SEQ ID NO:5), and CDRL3 (SEQ ID NO:6); or a variant thereof.

For example, the antigen binding protein may comprise CDRH3 (SEQ ID NO:3) and CDRH1

5 (SEQ ID NO:1), or variants thereof. The antigen binding protein may comprise CDRH3 (SEQ ID NO:3) and CDRH2 (SEQ ID NO:2), or variants thereof. The antigen binding protein may comprise CDRH1 (SEQ ID NO:1) and CDRH2 (SEQ ID NO:2), and CDRH3 (SEQ ID NO:3), or variants thereof.

10 The antigen binding protein may comprise CDRL1 (SEQ ID NO:4) and CDRL2 (SEQ ID NO:5), or variants thereof. The antigen binding protein may comprise CDRL2 (SEQ ID NO:5) and CDRL3 (SEQ ID NO:6), or variants thereof. The antigen binding protein may comprise CDRL1 (SEQ ID NO:4), CDRL2 (SEQ ID NO:5) and CDRL3 (SEQ ID NO:6), or variants thereof.

15 The antigen binding protein may comprise CDRH3 (SEQ ID NO:3) and CDRL3 (SEQ ID NO:6), or variants thereof. The antigen binding protein may comprise CDRH3 (SEQ ID NO:3), CDRH2 (SEQ ID NO:2) and CDRL3 (SEQ ID NO:6), or variants thereof. The antigen binding protein may comprise CDRH3 (SEQ ID NO:3), CDRH2 (SEQ ID NO:2), CDRL2 (SEQ ID NO:5) and CDRL3 (SEQ ID NO:6), or variants thereof.

20

The antigen binding protein may comprise CDRH1 (SEQ ID NO:1), CDRH2 (SEQ ID NO:2), CDRH3 (SEQ ID NO:3), CDRL1 (SEQ ID NO:4), CDRL2 (SEQ ID NO:5) and CDRL3 (SEQ ID NO:6), or variants thereof.

25 The present invention also provides an antigen binding protein which specifically binds to SAP and comprises CDRH3 of SEQ ID NO:13 or a variant CDR thereof. The antigen binding protein may further comprise one or more CDRs, or all CDRs, in any combination, selected from: CDRH1 (SEQ ID NO:11), CDRH2 (SEQ ID NO:12), CDRL1 (SEQ ID NO:14), CDRL2 (SEQ ID NO:15), and CDRL3 (SEQ ID NO:16); or a variant thereof.

30

The present invention also provides an antigen binding protein which specifically binds to SAP, wherein the antigen binding protein is a chimeric or a humanised antibody comprising

the corresponding CDRH3 of the variable domain sequence of SEQ ID NO:7, or a variant CDRH3.

5 The chimeric or humanised antigen binding protein may further comprise one or more, or all of the corresponding CDRs selected from the variable domain sequence of SEQ ID NO:7 or SEQ ID NO:9, or a variant CDR thereof.

10 For example, the antigen binding protein may comprise corresponding CDRH3 and corresponding CDRH1, or variants thereof. The antigen binding protein may comprise corresponding CDRH3 and corresponding CDRH2, or variants thereof. The antigen binding protein may comprise corresponding CDRH1, corresponding CDRH2, and corresponding CDRH3; or variants thereof.

15 The antigen binding protein may comprise corresponding CDRL1 and corresponding CDRL2, or variants thereof. The antigen binding protein may comprise corresponding CDRL2 and corresponding CDRL3, or variants thereof. The antigen binding protein may comprise corresponding CDRL1, corresponding CDRL2 and corresponding CDRL3, or variants thereof.

20 The antigen binding protein may comprise corresponding CDRH3 and corresponding CDRL3, or variants thereof. The antigen binding protein may comprise corresponding CDRH3, corresponding CDRH2 and corresponding CDRL3, or variants thereof. The antigen binding protein may comprise corresponding CDRH3, corresponding CDRH2, corresponding CDRL2 and corresponding CDRL3, or variants thereof.

25 The antigen binding protein may comprise corresponding CDRH1, corresponding CDRH2, corresponding CDRH3, corresponding CDRL1, corresponding CDRL2 and corresponding CDRL3, or variants thereof.

30 The corresponding CDRs can be defined by reference to Kabat (1987), Chothia (1989), AbM or contact methods, or a combination of these methods. One definition of each of the methods can be found at Table 1 and can be applied to the reference heavy chain variable

domain SEQ ID NO:7 and the reference light chain variable domain SEQ ID NO:9 to determine the corresponding CDR.

The present invention also provides an antigen binding protein which specifically binds to

5 SAP, wherein the antigen binding protein is a chimeric or a humanised antibody comprising the corresponding CDRH3 of the variable domain sequence of SEQ ID NO:17, or a variant CDRH3.

The chimeric or humanised antigen binding protein may further comprise one or more, or

10 all of the corresponding CDRs selected from the variable domain sequence of SEQ ID NO:17 or SEQ ID NO:19, or a variant CDR thereof.

The present invention also provides an antigen binding protein which specifically binds to SAP, and comprises a binding unit H3 comprising Kabat residues 95-101 of SEQ ID NO:7, or a

15 variant H3. The antigen binding protein may further comprise one or more or all binding units selected from: H1 comprising Kabat residues 31-32 of SEQ ID NO:7, H2 comprising Kabat residues 52-56 of SEQ ID NO:7, L1 comprising Kabat residues 30-34 of SEQ ID NO:9, L2 comprising Kabat residues 50-55 of SEQ ID NO:9 and L3 comprising Kabat residues 89-96 of SEQ ID NO:9; or a variant binding unit.

20

For example, the antigen binding protein may comprise a binding unit H3 and a binding unit H1, or variants thereof. The antigen binding protein may comprise a binding unit H3 and a binding unit H2, or variants thereof. The antigen binding protein may comprise a binding unit H1, a binding unit H2, and a binding unit H3; or variants thereof.

25

The antigen binding protein may comprise a binding unit L1 and a binding unit L2, or variants thereof. The antigen binding protein may comprise a binding unit L2 and a binding unit L3, or variants thereof. The antigen binding protein may comprise a binding unit L1, a binding unit L2, and a binding unit L3; or variants thereof.

30

The antigen binding protein may comprise a binding unit H3 and a binding unit L3, or variants thereof. The antigen binding protein may comprise a binding unit H3, a binding unit

H2, and a binding unit L3; or variants thereof. The antigen binding protein may comprise a binding unit H3, a binding unit H2, a binding unit L2, and a binding unit L3; or variants thereof.

5 The antigen binding protein may comprise a binding unit H1, a binding unit H2, a binding unit H3, a binding unit L1, a binding unit L2, and a binding unit L3; or variants thereof.

The present invention also provides an antigen binding protein which specifically binds to SAP, and comprises a binding unit H3 comprising Kabat residues 95-101 of SEQ ID NO:17, or 10 a variant H3. The antigen binding protein may further comprise one or more or all binding units selected from: H1 comprising Kabat residues 31-32 of SEQ ID NO:17, H2 comprising Kabat residues 52-56 of SEQ ID NO:17, L1 comprising Kabat residues 30-34 of SEQ ID NO:19, L2 comprising Kabat residues 50-55 of SEQ ID NO:19 and L3 comprising Kabat residues 89-96 of SEQ ID NO:19; or a variant binding unit.

15

A CDR variant or variant binding unit includes an amino acid sequence modified by at least one amino acid, wherein said modification can be chemical or a partial alteration of the amino acid sequence (for example by no more than 10 amino acids), which modification permits the variant to retain the biological characteristics of the unmodified sequence. For 20 example, the variant is a functional variant which specifically binds to SAP and activates clearance of complexes of SAP bound to amyloid from tissues. A partial alteration of the CDR amino acid sequence may be by deletion or substitution of one to several amino acids, or by addition or insertion of one to several amino acids, or by a combination thereof (for example by no more than 10 amino acids). The CDR variant or binding unit variant may 25 contain 1, 2, 3, 4, 5 or 6 amino acid substitutions, additions or deletions, in any combination, in the amino acid sequence. The CDR variant or binding unit variant may contain 1, 2 or 3 amino acid substitutions, insertions or deletions, in any combination, in the amino acid sequence. The substitutions in amino acid residues may be conservative substitutions, for example, substituting one hydrophobic amino acid for an alternative hydrophobic amino 30 acid. For example leucine may be substituted with valine, or isoleucine.

One or more of the CDRs, corresponding CDRs, variant CDRs or binding units described herein may be present in the context of a human framework, for example as a humanised or chimeric variable domain. Fully human antibodies comprising one or more of the CDRs, corresponding CDRs, variant CDRs or binding units described herein are also contemplated and are within the scope of the invention.

The CDRs L1, L2, L3, H1 and H2 tend to structurally exhibit one of a finite number of main chain conformations. The particular canonical structure class of a CDR is defined by both the length of the CDR and by the loop packing, determined by residues located at key positions in both the CDRs and the framework regions (structurally determining residues or SDRs). Martin and Thornton (1996; *J Mol Biol* 263:800-815) have generated an automatic method to define the “key residue” canonical templates. Cluster analysis is used to define the canonical classes for sets of CDRs, and canonical templates are then identified by analysing buried hydrophobics, hydrogen-bonding residues, and conserved glycines and prolines. The CDRs of antibody sequences can be assigned to canonical classes by comparing the sequences to the key residue templates and scoring each template using identity or similarity matrices.

Examples of CDR canonicals within the scope of the invention are given below. The amino acid numbering used is Kabat.

Examples of canonicals for CDRH1 as set out in SEQ ID NO:1, a variant thereof, the CDRH1 of SEQ ID NO:7 or a corresponding CDR are: Tyr 32 is substituted for Ile, His, Phe, Thr, Asn, Cys, Glu or Asp; Asn 33 is substituted for Tyr, Ala, Trp, Gly, Thr, Leu or Val; Met 34 is substituted for Ile, Val or Trp; and/or His 35 is substituted for Glu, Asn, Gln, Ser, Tyr or Thr.

Examples of canonicals for CDRH2 as set out in SEQ ID NO:2, a variant thereof, the CDRH2 of SEQ ID NO:7 or a corresponding CDR are: Tyr 50 is substituted for Arg, Glu, Trp, Gly, Gln, Val, Leu, Asn, Lys or Ala; Ile51 is substituted for Leu, Val, Thr, Ser or Asn; Tyr 52 is substituted for Asp, Leu, Asn or Ser; Gly 53 is substituted for Ala, Tyr, Ser, Lys, Thr or Asn; Asp 54 is substituted for Asn, Ser, Thr, Lys or Gly; Asn 56 is substituted for Tyr, Arg, Glu, Asp, Gly, Val, Ser or Ala; and/or Asn 58 is substituted for Lys, Thr, Ser, Asp, Arg, Gly, Phe or Tyr.

Examples of canonicals for CDRH3 as set out in SEQ ID NO:3, a variant thereof, the CDRH3 of SEQ ID NO:7 or a corresponding CDR are: Ser 102 is substituted for Tyr, His, Val, Ile, Asp or Gly.

Examples of canonicals for CDRL1 as set out in SEQ ID NO:4, a variant thereof, the CDRL1 of

5 SEQ ID NO:9 or a corresponding CDR are: Asn 28 is substituted for Ser, Asp, Thr or Glu; Ile 29 is substituted for Val; Tyr 30 is substituted for Asp, Leu, Val, Ile, Ser, Asn, Phe, His, Gly or Thr; Ser 31 is substituted for Asn, Thr, Lys or Gly; Tyr 32 is substituted for Phe, Asn, Ala, His, Ser or Arg; Leu 33 is substituted for Met, Val, Ile or Phe; and/or Ala 34 is substituted for Gly, Asn, Ser, His, Val or Phe.

10 Examples of canonicals for CDRL2 as set out in SEQ ID NO:5, a variant thereof, the CDRL1 of SEQ ID NO:9 or a corresponding CDR are: Ala 51 is substituted for Thr, Gly or Val.

Examples of canonicals for CDRL3 as set out in SEQ ID NO:6, a variant thereof, the CDRL1 of

SEQ ID NO:9 or a corresponding CDR are: Gln 89 is substituted for Ser, Gly, Phe or Leu; His 90 is substituted for Gln or Asn; His 91 is substituted for Asn, Phe, Gly, Ser, Arg, Asp, Thr, Tyr

15 or Val; Tyr 92 is substituted for Asn, Trp, Thr, Ser, Arg, Gln, His, Ala or Asp; Gly 93 is substituted for Glu, Asn, His, Thr, Ser, Arg or Ala; Ala 94 is substituted for Asp, Tyr, Thr, Val, Leu, His, Asn, Ile, Trp, Pro or Ser; and/or Leu 96 is substituted for Pro, Tyr, Arg, Ile, Trp or Phe.

Examples of canonicals for CDRH1 as set out in SEQ ID NO:11, a variant thereof, the CDRH1

20 of SEQ ID NO:17 or a corresponding CDR are: Tyr 32 is substituted for Ile, His, Phe, Thr, Asn, Cys, Glu or Asp; Trp 33 is substituted for Tyr, Ala, Gly, Thr, Leu or Val; Met 34 is substituted for Ile, Val or Trp; and/or His 35 is substituted for Glu, Asn, Gln, Ser, Tyr or Thr.

Examples of canonicals for CDRH2 as set out in SEQ ID NO:12, a variant thereof, the CDRH1

of SEQ ID NO:17 or a corresponding CDR are: Met 50 is substituted for Arg, Glu, Trp, Tyr, Gly,

25 Gln, Val, Leu, Asn, Lys or Ala; Ile 51 is substituted for Leu, Val, Thr, Ser or Asn; His 52 is substituted for Asp, Leu, Asn, Ser or Tyr; Asn 53 is substituted for Ala, Gly, Tyr, Ser, Lys or Thr; Ser 54 is substituted for Asn, Thr, Lys, Asp or Gly; Asn 56 is substituted for Tyr, Arg, Glu, Asp, Gly, Val, Ser or Ala; and/or Asn 58 is substituted for Lys, Thr, Ser, Asp, Arg, Gly, Phe or Tyr.

Examples of canonicals for CDRH3 as set out in SEQ ID NO:13, a variant thereof, the CDRH1 of SEQ ID NO:17 or a corresponding CDR are: Val 102 is substituted for Tyr, His, Ile, Ser, Asp or Gly.

Examples of canonicals for CDRL1 as set out in SEQ ID NO:14, a variant thereof, the CDRL1 of

5 SEQ ID NO:19 or a corresponding CDR are: Asn 28 is substituted for Ser, Asp, Thr or Glu; Val 29 is substituted for Ile; Asn 30 is substituted for Asp, Leu, Tyr, Val, Ile, Ser, Phe, His, Gly or Thr; Ser 31 is substituted for Asn, Thr, Lys or Gly; Asn 32 is substituted for Phe, Tyr, Ala, His, Ser or Arg; Val 33 is substituted for Met, Leu, Ile or Phe; Ala 34 is substituted for Gly, Asn, Ser, His, Val or Phe.

10 Examples of canonicals for CDRL2 as set out in SEQ ID NO:15, a variant thereof, the CDRL1 of SEQ ID NO:19 or a corresponding CDR are: Ala 51 is substituted for Thr, Gly or Val.

Examples of canonicals for CDRL3 as set out in SEQ ID NO:16, a variant thereof, the CDRL1 of SEQ ID NO:19 or a corresponding CDR are: Gln 89 is substituted for Ser, Gly, Phe or Leu; Gln 90 is substituted for Asn or His; Cys 91 is substituted for Asn, Phe, Gly, Ser, Arg, Asp, His, Thr,

15 Tyr or Val; Asn 92 is substituted for Tyr, Trp, Thr, Ser, Arg, Gln, His, Ala or Asp; Asn 93 is substituted for Glu, Gly, His, Thr, Ser, Arg or Ala; Tyr 94 is substituted for Asp, Thr, Val, Leu, His, Asn, Ile, Trp, Pro or Ser; and/or Phe 96 is substituted for Pro, Leu, Tyr, Arg, Ile or Trp.

There may be multiple variant CDR canonical positions per CDR, per corresponding CDR, per

20 binding unit, per heavy or light chain variable region, per heavy or light chain, and per antigen binding protein, and therefore any combination of substitution may be present in the antigen binding protein of the invention, provided that the canonical structure of the CDR is maintained such that the antigen binding protein is capable of specifically binding SAP.

As discussed above, the particular canonical structure class of a CDR is defined by both the

25 length of the CDR and by the loop packing, determined by residues located at key positions in both the CDRs and the framework regions.

Thus in addition to the CDRs listed in SEQ ID NO: 1-6 or 11-16, CDRs of SEQ ID NO:7, 9, 17 or 19, corresponding CDRs, binding units, or variants thereof, the canonical framework

residues of an antigen binding protein of the invention may include (using Kabat numbering):

Heavy chain: Val, Ile or Gly at position 2; Leu or Val at position 4; Leu, Ile, Met or Val at position 20; Cys at position 22; Thr, Ala, Val, Gly or Ser at position 24; Gly at position 26; Ile, 5 Phe, Leu or Ser at position 29; Trp at position 36; Trp or Tyr at position 47; Ile, Met, Val or Leu at position 48; Ile, Leu, Phe, Met or Val at position 69; Val, Ala or Leu at position 71; Ala, Leu, Val, Tyr or Phe at position 78; Leu or Met at position 80; Tyr or Phe at position 90; Cys at position 92; and/or Arg, Lys, Gly, Ser, His or Asn at position 94.

Light chain: Ile, Leu or Val at position 2; Val, Gln, Leu or Glu at position 3; Met or Leu at 10 position 4; Cys at position 23; Trp at position 35; Tyr, Leu or Phe at position 36; Leu, Arg or Val at position 46; Tyr, His, Phe or Lys at position 49; Tyr or Phe at position 71; Cys at position 88; and/or Phe at position 98.

In a particular embodiment, the heavy chain framework comprises the following residues: Val at position 2, Leu at position 4, Val at position 20, Cys at position 22, Ala at position 24, 15 Gly at position 26, Phe at position 29, Trp at position 36, Trp at position 47, Met at position 48, Ile at position 69, Ala at position 71, Ala at position 78, Met at position 80, Tyr at position 90, Cys at position 92, and Arg at position 94; and the light chain framework comprises the following residues: Ile at position 2, Gln at position 3, Met at position 4, Cys at position 23, Trp at position 35, Tyr at position 36, Leu at position 46, His at position 49, Phe 20 at position 71, Cys at position 88, and Phe at position 98.

Any one, any combination, or all of the framework positions described above may be present in the antigen binding protein of the invention. There may be multiple variant framework canonical positions per heavy or light chain variable region, per heavy or light chain, and per antigen binding protein, and therefore any combination may be present in 25 the antigen binding protein of the invention, provided that the canonical structure of the framework is maintained.

The humanised heavy chain variable domain may comprise the CDRs listed in SEQ ID NO:1-3; variant CDRs; corresponding CDRs in SEQ ID NO:7; binding units; or variants thereof, within an acceptor antibody framework having 75% or greater, 80% or greater, 85% or

greater, 90% or greater, 95% or greater, 98% or greater, 99% or greater or 100% identity in the framework regions to the human acceptor variable domain sequence in SEQ ID NO:25. The humanised light chain variable domain may comprise the CDRs listed in SEQ ID NO:4-6; variant CDRs; corresponding CDRs in SEQ ID NO:9; binding units; or variants thereof, within 5 an acceptor antibody framework having 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 98% or greater, 99% or greater or 100% identity in the framework regions to the human acceptor variable domain sequence in SEQ ID NO:32.

The humanised heavy chain variable domain may comprise the CDRs listed in SEQ ID NO:11-13; variant CDRs; corresponding CDRs in SEQ ID NO:17; binding units; or variants thereof, 10 within an acceptor antibody framework having 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 98% or greater, 99% or greater or 100% identity in the framework regions to the human acceptor variable domain sequence in SEQ ID NO:25. The humanised light chain variable domain may comprise the CDRs listed in SEQ ID NO:14-16; variant CDRs; corresponding CDRs in SEQ ID NO:19; binding units; or variants thereof, 15 within an acceptor antibody framework having 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 98% or greater, 99% or greater or 100% identity in the framework regions to the human acceptor variable domain sequence in SEQ ID NO:32.

The invention also provides an antigen binding protein which specifically binds to SAP and comprises a heavy chain variable region selected from any one of SEQ ID NO:27-31. The 20 antigen binding protein may comprise a light chain variable region selected from any one of SEQ ID NO:34-36. Any of the heavy chain variable regions may be combined with any of the light chain variable regions.

The antigen binding protein may comprise any one of the following heavy chain and light 25 chain variable region combinations: H0L0 (SEQ ID NO:27 and SEQ ID NO:34), H0L1 (SEQ ID NO:27 and SEQ ID NO:35), H0L2 (SEQ ID NO:27 and SEQ ID NO:36), H1L0 (SEQ ID NO:28 and SEQ ID NO:34), H1L1 (SEQ ID NO:28 and SEQ ID NO:35), H1L2 (SEQ ID NO:28 and SEQ ID NO:36), H2L0 (SEQ ID NO:29 and SEQ ID NO:34), H2L1 (SEQ ID NO:29 and SEQ ID NO:35), H2L2 (SEQ ID NO:29 and SEQ ID NO:36), H3L0 (SEQ ID NO:30 and SEQ ID NO:34), H3L1 (SEQ 30 ID NO:30 and SEQ ID NO:35), H3L2 (SEQ ID NO:30 and SEQ ID NO:36), H4L0 (SEQ ID NO:31

and SEQ ID NO:34), H4L1 (SEQ ID NO:31 and SEQ ID NO:35), or H4L2 (SEQ ID NO:31 and SEQ ID NO:36).

The invention also provides an antigen binding protein which specifically binds to SAP and comprises a heavy chain variable region selected from any one of SEQ ID NO:37-40. The 5 antigen binding protein may comprise a light chain variable region of SEQ ID NO:41, SEQ ID NO:42 or SEQ ID NO:74. Any of the heavy chain variable regions may be combined with any of the light chain variable regions.

The antigen binding protein may comprise any one of the following heavy chain and light chain variable region combinations: H0L0 (SEQ ID NO:37 and SEQ ID NO:41), H0L1 (SEQ ID 10 NO:37 and SEQ ID NO:42), H1L0 (SEQ ID NO:38 and SEQ ID NO:41), H1L1 (SEQ ID NO:38 and SEQ ID NO:42), H2L0 (SEQ ID NO:39 and SEQ ID NO:41), H2L1 (SEQ ID NO:39 and SEQ ID NO:42), H3L0 (SEQ ID NO:40 and SEQ ID NO:41), or H3L1 (SEQ ID NO:40 and SEQ ID NO:42).

L0 (SEQ ID NO:41) may be substituted with L0 91 A (SEQ ID NO:74).

The antibody heavy chain variable region may have 75% or greater, 80% or greater, 85% or 15 greater, 90% or greater, 95% or greater, 96% or greater, 97% or greater, 98% or greater, 99% or greater or 100% identity to SEQ ID NO:28. The antibody light chain variable region may have 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 96% or greater, 97% or greater, 98% or greater, 99% or greater, or 100% identity to SEQ ID NO:35.

20 The antibody heavy chain variable region may have 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 96% or greater, 97% or greater, 98% or greater, 99% or greater or 100% identity to SEQ ID NO:40. The antibody light chain variable region may have 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 96% or greater, 97% or greater, 98% or greater, 99% or greater, or 100% identity to SEQ ID 25 NO:41. The antibody light chain variable region may have 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 96% or greater, 97% or greater, 98% or greater, 99% or greater, or 100% identity to SEQ ID NO:74.

The antibody heavy chain variable region may be a variant of any one of SEQ ID NO:27-31 which contains 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions, insertions 30 or deletions. The antibody light chain variable region may be a variant of any one of SEQ ID

NO:34-36 which contains 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions, insertions or deletions.

The antibody heavy chain variable region may be a variant of any one of SEQ ID NO:37-40 which contains 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions, insertions or deletions. The antibody light chain variable region may be a variant of SEQ ID NO:41, 42 or 74 which contains 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions, insertions or deletions.

For example, the canonical CDRs and canonical framework residue substitutions described above may also be present in the variant heavy or light chain variable regions as variant sequences that are at least 75% identical or which contain up to 30 amino acid substitutions.

Any of the heavy chain variable regions may be combined with a suitable human constant region. Any of the light chain variable regions may be combined with a suitable constant region.

15 The antigen binding protein of the invention may comprise a heavy chain of SEQ ID NO:62 and/or a light chain variable region of SEQ ID NO:64.

The antibody heavy chain may have 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 96% or greater, 97% or greater, 98% or greater, 99% or greater or 100% identity to SEQ ID NO:62. The antibody light chain may have 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 96% or greater, 97% or greater, 98% or greater, 99% or greater, or 100% identity to SEQ ID NO:64.

The antibody heavy chain may be a variant of any one of SEQ ID NO:62 which contains 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions, insertions or deletions. The antibody light chain may be a variant of any one of SEQ ID NO:64 which contains 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions, insertions or deletions.

30 The disc-like SAP molecule has two faces. The single alpha helix present on each of the 5 protomers is located on the A face. The calcium dependent ligand binding pocket of each protomer is located on the B face and this face is therefore occluded when SAP is bound to amyloid fibrils. For antigen binding proteins of the present invention to have therapeutic utility, the epitope recognised by the antigen binding protein described herein is desirably

accessible in SAP when SAP is bound to amyloid deposits and is therefore located on the A face or the edges of the SAP molecule. The antigen binding protein can then recognise and bind to amyloid bound SAP, leading to complement activation that triggers the body's efficient macrophage dependent clearance mechanism. Accordingly, in an embodiment of 5 the invention the antigen binding protein binds human SAP which is bound to amyloid fibrils *in vivo*. In another embodiment of the invention, the antigen binding protein binds to the A face of human SAP.

The antigen binding protein may be derived from rat, mouse, rabbit, camel (or related camelid species), or primate (e.g. cynomolgus, Old World monkey, Great Ape or human). In 10 a particular embodiment the antigen binding protein is derived from mouse. In another embodiment the antigen binding protein is derived from human. The antigen binding protein may be a humanised or chimeric antibody. The antigen binding protein may be a human antibody. The antigen binding protein is not a murine antibody.

The antigen binding protein may comprise a constant region, which may be of any isotype 15 or subclass. The constant region may be of the IgG isotype, for example IgG1, IgG2, IgG3, IgG4 or variants thereof. The antigen binding protein constant region may be IgG1.

In a particular embodiment of the invention, the antigen binding protein comprises a constant region that is functional in activating complement e.g. human IgG1, IgG2 or IgG3.

In another embodiment of the invention, the antigen binding protein comprises a constant 20 region that is functional in binding macrophages e.g. human IgG1 or IgG3.

In a further embodiment of the invention, the antigen binding protein comprises a constant region that is functional in both activating complement and binding macrophages e.g. human IgG1 or IgG3.

The antigen binding protein may comprise one or more modifications selected from a 25 mutated constant domain such that the antibody has altered effector functions/ADCC and/or complement activation. Examples of suitable modifications are described in Shields et al. J. Biol. Chem (2001) 276: 6591-6604, Lazar et al. PNAS (2006) 103: 4005-4010 and US6737056, WO2004063351 and WO2004029207.

The antigen binding protein may comprise a constant domain with an altered glycosylation 30 profile such that the antigen binding protein has altered effector functions/ADCC and/or

complement activation. Examples of suitable methodologies to produce an antigen binding protein with an altered glycosylation profile are described in WO2003/011878, WO2006/014679 and EP1229125.

In an embodiment of the invention, antigen binding proteins are selected which do not have

5 residues within regions that are responsible for antigen binding, e.g. the CDRs, that are susceptible to deamidation. In a further embodiment of the invention, antigen binding proteins are selected which do not have residues within regions responsible for complement activation that are susceptible to deamidation.

The present invention also provides a nucleic acid molecule which encodes an antigen

10 binding protein as described herein. The nucleic acid molecule may comprise sequences encoding both the heavy chain variable or full length sequence; and the light chain variable or full length sequence. Alternatively, the nucleic acid molecule which encodes an antigen binding protein described herein may comprise sequences encoding the heavy chain variable or full length sequence; or light chain variable or full length sequence.

15 The nucleic acid molecule which encodes the heavy chain variable region may comprise any one of SEQ ID NO:51 or 53-57. The nucleic acid molecule which encodes the light chain variable region may comprise any one of SEQ ID NO:52 or 58-60.

The nucleic acid molecule which encodes the heavy chain may comprise SEQ ID NO:61. The nucleic acid molecule which encodes the light chain may comprise SEQ ID NO:63.

20 The nucleic acid molecule which encodes the heavy chain variable region may comprise any one of SEQ ID NO:65 or 67-70. The nucleic acid molecule which encodes the light chain variable region may comprise any one of SEQ ID NO:66 or 71-73.

The nucleic acid molecule may also contain one or more nucleotide substitutions which do not alter the amino acid sequence of the encoded heavy and/or light chain.

25 The present invention also provides an expression vector comprising a nucleic acid molecule as described herein. Also provided is a recombinant host cell, comprising an expression vector as described herein.

The antigen binding protein described herein may be produced in a suitable host cell. A method for the production of the antigen binding protein as described herein may comprise

the step of culturing a host cell as described herein and recovering the antigen binding protein. A recombinant transformed, transfected, or transduced host cell may comprise at least one expression cassette, whereby said expression cassette comprises a polynucleotide encoding a heavy chain of the antigen binding protein described herein and further

5 comprises a polynucleotide encoding a light chain of the antigen binding protein described herein. Alternatively, a recombinant transformed, transfected or transduced host cell may comprise at least one expression cassette, whereby a first expression cassette comprises a polynucleotide encoding a heavy chain of the antigen binding protein described herein and further comprise a second cassette comprising a polynucleotide encoding a light chain of

10 the antigen binding protein described herein. A stably transformed host cell may comprise a vector comprising one or more expression cassettes encoding a heavy chain and/or a light chain of the antigen binding protein described herein. For example such host cells may comprise a first vector encoding the light chain and a second vector encoding the heavy chain.

15 The host cell may be eukaryotic, for example mammalian. Examples of such cell lines include CHO or NS0. The host cell may be cultured in a culture media, for example serum-free culture media. The antigen binding protein may be secreted by the host cell into the culture media. The antigen binding protein can be purified to at least 95% or greater (e.g. 98% or greater) with respect to said culture media containing the antigen binding protein.

20 A pharmaceutical composition comprising the antigen binding protein and a pharmaceutically acceptable carrier may be provided. A kit-of-parts comprising the pharmaceutical composition together with instructions for use may be provided. For convenience, the kit may comprise the reagents in predetermined amounts with instructions for use.

25

### **Antibody Structures**

#### Intact Antibodies

The light chains of antibodies from most vertebrate species can be assigned to one of two types called Kappa and Lambda based on the amino acid sequence of the constant region.

30 Depending on the amino acid sequence of the constant region of their heavy chains, human

antibodies can be assigned to five different classes, IgA, IgD, IgE, IgG and IgM. IgG and IgA can be further subdivided into subclasses, IgG1, IgG2, IgG3 and IgG4; and IgA1 and IgA2. Species variants exist with mouse and rat having at least IgG2a, IgG2b.

The more conserved portions of the variable region are called Framework regions (FR). The 5 variable domains of intact heavy and light chains each comprise four FR connected by three CDRs. The CDRs in each chain are held together in close proximity by the FR regions and with the CDRs from the other chain contribute to the formation of the antigen binding site of antibodies.

The constant regions are not directly involved in the binding of the antibody to the antigen 10 but exhibit various effector functions such as participation in antibody dependent cell-mediated cytotoxicity (ADCC), phagocytosis via binding to Fc<sub>y</sub> receptor, half-life/clearance rate via neonatal Fc receptor (FcRn) and complement activation via the C1q component, leading to the chemotactic, opsonic and, potentially in the case of a viable cellular antigen 15 target, cytolytic actions of complement. Human antibodies of the IgG1 class are the most potent in activating the complement system and are therefore the desirable isotype for the therapeutic application of the antibodies of the present invention.

The human IgG2 constant region has been reported to essentially lack the ability to activate complement by the classical pathway or to mediate antibody-dependent cellular cytotoxicity. The IgG4 constant region has been reported to lack the ability to activate 20 complement by the classical pathway and mediates antibody-dependent cellular cytotoxicity only weakly. Antibodies essentially lacking these effector functions may be termed 'non-lytic' antibodies.

#### Human antibodies

Human antibodies may be produced by a number of methods known to those of skill in the 25 art. Human antibodies can be made by the hybridoma method using human myeloma or mouse-human heteromyeloma cells lines see Kozbor (1984) *J. Immunol* 133, 3001, and Brodeur, *Monoclonal Antibody Production Techniques and Applications*, 51-63 (Marcel Dekker Inc, 1987). Alternative methods include the use of phage libraries or transgenic mice both of which utilize human variable region repertoires (see Winter (1994) *Annu. Rev. 30 Immunol* 12: 433-455; Green (1999) *J. Immunol. Methods* 231: 11-23).

Several strains of transgenic mice are now available wherein their mouse immunoglobulin loci has been replaced with human immunoglobulin gene segments (see Tomizuka (2000) PNAS 97: 722-727; Fishwild (1996) Nature Biotechnol. 14: 845-851; Mendez (1997) Nature Genetics, 15: 146-156). Upon antigen challenge such mice are capable of producing a 5 repertoire of human antibodies from which antibodies of interest can be selected.

Phage display technology can be used to produce human antigen binding proteins (and fragments thereof), see McCafferty (1990) Nature 348: 552-553 and Griffiths et al. (1994) EMBO 13: 3245-3260.

The technique of affinity maturation (Marks Bio/technol (1992) 10: 779-783) may be used to 10 improve binding affinity wherein the affinity of the primary human antibody is improved by sequentially replacing the heavy (H) and light (L) chain variable regions with naturally occurring variants and selecting on the basis of improved binding affinities. Variants of this technique such as "epitope imprinting" are now also available, see for example WO 93/06213; Waterhouse (1993) Nucl. Acids Res. 21: 2265-2266.

15 Chimeric and Humanised Antibodies

Chimeric antibodies are typically produced using recombinant DNA methods. DNA encoding the antibodies (e.g. cDNA) is isolated and sequenced using conventional procedures (e.g. by using oligonucleotide probes that are capable of binding specifically to genes encoding the H and L chains of the antibody. Hybridoma cells serve as a typical source of such DNA. Once 20 isolated, the DNA is placed into expression vectors which are then transfected into host cells such as E. coli, COS cells, CHO cells or myeloma cells that do not otherwise produce immunoglobulin protein to obtain synthesis of the antibody. The DNA may be modified by substituting the coding sequence for human L and H chains for the corresponding non-human (e.g. murine) H and L constant regions, see for example Morrison (1984) PNAS 81: 25 6851.

A large decrease in immunogenicity can be achieved by grafting only the CDRs of non-human (e.g. murine) antibodies ("donor" antibodies) onto human framework ("acceptor framework") and constant regions to generate humanised antibodies (see Jones et al. (1986) Nature 321: 522-525; and Verhoeyen et al. (1988) Science 239: 1534-1536). 30 However, CDR grafting per se may not result in the complete retention of antigen-binding

properties and it is frequently found that some framework residues (sometimes referred to as "back mutations") of the donor antibody need to be preserved in the humanised molecule if significant antigen-binding affinity is to be recovered (see Queen et al. (1989) PNAS 86: 10,029-10,033; Co et al. (1991) Nature 351: 501-502). In this case, human variable regions showing the greatest sequence homology to the non-human donor antibody are chosen from a database in order to provide the human framework (FR). The selection of human FRs can be made either from human consensus or individual human antibodies. Where necessary, key residues from the donor antibody can be substituted into the human acceptor framework to preserve CDR conformations. Computer modelling of the antibody maybe used to help identify such structurally important residues, see WO 99/48523.

Alternatively, humanisation maybe achieved by a process of "veneering". A statistical analysis of unique human and murine immunoglobulin heavy and light chain variable regions revealed that the precise patterns of exposed residues are different in human and murine antibodies, and most individual surface positions have a strong preference for a small number of different residues (see Padlan et al. (1991) Mol. Immunol. 28: 489-498; and Pedersen et al. (1994) J. Mol. Biol. 235: 959-973). Therefore it is possible to reduce the immunogenicity of a non-human Fv by replacing exposed residues in its framework regions that differ from those usually found in human antibodies. Because protein antigenicity may be correlated with surface accessibility, replacement of the surface residues may be sufficient to render the mouse variable region "invisible" to the human immune system (see also Mark et al. (1994) in Handbook of Experimental Pharmacology Vol. 113: The pharmacology of Monoclonal Antibodies, Springer-Verlag, 105-134). This procedure of humanisation is referred to as "veneering" because only the surface of the antibody is altered, the supporting residues remain undisturbed. Further alternative approaches include that set out in WO04/006955 and the procedure of Humaneering<sup>TM</sup> (Kalobios) which makes use of bacterial expression systems and produces antibodies that are close to human germline in sequence (Alfenito-M Advancing Protein Therapeutics January 2007, San Diego, California).

#### Bispecific antigen binding proteins

A bispecific antigen binding protein is an antigen binding protein having binding specificities for at least two different epitopes. Methods of making such antigen binding proteins are

known in the art. Traditionally, the recombinant production of bispecific antigen binding proteins is based on the co-expression of two immunoglobulin H chain-L chain pairs, where the two H chains have different binding specificities, see Millstein et al. (1983) *Nature* 305: 537-539; WO 93/08829; and Traunecker et al. (1991) *EMBO* 10: 3655-3659. Because of the 5 random assortment of H and L chains, a potential mixture of ten different antibody structures are produced of which only one has the desired binding specificity. An alternative approach involves fusing the variable domains with the desired binding specificities to heavy chain constant region comprising at least part of the hinge region, CH2 and CH3 regions. The CH1 region containing the site necessary for light chain binding may be present in at least 10 one of the fusions. DNA encoding these fusions, and if desired the L chain are inserted into separate expression vectors and are then co-transfected into a suitable host organism. It is possible though to insert the coding sequences for two or all three chains into one expression vector. In one approach, the bispecific antibody is composed of a H chain with a first binding specificity in one arm and a H-L chain pair, providing a second binding 15 specificity in the other arm, see WO 94/04690. Also see Suresh et al. (1986) *Methods in Enzymology* 121: 210.

#### Antigen Binding Fragments

Fragments lacking the constant region lack the ability to activate complement by the classical pathway or to mediate antibody-dependent cellular cytotoxicity. Traditionally such 20 fragments are produced by the proteolytic digestion of intact antibodies by e.g. papain digestion (see for example, WO 94/29348) but may be produced directly from recombinantly transformed host cells. For the production of ScFv, see Bird et al. (1988) *Science* 242: 423-426. In addition, antigen binding fragments may be produced using a variety of engineering techniques as described below.

25 Fv fragments appear to have lower interaction energy of their two chains than Fab fragments. To stabilise the association of the VH and VL domains, they have been linked with peptides (Bird et al. (1988) *Science* 242: 423-426; Huston et al. (1988) *PNAS* 85(16): 5879-5883), disulphide bridges (Glockshuber et al. (1990) *Biochemistry* 29: 1362-1367) and "knob in hole" mutations (Zhu et al. (1997) *Protein Sci.*, 6: 781-788). ScFv fragments can be 30 produced by methods well known to those skilled in the art, see Whitlow et al. (1991) *Methods Companion Methods Enzymol*, 2: 97-105 and Huston et al. (1993) *Int. Rev.*

Immunol 10: 195-217. ScFv may be produced in bacterial cells such as *E. coli* or in eukaryotic cells. One disadvantage of ScFv is the monovalency of the product, which precludes an increased avidity due to polyvalent binding, and their short half-life. Attempts to overcome these problems include bivalent (ScFv')<sup>2</sup> produced from ScFv containing an additional C-terminal cysteine by chemical coupling (Adams et al. (1993) Can. Res 53: 4026-4034; and McCartney et al. (1995) Protein Eng. 8: 301-314) or by spontaneous site-specific dimerisation of ScFv containing an unpaired C-terminal cysteine residue (see Kipriyanov et al. (1995) Cell. Biophys 26: 187-204). Alternatively, ScFv can be forced to form trimers by shortening the peptide linker to 3 to 12 residues to form "diabodies", see Holliger et al. (1993) PNAS 90: 6444-6448. Reducing the linker still further can result in ScFv trimers ("triabodies", see Kortt et al. (1997) Protein Eng 10: 423-433) and tetramers ("tetrabodies", see Le Gall et al. (1999) FEBS Lett, 453: 164-168). Construction of bivalent ScFv molecules can also be achieved by genetic fusion with protein dimerising motifs to form "miniantibodies" (see Pack et al. (1992) Biochemistry 31: 1579-1584) and "minibodies" (see 15 Hu et al. (1996) Cancer Res. 56: 3055-3061). ScFv-Sc-Fv tandems ((ScFv)<sup>2</sup>) may also be produced by linking two ScFv units by a third peptide linker, see Kurucz et al. (1995) J. Immunol. 154: 4576-4582. Bispecific diabodies can be produced through the non-covalent association of two single chain fusion products consisting of VH domain from one antibody connected by a short linker to the VL domain of another antibody, see Kipriyanov et al. 20 (1998) Int. J. Can 77: 763-772. The stability of such bispecific diabodies can be enhanced by the introduction of disulphide bridges or "knob in hole" mutations as described supra or by the formation of single chain diabodies (ScDb) wherein two hybrid ScFv fragments are connected through a peptide linker see Kontermann et al. (1999) J. Immunol. Methods 226:179-188. Tetravalent bispecific molecules are available by e.g. fusing a ScFv fragment to 25 the CH3 domain of an IgG molecule or to a Fab fragment through the hinge region, see Coloma et al. (1997) Nature Biotechnol. 15: 159-163. Alternatively, tetravalent bispecific molecules have been created by the fusion of bispecific single chain diabodies (see Alt et al. (1999) FEBS Lett 454: 90-94. Smaller tetravalent bispecific molecules can also be formed by 30 the dimerization of either ScFv-ScFv tandems with a linker containing a helix-loop-helix motif (DiBi miniantibodies, see Muller et al. (1998) FEBS Lett 432: 45-49) or a single chain molecule comprising four antibody variable domains (VH and VL) in an orientation preventing intramolecular pairing (tandem diabody, see Kipriyanov et al. (1999) J. Mol. Biol.

293: 41-56). Bispecific F(ab')2 fragments can be created by chemical coupling of Fab' fragments or by heterodimerization through leucine zippers (see Shalaby et al. (1992) J. Exp. Med. 175: 217-225; and Kostelny et al. (1992), J. Immunol. 148: 1547-1553). Also available are isolated VH and VL domains (Domantis plc), see US 6,248,516; US 6,291,158; and US 5 6,172,197.

#### Heteroconjugate antibodies

Heteroconjugate antibodies are composed of two covalently joined antibodies formed using any convenient cross-linking methods. See, for example, US 4,676,980.

#### Other Modifications

10 The antigen binding proteins of the present invention may comprise other modifications to enhance or change their effector functions. The interaction between the Fc region of an antibody and various Fc receptors (FcγR) is believed to mediate the effector functions of the antibody which include antibody-dependent cellular cytotoxicity (ADCC), fixation of complement, phagocytosis and half-life/clearance of the antibody. Various modifications to  
15 the Fc region of antibodies may be carried out depending on the desired property. For example, specific mutations in the Fc region to render an otherwise lytic antibody, non-lytic are detailed in EP 0629240 and EP 0307434 or one may incorporate a salvage receptor binding epitope into the antibody to increase serum half life see US 5,739,277. Human Fcγ receptors include FcγR (I), FcγRIIa, FcγRIIb, FcγRIIIa and neonatal FcRn. Shields et al. (2001) J.  
20 Biol. Chem 276: 6591-6604 demonstrated that a common set of IgG1 residues is involved in binding all FcγRs, while FcγRII and FcγRIII utilize distinct sites outside of this common set. One group of IgG1 residues reduced binding to all FcγRs when altered to alanine: Pro-238, Asp-265, Asp-270, Asn-297 and Pro-239. All are in the IgG CH2 domain and clustered near the hinge joining CH1 and CH2. While FcγRI utilizes only the common set of IgG1 residues for  
25 binding, FcγRII and FcγRIII interact with distinct residues in addition to the common set. Alteration of some residues reduced binding only to FcγRII (e.g. Arg-292) or FcγRIII (e.g. Glu-293). Some variants showed improved binding to FcγRII or FcγRIII but did not affect binding to the other receptor (e.g. Ser-267Ala improved binding to FcγRII but binding to FcγRIII was unaffected). Other variants exhibited improved binding to FcγRII or FcγRIII with reduction in  
30 binding to the other receptor (e.g. Ser-298Ala improved binding to FcγRIII and reduced binding to FcγRII). For FcγRIIIa, the best binding IgG1 variants had combined alanine

substitutions at Ser-298, Glu-333 and Lys-334. The neonatal FcRn receptor is believed to be involved in both antibody clearance and the transcytosis across tissues (see Junghans (1997) Immunol. Res 16: 29-57; and Ghetie et al. (2000) Annu. Rev. Immunol. 18: 739-766). Human IgG1 residues determined to interact directly with human FcRn includes Ile253, Ser254, 5 Lys288, Thr307, Gln311, Asn434 and His435. Substitutions at any of the positions described in this section may enable increased serum half-life and/or altered effector properties of the antibodies.

Other modifications include glycosylation variants of the antibodies. Glycosylation of antibodies at conserved positions in their constant regions is known to have a profound 10 effect on antibody function, particularly effector functioning such as those described above, see for example, Boyd et al. (1996) Mol. Immunol. 32: 1311-1318. Glycosylation variants of the antibodies or antigen binding fragments thereof wherein one or more carbohydrate moiety is added, substituted, deleted or modified are contemplated. Introduction of an asparagine-X-serine or asparagine-X-threonine motif creates a potential site for enzymatic 15 attachment of carbohydrate moieties and may therefore be used to manipulate the glycosylation of an antibody. In Raju et al. (2001) Biochemistry 40: 8868-8876 the terminal sialylation of a TNFR-IgG immunoadhesin was increased through a process of regalactosylation and/or resialylation using beta-1, 4-galactosyltransferase and/or alpha, 2,3 sialyltransferase. Increasing the terminal sialylation is believed to increase the half-life of 20 the immunoglobulin. Antibodies, in common with most glycoproteins, are typically produced as a mixture of glycoforms. This mixture is particularly apparent when antibodies are produced in eukaryotic, particularly mammalian cells. A variety of methods have been developed to manufacture defined glycoforms, see Zhang et al. (2004) Science 303: 371: Sears et al. (2001) Science 291: 2344; Wacker et al. (2002) Science 298: 1790; Davis et al. 25 (2002) Chem. Rev. 102: 579; Hang et al. (2001) Acc. Chem. Res 34: 727. The antibodies (for example of the IgG isotype, e.g. IgG1) as herein described may comprise a defined number (e.g. 7 or less, for example 5 or less, such as two or a single) of glycoform(s).

The antibodies may be coupled to a non-proteinaceous polymer such as polyethylene glycol (PEG), polypropylene glycol or polyoxyalkylene. Conjugation of proteins to PEG is an 30 established technique for increasing half-life of proteins, as well as reducing antigenicity and immunogenicity of proteins. The use of PEGylation with different molecular weights and

styles (linear or branched) has been investigated with intact antibodies as well as Fab' fragments, see Koumenis et al. (2000) *Int. J. Pharmaceut.* 198: 83-95.

### Production Methods

- 5    Antigen binding proteins may be produced in transgenic organisms such as goats (see Pollock et al. (1999) *J. Immunol. Methods* 231: 147-157), chickens (see Morrow (2000) *Genet. Eng. News* 20: 1-55, mice (see Pollock et al.) or plants (see Doran (2000) *Curr. Opinion Biotechnol.* 11: 199-204; Ma (1998) *Nat. Med.* 4: 601-606; Baez et al. (2000) *BioPharm* 13: 50-54; Stoger et al. (2000) *Plant Mol. Biol.* 42: 583-590).
- 10    Antigen binding proteins may also be produced by chemical synthesis. However, antigen binding proteins are typically produced using recombinant cell culturing technology well known to those skilled in the art. A polynucleotide encoding the antigen binding protein is isolated and inserted into a replicable vector such as a plasmid for further cloning (amplification) or expression. One expression system is a glutamate synthetase system (such 15    as sold by Lonza Biologics), particularly where the host cell is CHO or NS0. Polynucleotide encoding the antigen binding protein is readily isolated and sequenced using conventional procedures (e.g. oligonucleotide probes). Vectors that may be used include plasmid, virus, phage, transposons, minichromosomes of which plasmids are typically used. Generally such vectors further include a signal sequence, origin of replication, one or more marker genes, 20    an enhancer element, a promoter and transcription termination sequences operably linked to the antigen binding protein polynucleotide so as to facilitate expression. Polynucleotide encoding the light and heavy chains may be inserted into separate vectors and introduced (for example by transformation, transfection, electroporation or transduction) into the same host cell concurrently or sequentially or, if desired, both the heavy chain and light chain can 25    be inserted into the same vector prior to said introduction.

Codon optimisation may be used with the intent that the total level of protein produced by the host cell is greater when transfected with the codon-optimised gene in comparison with the level when transfected with the sequence. Several methods have been published (Nakamura et al. (1996) *Nucleic Acids Research* 24: 214-215; W098/34640; W097/11086).

- 30    Due to the redundancy of the genetic code, alternative polynucleotides to those disclosed herein (particularly those codon optimised for expression in a given host cell) may also

encode the antigen binding proteins described herein. The codon usage of the antigen binding protein of this invention therefore can be modified to accommodate codon bias of the host cell such to augment transcript and/or product yield (e.g. Hoekema et al Mol Cell Biol 1987 7(8): 2914-24). The choice of codons may be based upon suitable compatibility 5 with the host cell used for expression.

#### Signal sequences

Antigen binding proteins may be produced as a fusion protein with a heterologous signal sequence having a specific cleavage site at the N-terminus of the mature protein. The signal sequence should be recognised and processed by the host cell. For prokaryotic host cells, 10 the signal sequence may be for example an alkaline phosphatase, penicillinase, or heat stable enterotoxin II leaders. For yeast secretion the signal sequences may be for example a yeast invertase leader,  $\alpha$  factor leader or acid phosphatase leaders see e.g. WO90/13646. In mammalian cell systems, viral secretory leaders such as herpes simplex gD signal and a native immunoglobulin signal sequence may be suitable. Typically the signal sequence is 15 ligated in reading frame to DNA encoding the antigen binding protein. A murine signal sequence such as that shown in SEQ ID NO: 79 may be used.

#### Origin of replication

Origin of replications are well known in the art with pBR322 suitable for most gram-negative bacteria,  $2\mu$  plasmid for most yeast and various viral origins such as SV40, polyoma, 20 adenovirus, VSV or BPV for most mammalian cells. Generally the origin of replication component is not needed for mammalian expression vectors but the SV40 may be used since it contains the early promoter.

#### Selection marker

Typical selection genes encode proteins that (a) confer resistance to antibiotics or other 25 toxins e.g. ampicillin, neomycin, methotrexate or tetracycline or (b) complement auxotrophic deficiencies or supply nutrients not available in the complex media or (c) combinations of both. The selection scheme may involve arresting growth of the host cell. Cells, which have been successfully transformed with the genes encoding the antigen binding protein, survive due to e.g. drug resistance conferred by the co-delivered selection 30 marker. One example is the DHFR selection marker wherein transformants are cultured in

the presence of methotrexate. Cells can be cultured in the presence of increasing amounts of methotrexate to amplify the copy number of the exogenous gene of interest. CHO cells are a particularly useful cell line for the DHFR selection. A further example is the glutamate synthetase expression system (Lonza Biologics). An example of a selection gene for use in 5 yeast is the trp1 gene, see Stinchcomb et al. (1979) *Nature* 282: 38.

#### Promoters

Suitable promoters for expressing antigen binding proteins are operably linked to DNA/polynucleotide encoding the antigen binding protein. Promoters for prokaryotic hosts include phoA promoter, beta-lactamase and lactose promoter systems, alkaline 10 phosphatase, tryptophan and hybrid promoters such as Tac. Promoters suitable for expression in yeast cells include 3-phosphoglycerate kinase or other glycolytic enzymes e.g. enolase, glyceraldehyde 3 phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose 6 phosphate isomerase, 3-phosphoglycerate mutase and 15 glucokinase. Inducible yeast promoters include alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, metallothionein and enzymes responsible for nitrogen metabolism or maltose/galactose utilization.

Promoters for expression in mammalian cell systems include viral promoters such as polyoma, fowlpox and adenoviruses (e.g. adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus (in particular the immediate early gene promoter), 20 retrovirus, hepatitis B virus, actin, rous sarcoma virus (RSV) promoter and the early or late Simian virus 40. Of course the choice of promoter is based upon suitable compatibility with the host cell used for expression. A first plasmid may comprise a RSV and/or SV40 and/or CMV promoter, DNA encoding light chain variable region (VL), κC region together with neomycin and ampicillin resistance selection markers and a second plasmid comprising a 25 RSV or SV40 promoter, DNA encoding the heavy chain variable region (VH), DNA encoding the γ1 constant region, DHFR and ampicillin resistance markers.

#### Enhancer element

Where appropriate, e.g. for expression in higher eukaryotes, an enhancer element operably linked to the promoter element in a vector may be used. Mammalian enhancer sequences 30 include enhancer elements from globin, elastase, albumin, fetoprotein and insulin.

Alternatively, one may use an enhancer element from a eukaryotic cell virus such as SV40 enhancer (at bp100-270), cytomegalovirus early promoter enhancer, polyclonal enhancer, baculoviral enhancer or murine IgG2a locus (see WO04/009823). The enhancer may be located on the vector at a site upstream to the promoter. Alternatively, the enhancer may 5 be located elsewhere, for example within the untranslated region or downstream of the polyadenylation signal. The choice and positioning of enhancer may be based upon suitable compatibility with the host cell used for expression.

#### Polyadenylation/termination

In eukaryotic systems, polyadenylation signals are operably linked to DNA/polynucleotide 10 encoding the antigen binding protein. Such signals are typically placed 3' of the open reading frame. In mammalian systems, non-limiting examples include signals derived from growth hormones, elongation factor-1 alpha and viral (e.g. SV40) genes or retroviral long terminal repeats. In yeast systems non-limiting examples of polyadenylation/termination signals include those derived from the phosphoglycerate kinase (PGK) and the alcohol 15 dehydrogenase 1 (ADH) genes. In prokaryotic systems, polyadenylation signals are typically not required and it is instead usual to employ shorter and more defined terminator sequences. The choice of polyadenylation/termination sequences may be based upon suitable compatibility with the host cell used for expression.

#### Other methods/elements for enhanced yields

20 In addition to the above, other features that can be employed to enhance yields include chromatin remodelling elements, introns and host-cell specific codon modification.

#### Host cells

Suitable host cells for cloning or expressing vectors encoding antigen binding proteins are 25 prokaryotic, yeast or higher eukaryotic cells. Suitable prokaryotic cells include eubacteria e.g. enterobacteriaceae such as Escherichia e.g. E. coli (for example ATCC 31,446; 31,537; 27,325), Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella e.g. Salmonella typhimurium, Serratia e.g. Serratia marcescens and Shigella as well as Bacilli such as B. subtilis and B. licheniformis (see DD 266 710), Pseudomonas such as P. aeruginosa and Streptomyces. Of the yeast host cells, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces 30 (e.g. ATCC 16,045; 12,424; 24178; 56,500), yarrowia (EP402, 226), Pichia pastoris (EP 183

070, see also Peng et al. (2004) *J. Biotechnol.* 108: 185-192), *Candida*, *Trichoderma reesia* (EP 244 234), *Penicillin*, *Tolypocladium* and *Aspergillus* hosts such as *A. nidulans* and *A. niger* are also contemplated.

Higher eukaryotic host cells include mammalian cells such as COS-1 (ATCC No.CRL 1650)

5 COS-7 (ATCC CRL 1651), human embryonic kidney line 293, baby hamster kidney cells (BHK) (ATCC CRL.1632), BHK570 (ATCC NO: CRL 10314), 293 (ATCC NO.CRL 1573), Chinese hamster ovary cells CHO (e.g. CHO-K1, ATCC NO: CCL 61, DHFR-CHO cell line such as DG44 (see Urlaub et al. (1986) *Somatic Cell Mol. Genet.* 12: 555-556), particularly those CHO cell lines adapted for suspension culture, mouse sertoli cells, monkey kidney cells, African green 10 monkey kidney cells (ATCC CRL-1587), HELA cells, canine kidney cells (ATCC CCL 34), human lung cells (ATCC CCL 75), Hep G2 and myeloma or lymphoma cells e.g. NS0 (see US 5,807,715), Sp2/0, Y0.

Such host cells may also be further engineered or adapted to modify quality, function and/or yield of the antigen binding protein. Non-limiting examples include expression of 15 specific modifying (e.g. glycosylation) enzymes and protein folding chaperones.

#### Cell Culturing Methods

Host cells transformed with vectors encoding antigen binding proteins may be cultured by any method known to those skilled in the art. Host cells may be cultured in spinner flasks, roller bottles or hollow fibre systems but for large scale production that stirred tank reactors 20 are used particularly for suspension cultures. The stirred tankers may be adapted for aeration using e.g. spargers, baffles or low shear impellers. For bubble columns and airlift reactors direct aeration with air or oxygen bubbles maybe used. Where the host cells are cultured in a serum free culture media, the media is supplemented with a cell protective agent such as pluronic F-68 to help prevent cell damage as a result of the aeration process.

25 Depending on the host cell characteristics, either microcarriers maybe used as growth substrates for anchorage dependent cell lines or the cells may be adapted to suspension culture (which is typical). The culturing of host cells, particularly invertebrate host cells may utilise a variety of operational modes such as fed-batch, repeated batch processing (see Drapeau et al. (1994) *Cytotechnology* 15: 103-109), extended batch process or perfusion 30 culture. Although recombinantly transformed mammalian host cells may be cultured in serum-containing media such as fetal calf serum (FCS), such host cells may be cultured in

synthetic serum-free media such as disclosed in Keen et al. (1995) *Cytotechnology* 17: 153-163, or commercially available media such as ProCHO-CDM or UltraCHO™ (Cambrex NJ, USA), supplemented where necessary with an energy source such as glucose and synthetic growth factors such as recombinant insulin. The serum-free culturing of host cells may 5 require that those cells are adapted to grow in serum free conditions. One adaptation approach is to culture such host cells in serum containing media and repeatedly exchange 80% of the culture medium for the serum-free media so that the host cells learn to adapt in serum free conditions (see e.g. Scharfenberg et al. (1995) in *Animal Cell Technology: Developments towards the 21st century* (Beuvery et al. eds, 619-623, Kluwer Academic 10 publishers)).

Antigen binding proteins secreted into the media may be recovered and purified using a variety of techniques to provide a degree of purification suitable for the intended use. For example the use of antigen binding proteins for the treatment of human patients typically mandates at least 95% purity, more typically 98% or 99% or greater purity (compared to the 15 crude culture medium). Cell debris from the culture media is typically removed using centrifugation followed by a clarification step of the supernatant using e.g. microfiltration, ultrafiltration and/or depth filtration. A variety of other techniques such as dialysis and gel electrophoresis and chromatographic techniques such as hydroxyapatite (HA), affinity chromatography (optionally involving an affinity tagging system such as polyhistidine) 20 and/or hydrophobic interaction chromatography (HIC, see US 5, 429,746) are available. The antibodies, following various clarification steps, can be captured using Protein A or G affinity chromatography. Further chromatography steps can follow such as ion exchange and/or HA chromatography, anion or cation exchange, size exclusion chromatography and ammonium sulphate precipitation. Various virus removal steps may also be employed (e.g. 25 nanofiltration using e.g. a DV-20 filter). Following these various steps, a purified (for example a monoclonal) preparation comprising at least 75mg/ml or greater, or 100mg/ml or greater, of the antigen binding protein is provided. Such preparations are substantially free of aggregated forms of antigen binding proteins.

Bacterial systems may be used for the expression of antigen binding fragments. Such 30 fragments can be localised intracellularly, within the periplasm or secreted extracellularly. Insoluble proteins can be extracted and refolded to form active proteins according to

methods known to those skilled in the art, see Sanchez et al. (1999) *J. Biotechnol.* 72: 13-20; and Cupit et al. (1999) *Lett Appl Microbiol* 29: 273-277.

Deamidation is a chemical reaction in which an amide functional group is removed. In biochemistry, the reaction is important in the degradation of proteins because it damages the amide-containing side chains of the amino acids asparagine and glutamine. Asparagine is converted to a mixture of isoaspartate and aspartate. Deamidation of glutamine residues occurs at a much lower rate. Deamidation reactions are believed to be one of the factors that can limit the useful lifetime of a protein, they are also one of the most common post-translational modifications occurring during the manufacture of therapeutic proteins. For example, a reduction or loss of in vitro or in vivo biological activity has been reported for recombinant human DNase and recombinant soluble CD4, whereas other recombinant proteins appear to be unaffected.

### **Pharmaceutical Compositions**

Purified preparations of an antigen binding protein as described herein may be incorporated into pharmaceutical compositions for use in the treatment of the human diseases, disorders and conditions described herein. The terms diseases, disorders and conditions are used interchangeably. The pharmaceutical composition can be used in the treatment of any diseases where amyloid deposits are present in the tissues and contribute to structural and functional damage leading to clinical illness. SAP is always present in all amyloid deposits *in vivo* and the pharmaceutical composition comprising a therapeutically effective amount of the antigen binding protein described herein can be used in the treatment of diseases responsive to clearance of amyloid deposits from the tissues.

The pharmaceutical preparation may comprise an antigen binding protein in combination with a pharmaceutically acceptable carrier. The antigen binding protein may be administered alone, or as part of a pharmaceutical composition.

Typically such compositions comprise a pharmaceutically acceptable carrier as known and called for by acceptable pharmaceutical practice, see e.g. Remingtons Pharmaceutical Sciences, 16th edition (1980) Mack Publishing Co. Examples of such carriers include

sterilised carriers such as saline, Ringers solution or dextrose solution, optionally buffered with suitable buffers to a pH within a range of 5 to 8.

Pharmaceutical compositions may be administered by injection or continuous infusion (e.g. intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular or intraportal). Such 5 compositions are suitably free of visible particulate matter. Pharmaceutical compositions may also be administered orally, specifically those containing CPHPC.

Pharmaceutical compositions may comprise between 1mg to 10g of antigen binding protein, for example between 5 mg and 1 g of antigen binding protein. Alternatively, the composition may comprise between 5 mg and 500 mg, for example between 5 mg and 50 10 mg.

Methods for the preparation of such pharmaceutical compositions are well known to those skilled in the art. Pharmaceutical compositions may comprise between 1 mg to 10 g of antigen binding protein in unit dosage form, optionally together with instructions for use. Pharmaceutical compositions may be lyophilised (freeze dried) for reconstitution prior to 15 administration according to methods well known or apparent to those skilled in the art. Where antibodies have an IgG1 isotype, a chelator of copper, such as citrate (e.g. sodium citrate) or EDTA or histidine, may be added to the pharmaceutical composition to reduce the degree of copper-mediated degradation of antibodies of this isotype, see EP0612251. Pharmaceutical compositions may also comprise a solubiliser such as arginine base, a 20 detergent/anti-aggregation agent such as polysorbate 80, and an inert gas such as nitrogen to replace vial headspace oxygen.

Effective doses and treatment regimes for administering the antigen binding protein are generally determined empirically and may be dependent on factors such as the age, weight and health status of the patient and disease or disorder to be treated. Such factors are 25 within the purview of the attending physician. Guidance in selecting appropriate doses may be found in e.g. Smith et al (1977) Antibodies in human diagnosis and therapy, Raven Press, New York.

The dosage of antigen binding protein administered to a subject is generally between 1 30  $\mu\text{g}/\text{kg}$  to 150  $\mu\text{g}/\text{kg}$ , between 0.1 mg/kg and 100 mg/kg, between 0.5 mg/kg and 50 mg/kg, between 1 and 25 mg/kg or between 1 and 10 mg/kg of the subject's body weight. For

example, the dose may be 10 mg/kg, 30 mg/kg, or 60 mg/kg. The antigen binding protein may be administered parenterally, for example subcutaneously, intravenously or intramuscularly.

The SAP-depleting compound may be administered at a dose of between 0.1 mg/kg and 2 mg/kg, depending on its activity. The SAP-depleting compound may be administered as a fixed dose, independent of a dose per subject weight ratio. The SAP-depleting compound may be administered in one or more separate, simultaneous or sequential parenteral doses of 100 mg or less, of 50 mg or less, 25 mg or less, or 10 mg or less.

If desired, the effective daily dose of a therapeutic composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.

The antigen binding protein may be administered in a single large dose or in smaller repeated doses.

The administration of a dose may be by slow continuous infusion over a period of from 2 to 24 hours, such as from 2 to 12 hours, or from 2 to 6 hours. This may result in reduced toxic side effects.

The administration of a dose may be repeated one or more times as necessary, for example, three times daily, once every day, once every 2 days, once a week, once a fortnight, once a month, once every 3 months, once every 6 months, or once every 12 months. The antigen binding proteins may be administered by maintenance therapy, for example once a week for a period of 6 months or more. The antigen binding proteins may be administered by intermittent therapy, for example for a period of 3 to 6 months and then no dose for 3 to 6 months, followed by administration of antigen binding proteins again for 3 to 6 months, and so on in a cycle.

For example, the dose may be administered subcutaneously, once every 14 or 28 days in the form of multiple sub-doses on each day of administration.

The antigen binding protein may be administered to the subject in such a way as to target therapy to a particular site. For example, the antigen binding protein may be injected locally into a circumscribed local amyloid mass in the tissues, or infused into the blood supply to an amyloidotic organ.

The antigen binding protein must be used in combination with one or more other therapeutically active agents, specifically SAP depleting compounds, for the treatment of the diseases described herein. Effective depletion of SAP from the circulation must be achieved before administration of the SAP binding protein in order for the latter to be given both safely and

5 effectively.

The SAP depleting compound is administered first so that almost all of the circulating SAP is cleared. Since this leaves substantial amounts of SAP associated with the amyloid deposits in the tissues the sequential administration of an anti-SAP antigen binding protein enables the localisation and specific binding to the amyloid deposits to promote their rapid and

10 extensive regression. Suitably, the anti-SAP antigen binding protein may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20 or 25 or more days after starting the treatment(s) with the SAP depleting compound.

The sequential administration may involve two or more sequential treatments with SAP depleting compound followed by two or more sequential treatments with the anti-SAP

15 antigen binding protein.

The sequential administration may involve one treatment with SAP depleting compound followed by one sequential treatment with the anti-SAP antigen binding protein, which is then repeated one or more times.

The sequential/subsequent dose may be an amount that is more than the initial/previous

20 dose or less than the initial/previous dose.

The administration of an initial dose of SAP-depleting compound protein may be followed by the administration of one or more sequential (e.g. subsequent) doses of SAP depleting compound and/or the anti-SAP antigen binding protein, and wherein said one or more sequential doses may be in an amount that is approximately the same or less than the initial

25 dose.

After initial depletion of circulating SAP, the administration of further doses of SAP depleting compound and the first dose of anti-SAP antigen binding protein may be followed by the administration of one or more sequential (e.g. subsequent) doses, and wherein at least one of the subsequent doses is in an amount that is more than the initial dose.

Accordingly, the administration may use a pre-determined or routine schedule for administration, thereby resulting in a predetermined designated period of time between dose administrations. The schedule may encompass periods of time which are identical or which differ in length, as long as the schedule is predetermined. Any particular combination

5 would be covered by the schedule as long as it is determined ahead of time that the appropriate schedule involves administration on a certain day.

The pharmaceutical composition may comprise a kit of parts of the antigen binding protein together with other medicaments, optionally with instructions for use. For convenience, the kit may comprise the reagents in predetermined amounts with instructions for use.

10 The terms "individual", "subject" and "patient" are used herein interchangeably. The subject may be a primate (e.g. a marmoset or monkey). The subject is typically a human.

Treatment can be therapeutic, prophylactic or preventative. The subject will be one who is in need thereof. Those in need of treatment may include individuals already suffering from a particular medical disease in addition to those who may develop the disease in the future.

15 Thus, the SAP depleting compound followed by the SAP antigen binding protein described herein can be used for prophylactic or preventative treatment. In this case, the sequential treatments described herein are administered to an individual in order to prevent or delay the onset of one or more aspects or symptoms of the disease. The subject can be asymptomatic or may have a genetic predisposition to the disease, as amyloid deposits are

20 known to be present in the tissues and to accumulate for periods of time before they cause sufficient damage to produce clinical symptoms. Such sub-clinical amyloid deposition can be detected by histological examination of tissue biopsies or by non-invasive imaging procedures, including radiolabelled SAP scintigraphy, echocardiography and cardiac magnetic resonance imaging. After first depleting circulating SAP, a prophylactically

25 effective amount of the antigen binding protein is administered to such an individual. A prophylactically effective amount is an amount which prevents or delays the onset of one or more aspects or symptoms of a disease described herein.

The antigen binding protein described herein may also be used in methods of therapy. The term "therapy" encompasses alleviation, reduction, or prevention of at least one aspect or

30 symptom of a disease. For example, the antigen binding protein described herein may be

used to ameliorate or reduce one or more aspects or symptoms of a disease described herein.

The antigen binding protein described herein is used in an effective amount for therapeutic, prophylactic or preventative treatment. A therapeutically effective amount of the antigen binding protein described herein is an amount effective to ameliorate or reduce one or more aspects or symptoms of the disease. The antigen binding protein described herein may also be used to treat, prevent, or cure the disease described herein.

The antigen binding protein described herein can have a generally beneficial effect on the subject's health, for example it can increase the subject's expected longevity.

The antigen binding protein described herein need not affect a complete cure, or eradicate every symptom or manifestation of the disease to constitute a viable therapeutic treatment. As is recognised in the pertinent field, drugs employed as therapeutic agents may reduce the severity of a given disease state, but need not abolish every manifestation of the disease to be regarded as useful therapeutic agents. Similarly, a prophylactically administered treatment need not be completely effective in preventing the onset of a disease in order to constitute a viable prophylactic agent. Simply reducing the impact of a disease (for example, by reducing the number or severity of its symptoms, or by increasing the effectiveness of another treatment, or by producing another beneficial effect), or reducing the likelihood that the disease will occur (for example by delaying the onset of the disease) or worsen in a subject, is sufficient.

Antigen binding proteins described herein may be used in treating or preventing a disease associated with amyloid deposition i.e. amyloidosis.

"Amyloidosis" is any disease characterized by the extracellular accumulation of amyloid in various organs and tissues of the body.

The term "amyloid" refers to extracellular deposits in the tissues of insoluble protein fibres composed of fibrils with characteristic ultrastructural morphology, a cross- $\beta$  sheet core structure and the pathognomonic histochemical tinctorial property of binding Congo red dye from alkaline alcoholic solution and then giving red-green dichroism when viewed microscopically in strong cross polarised light. About 25 different unrelated proteins are known to form amyloid fibrils which deposit in human tissues and share all these typical

properties. Amyloid deposits in the brain substance, cerebral amyloid, differ somewhat from amyloid deposits elsewhere in the body in that they are always focal and microscopic in size, and are commonly referred to as amyloid plaques.

Amyloidosis, that is disease directly caused by deposition of amyloid in the tissues,

5 comprises both local amyloidosis, in which the deposits are confined to one anatomical region and/or one tissue or organ system, and systemic amyloidosis in which the deposits can occur in any organ or tissue in the body, including blood vessels and connective tissues. The cause of amyloidosis can be either acquired or hereditary. Acquired amyloidosis arises as a complication of a preceding medical condition, which can itself be either acquired or  
10 hereditary. Thus reactive systemic amyloidosis, known as amyloid A protein (AA) type is a complication of chronic active inflammatory diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, Crohn's disease, chronic infections and chronic sepsis, and of hereditary periodic fever syndromes such as familial Mediterranean fever, Muckle-Wells syndrome and CINCA syndrome. Dialysis related amyloidosis is caused by accumulation of  
15  $\beta$ 2-microglobulin as a result of end stage renal failure. Monoclonal immunoglobulin light chain (AL) amyloidosis is a complication of multiple myeloma or otherwise benign monoclonal gammopathy (monoclonal gammopathy of uncertain significance, MGUS). Acquired amyloidosis of transthyretin type can occur without any preceding illness and is merely a complication of old age. Hereditary amyloidosis is caused by mutations in the  
20 genes for various proteins which encode expression of variant proteins having an increased propensity to form amyloid fibrils, and includes disease caused by transthyretin, apolipoprotein A1, gelsolin, lysozyme, cystatin C and amyloid  $\beta$ -protein. Comprehensive descriptions of all the different forms of amyloidosis and the proteins involved are available in textbooks and the scientific literature (Pepys, M.B. (2006) Annu. Rev. Med., 57: 223-241;  
25 Pepys and Hawkins (2003) Amyloidosis. Oxford Textbook of Medicine, 4<sup>th</sup> Ed., Vol. 2, Oxford University Press, Oxford, pp. 162-173; Pepys and Hawkins (2001) Amyloidosis. Samter's Immunologic Diseases, Sixth Ed., Vol. 1, Lippincott Williams & Williams, Philadelphia, pp. 401-412).

Local amyloid deposition, confined to one organ or tissue, can be clinically silent or can

30 cause serious tissue damage and disease. For example, cerebral amyloid angiopathy in which the vascular amyloid deposits are composed of A $\beta$  protein, is usually a sporadic

acquired condition arising for reasons which are not understood in the absence of any other pathology, and is a major cause of cerebral haemorrhage and stroke. There are several very important and common diseases, particularly Alzheimer's disease (AD) and type 2 diabetes, in which amyloid deposits are always present but in which the precise mechanisms causing 5 these respective diseases are not yet known. Nevertheless the local deposition of amyloid in the brain and cerebral blood vessels in Alzheimer's disease, and in the pancreatic islets in diabetes is very likely to exacerbate pathology and disease. Accordingly, the present invention includes treatment of both Alzheimer's disease and type 2 diabetes, indeed of any condition associated with the presence of amyloid deposits in the tissues, with antigen 10 binding proteins as disclosed herein.

Many forms of transmissible spongiform encephalopathy (prion diseases) are associated with amyloid deposits in the brain, and the present invention therefore relates to all these conditions, including variant Creutzfeldt-Jakob disease in humans, Creutzfeldt-Jakob disease itself, kuru and the various other forms of human prion disease, and also bovine spongiform 15 encephalopathy, chronic wasting disease of mule-deer and elk, and transmissible encephalopathy of mink.

#### **Diagnostic methods of use**

The antigen binding proteins described herein may be used to detect SAP in a biological 20 sample in vitro or in vivo for diagnostic purposes. For example, the anti-SAP antigen binding proteins can be used to detect SAP in serum or in associated with amyloid e.g. amyloid plaques. The amyloid may have been first removed (for example a biopsy) from a human or animal body. Conventional immunoassays may be employed, including ELISA, Western blot, immunohistochemistry, or immunoprecipitation.

25 The antigen binding proteins may be provided in a diagnostic kit comprising one or more antigen binding proteins, a detectable label, and instructions for use of the kit. For convenience, the kit may comprise the reagents in predetermined amounts with instructions for use.

## EXAMPLES

### Example 1 - Sequencing of Hybridoma Variable domains: SAP-E and SAP-K

SAP-E and SAP-K are from two groups of anti-SAP monoclonals, each group having been tested separately for their binding to human SAP *in vitro*. SAP-E and SAP-K showed the 5 strongest binding to SAP, within their groups, and were compared with each other in different assays.

The first group of antibodies comprised antibodies from 7 hybridomas generated in a single conventional immunization with purified human SAP (SEQ ID NO:43 shown below) (details of method for purifying human SAP are given in Hawkins *et al.* (1991) Clin. Exp. Immunol. 10 84, 308-316) and fusion protocol and are designated SAP-A to SAP-G. Two of these antibodies, SAP-E and SAP-B, are IgG2a isotype while the others are all IgG1 isotype (see Example 13, Table 11).

The second group of antibodies comprised 6 different IgG2a monoclonals (SAP-H to SAP-M) derived by standard techniques from immunization with purified human SAP (SEQ ID NO:43 15 shown below) (Hawkins *et al.* (1991) Clin. Exp. Immunol. 84, 308-316) and a conventional fusion to produce hybridomas which were cloned by routine methods.

### homo sapiens SAP mature amino acid sequence (SEQ ID NO:43)

HTDLSGKVFVFPRESVTDHVNLITPLEKPLQNFTLCFRAYSDLSRAYSLSYNTQGRDNELLVYKERVGEYS  
LYIGRHVKVTSKVIEKFPAPVHICVSWESSGIAEFWINGTPLVKKGLRQGYFVEAQPKIVLGQEQQDSYGGK  
20 FDRSQSFVGEIGDLYMWDSVLPENILSAYQGTPLPANILDWQALNYEIRGYVIKPLVWV

For comparison purposes, the mouse SAP sequence, which has a 69.4% identity with human SAP, is given below.

### mus musculus SAP mature protein (SEQ ID NO:44)

QTDLKRKVVFVFPRESETDHVKLIPHLEKPLQNFTLCFRYSDLSRSQSLFSYSVKGRDNELLIYKEVGEYSLY  
25 IGQSKVTVRGMEEYLSPVHLCTTWESSSGIVEFWVNGKPWVKKSLQREYTVKAPPSIVLGQEQQDNYGG  
GFQRSQSFVGEFSDLYMWVDYVLTPQDILFVYRDSPVNPNIWNWQALNYEINGYVIRPRVW

Total RNA was extracted from hybridoma cell pellets of approximately  $10^6$  cells using the RNeasy kit from Qiagen (#74106). AccessQuick RT-PCR System (A1702) was used to produce cDNA of the variable heavy and light regions using degenerate primers specific for the murine immunoglobulin gene leader sequences and murine IgG2a/κ constant regions. The 5 purified RT-PCR fragments were cloned using the TA cloning kit from Invitrogen (K2000-01). A consensus sequence was obtained for each hybridoma by sequence alignment, and alignment with known immunoglobulin variable sequences listed in KABAT (Sequences of Proteins of Immunological Interest, 4th Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987)). The consensus sequences for SAP-E and SAP-K are 10 shown below.

**SAP-E sequences****SAP-E CDRH1 (SEQ ID NO:1)**

TYNMH

**SAP-E CDRH2 (SEQ ID NO:2)**

15 YIYPGDGNANYNQQFKG

**SAP-E CDRH3 (SEQ ID NO:3)**

GDFDYDGGYYFDS

**SAP-E CDRL1 (SEQ ID NO:4)**

RASENIYSYLA

20 **SAP-E CDRL2 (SEQ ID NO:5)**

NAKTLAE

**SAP-E CDRL3 (SEQ ID NO:6)**

QHHYGAPLT

SAP-E V<sub>H</sub> amino acid sequence (SEQ ID NO:7) with CDRs underlined

QASLQQSGTELVRSGASVKMSCKASGFTFATYNMHWIKQTPGQGLEWIGYIYPGDGNANYNQQFKGK  
 ATLTADTSSNTAYMQISSLTSEDSAVYFCARGGDFDYDGGYYFDSWGQGTTLVSS

SAP-E V<sub>H</sub> DNA sequence (SEQ ID NO:8)

5 CAGGCTTCTCTACAGCAGTCTGGACTGAGCTGGTGAGGTCTGGGCCTCAGTGAAGATGTCCTGC  
 AAGGCTTCTGGCTTCACATTGCCACTACAATATGCACTGGATTAAGCAGACACCCGGACAGGGCC  
 TCCAATGGATTGGGTATATTATCCTGGAGATGGAATGCTAACTACAATCAGCAGTTCAAGGGCAA  
 GGCCACATTGACTGCAGACACATCCTCCAACACAGCCTACATGCAGATCAGCAGCCTGACATCTGAA  
 GACTCTGCGGTCTATTCTGTGCAAGAGGGACTTGATTACGACGGAGGGTACTACTTGACTCCT  
 10 GGGGCCAGGGCACCACTCTCACAGTCTCCTCA

SAP-E V<sub>L</sub> amino acid sequence (SEQ ID NO:9) with CDRs underlined

DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGRSPQLLVHNAKTLAEGVPSRVSGSGSGTH  
 FSLKINGLQPEDFGNYYCQHHYGAPLTFGAGTKLEK

SAP-E V<sub>L</sub> DNA sequence (SEQ ID NO:10)

15 GACATCCAGATGACTCAGTCTCCAGCCTCCATCTGCATCTGTGGGAGAAACTGTCACCACATG  
 TCGAGCAAGTGAGAATATTACAGTTTTAGCATGGTATCAGCAGAACAGGGAAGATCCCCTCAG  
 CTCCTGGTCCATAATGCAAAAACCTTAGCAGAAGGTGTGCCATCAAGGGTCAGTGGCAGTGGATCA  
 GGCACACACTTTCTGAAGATCAACGGCCTGCAGCCTGAAGATTGGATTACTGTCAAC  
 ATCATTATGGTGTCCGCTCACGTTGGTGTGGGACCAAGCTGGAAGTGA  
 20

**SAP-K sequences**SAP-K CDRH1 (SEQ ID NO:11)

SYWMH

SAP-K CDRH2 (SEQ ID NO:12)

MIHPNSVNTNYNEKFKS

SAP-K CDRH3 (SEQ ID NO:13)

RNDYYWYFDV

SAP-K CDRL1 (SEQ ID NO:14)

KASQNVNSNVA

5 SAP-K CDRL2 (SEQ ID NO:15)

SASYRYS

SAP-K CDRL3 (SEQ ID NO:16)

QQCNNYPFT

SAP-K V<sub>H</sub> amino acid sequence (SEQ ID NO:17) with CDRs underlined10 QVQLQQPGAE~~LIKPGASV~~KLSCKASGYTFTSYWMHWVKQRPGQGLEWIGMIHPNSVNTNYNEKFKS  
ATLTVDKSSSTAYMQLNSLTSEDSAVYYCARRNDYYWYFDVWGTGTTVTVSSSAP-K V<sub>H</sub> DNA sequence (SEQ ID NO:18)15 CAGGTCCAACTGCAGCAGCCTGGGGCTGAGCTGATAAAAGCCTGGGGCTTCAGTGAAGTTGCCTGC  
AAGGCTTCTGGCTACACTTCACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCTGGACAGGC  
CTTGAGTGGATTGGAAATGATTCATCTTAATAGTGTTAACTAACTACAATGAGAAGTTCAAGAGTA  
AGGCCACACTGACTGTAGACAAATCCCAGCACGCCTACATGCAACTCAACAGCCTGACATCTGA  
GGACTCTGCGGTCTATTACTGTGCAAGACGGAATGATTACTACTGGTACTCGATGTCTGGGCACA  
GGGACCACGGTCACCGTCTCCTCASAP-K V<sub>L</sub> amino acid sequence (SEQ ID NO:19) with CDRs underlined20 DIVMTQSQKFMSTSVGDRVSVTCKASQNVNSNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSG  
TDFTLTITNVQSEDLAEYFCQQCNNYPFTFGSGTKLEIKSAP-K V<sub>L</sub> DNA sequence (SEQ ID NO:20)25 GACATTGTGATGACCCAGTCTAAAAATTCATGTCACATCAGTAGGGAGACAGGGTCGGTCACT  
GCAAGGCCAGTCAGAATGTGAATTCTAATGTAGCCTGGTATCAACAGAAACCAGGGCAATCTCTAA  
AGCACTGATTACTCGGCTCCTACCGGTACAGTGGAGTCCTGATCGCTCAAGGGCAGGGATCT

GGGACAGATTCACTCTACCACATACCAATGTGCAGTCTGAAGACTTGGCAGAGTATTCTGTCAGC  
AATGTAACAACATCCATTACGTTGGCTGGGGACAAAGTTGGAAATAAAA

Example 2: Construction of chimeric antibodies

Chimeric antibodies, comprising parent murine variable domains grafted onto human IgG1/κ wild-type constant regions were constructed by PCR cloning for SAP-E and SAP-K. Based on the consensus sequence, primers to amplify the murine variable domains were designed, incorporating restriction sites required to facilitate cloning into mammalian expression vectors. Through introduction of the restriction site in FR4 (Framework Region 4 (V-region sequence following CDR3 and preceding first constant domain)) the  $V_H$  amino acid sequence in SAP-E was changed from TTLTVSS as shown in SEQ ID NO:7 to TLTVVSS and the  $V_H$  amino acid sequence in SAP-K was changed from TTGTVSS as shown in SEQ ID NO:17 to TLTVVSS. In the SAP-K variable light chain an internal EcoRI site was present in CDRL1 and mutagenesis primers were designed to remove this undesired internal EcoRI site by changing one base pair – this did not change the amino acid sequence.

The full length heavy and light chain protein sequences of the SAP-E chimeric antibody (cSAP-E) are given in SEQ ID NO:21 and SEQ ID NO:22 respectively. The full length heavy and light chain protein sequences of the SAP-K chimeric antibody (cSAP-K) are given in SEQ ID NO:23 and SEQ ID NO:24 respectively.

SAP-E VH chimera nucleotide sequence (SEQ ID NO:45)

CAGGCTTCTACAGCAGTCTGGACTGAGCTGGTGGAGGTCTGGGGCTCAGTGAAGATGTCCTGC  
AAGGCTTCTGGCTTCACATTGCCACTTACAATATGCACTGGATTAAGCAGACACCCGGACAGGGCC  
TGGAATGGATTGGGTATATTATCCTGGAGATGGTAATGCTAACTACAATCAGCAGTTCAAGGGCAA  
GGCCACATTGACTGCAGACACATCCTCCAACACAGCCTACATGCAGATCAGCAGCCTGACATCTGAA  
GACTCTGCGGTCTATTCTGTGCAAGAGGGACTTGATTACGACGGAGGGTACTACTTGACTCCT  
GGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTCCCCCTGG  
CCCCCAGCAGCAAGAGCACCGAGCGGCGGCACAGCCGCCCTGGCTGCCTGGTGAAGGACTACTTCC  
CCGAACCGGTGACCGTGTCTGGAACAGCGGAGCCCTGACCAGCGCGTGCACACCTCCCCGCCG  
TGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTACCGTGCCTGGCAGCAGCAGCCTGGC  
ACCCAGACCTACATCTGTAAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAG

CCCAAGAGCTGTGACAAGACCCACACCTGCCCTGCCCTGCCCTGAGCTGCTGGAGGCCCA  
 GCGTGTTCCTGTTCCCCCAAGCCTAAGGACACCCCTGATGATCAGCAGAACCCCGAGGTGACCTG  
 TGTGGTGGATGTGAGCCACGAGGACCTGAGGTGAAGTTCAACTGGTACGTGGACGGCTGG  
 AGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCC  
 5 GTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAAGGTGTCCAACAAG  
 GCCCTGCCTGCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTG  
 TACACCCTGCCCTAGCAGAGATGAGCTGACCAAGAACCAAGGTGTCCCTGACCTGCCCTGGTGAAG  
 GGCTTCTACCCAGCGACATGCCGTGGAGTGGAGAGCAACGCCAGCCCAGAACAACACTACAA  
 GACCACCCCCCTGTGCTGGACAGCGATGGCAGCTTCTGTACAGCAAGCTGACCGTGGACAAG  
 10 AGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTATGCACGAGGCCCTGACAATCACTAC  
 ACCCAGAAGAGCCTGAGCCTGCCCTGGCAAG

SAP-E VH chimera amino acid sequence (SEQ ID NO:21)

QASLQQSGTELVRSGASVKMSCKASGFTFATYNMHWIKQTPQGLEWIGIYIPGDGNANYNQQFKGK  
 ATLTADTSSNTAYMQISSLTSEDSAVYFCARGDFDYDGGYYFDSWGQGTLVTVSSASTKGPSVFPLAPSS  
 15 KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQTYICNVN  
 HKPSNTKVDKKVEPKSCDKTHCPPCPAPELLGGPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK  
 FNWYVDGVEVHNAKTPREEQYNSTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP  
 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDK  
 SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

20 SAP-E VL chimera nucleotide sequence (SEQ ID NO:46)

GACATCCAGATGACTCAGTCTCCAGCCTCCATCTGCATCTGTGGGAGAACTGTCACCATCACATG  
 TCGAGCAAGTGAGAATATTACAGTTTTAGCATGGTATCAGCAGAACAGGGAAAGATCCCCTCAG  
 CTCCTGGTCCATAATGCAAAACCTTAGCAGAAGGTGTGCCATCAAGGGTCAGTGGCAGTGGATCA  
 GGCACACACTTCTGAAGATCAACGGCCTGCAGCCTGAAGATTGGATTACTGTCAAC  
 25 ATCATTATGGTGCTCGCTCACGTTGGTGCTGGGACCAAGCTGAACTGAAACGTACGGTGGCG  
 CCCCCAGCGTGTTCATCTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGT  
 GTCTGCTGAACAACCTTACCCCCGGGAGGCCAAGGTGCAGTGGAAAGGTGGACAATGCCCTGCAGA  
 GCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGC  
 ACCCTGACCTGAGCAAGGCCACTACGAGAAGCACAAGGTGTACGCCGTGAGGTGACCCACCAAG  
 30 GGCCTGTCCAGCCCCGTGACCAAGAGCTCAACCGGGCGAGTGC

SAP-E VL chimera amino acid sequence (SEQ ID NO:22)

DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGRSPQLLVHNAKTLAEGVPSRVSGSGSGTH  
FSLKINGLQPEDFGNYYCQHHYGAPLTGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYP  
REAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTSKADYEKHKVYACEVTHQGLSSPVTKSFR

5 GEC

SAP-K VH chimera nucleotide sequence (SEQ ID NO:47)

CAGGTCCAAC TG CAG CAG CCT GGG GCT GAG CT GATA AAG CCT GGG GCT T CAG T GAA G T T G T C C T G C  
AAG GCT T C T G G C T A C A C T T C A C C A G C T A C T G G A T G C A C T G G G T G A A G C A G A G G C T G G A C A A G G C  
C T T G A G T G G A T T G G A A T G A T T C A T C C T A A T A G T G T T A A T A C T A A C T A C A A T G A G A A G T T C A A G A G T A  
10 A G G C C A C A C T G A C T G T A G A C A A A T C C T C A G C A C A G C C T A C A T G C A A C T C A A C A G C C T G A C A T C T G A  
G G A C T C T G C G G T C T A T T A C T G T G C A A G A C G G A A T G A T T A C T A C T G G T A C T T C G A T G T C T G G G G C A C A  
G G G A C A C T A G T G A C C G T G T C C A G C G C C A G C A C C A A G G G C C C C A G C G T G T C C C C T G G C C C C C A G C  
A G C A A G A G C A C C A G C G G C G G C A C A G C C G C C T G G G C T G C C T G G T G A A G G A C T A C T T C C C G A A C C G  
G T G A C C G T G T C C T G G A A C A G C G G A G C C C T G A C C A G C G G C G T G C A C A C T T C C C G C C G T G C T G C A G  
15 A G C A G C G G C C T G T A C A G C C T G A G C A G C G T G G T G A C C G T G C C C A G C A G C A G C C T G G G C A C C C A G A C  
C T A C A T C T G T A A C G T G A A C C A A G G C C A G C A A C A C C A A G G T G G A C A A G A A G G T G G A G C C C A A G A  
G C T G T G A C A A G A C C C A C A C C T G C C C C C C T G C C C T G C C C C G A G C T G C T G G G A G G G C C C A G C G T G T T  
C C T G T T C C C C C C A A G C C T A A G G A C A C C C T G A T G A T C A G C A G A A C C C C G A G G T G A C C T G T G G T G  
G T G G A T G T G A G C C A C G A G G A C C C T G A G G T G A A G T T C A A C T G G T A C G T G G A C G G C G T G G A G G T G C A  
20 C A A T G C C A A G A C C A A G G C C A G G G A G G A G C A G T A C A A C A G C A C C T A C C G G G T G G T C C G T G C T G A C  
C G T G C T G C A C C A G G A T T G G C T G A A C G G C A A G G A G T A C A A G T G T A A G G T G T C C A A C A A G G C C T G C C  
T G C C C C T A T C G A G A A A C C A T C A G C A A G G C C A A G G G C C A G C C C A G A G A G G C C C A G G T G T A C A C C C T  
G C C C C C T A G C A G A G A T G A G C T G A C C A A G A A C C A G G T G T C C C T G A C C T G C C T G G T G A A G G G C T T C T A  
C C C C A G C G A C A T C G C C G T G G A G T G G G A G A G C A A C G G C C A G C C C G A G A A C A A C T A C A A G A C C A C C C  
25 C C C C T G T G C T G G A C A G C G A T G G C A G C T T C T C C T G T A C A G C A A G C T G A C C G T G G A C A A G A G C A G A T  
G G C A G C A G G G C A A C G T G T T C A G C T G C T C C G T G A T G C A C G A G G G C C T G C A C A A T C A C T A C A C C C A G A  
A G A G C C T G A G C C T G T C C C T G G C A A G

SAP-K VH chimera amino acid sequence (SEQ ID NO:23)

QVQLQQPGAELIKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGMIHPNSVNTNYNEKFKSK  
 ATLTVDKSSSTAYMQLNSLTSEDSAVYYCARRNDYYWYFDVWGTGTLTVSSASTKGPSVFPLAPSSKST  
 SGGTAALGCLVKDYFPEPVTWSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP

5 SNTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVLFPPKPKDTLMISRPEVTCVVVDVSHEDPEVKFN  
 WYVDGVEVHNNAKTKPREEQYNSTYRVVSVLVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE  
 PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR  
 WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SAP-K VL chimera nucleotide sequence (SEQ ID NO:48)

10 GACATTGTGATGACCCAGTCTAAAAATTATGTCCACATCAGTAGGAGACAGGGTCAGCGTCACCT  
 GCAAGGCCAGTCAGAATGTGAACCTAAATGTAGCCTGGTATCAACAGAAACCAGGGCAATCTCTA  
 AAGCACTGATTTACTCGGCTTCCCTACCGGTACAGTGGAGTCCCTGATCGCTTCACAGGCAGTGGATC  
 TGGGACAGATTCACTCTCACCATCACCAATGTGCAGTCTGAAGACTTGGCAGAGTATTCTGTCA  
 CAATGTAACAACATCCATTACGTTGGCTCGGGACAAAGTTGAAATAAACGTACGGTGGCC  
 15 GCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTG  
 TGTCTGCTGAACAACCTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAAGGTGGACAATGCCCTGCAG  
 AGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGCACAGCAAGGACTCCACCTACAGCCTGAGCAG  
 CACCTGACCCCTGAGCAAGGCCGACTACGAGAACAGCAAGGTGTACGCCTGTGAGGTGACCCACCA  
 GGGCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGCGAGTGC

SAP-K VL chimera amino acid sequence (SEQ ID NO:24)

DIVMTQSQKFMSTSVGDRSVTCKASQNVNSNVAWYQQKPGQSPKALIYSASYRYSVPDRFTGSGSG  
 TDFTLTITNVQSEDLAEYFCQQCNYPFTFGSGTKLEIKRTVAAPSVIFPPSDEQLKSGTASVVCLNNFY  
 PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFN  
 RGECA

Example 3: Humanisation strategy

Humanised antibodies were generated by a process of grafting CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 from the murine antibody onto a suitable human framework sequence.

5 SAP-E Humanisation StrategySAP-E Heavy chain humanisation

For the SAP-E mouse variable heavy chain sequence a human germ line acceptor framework was selected (IGHV1-69, SEQ ID NO:25) which had 60% identity (including CDRs) with the mouse SAP-E variable heavy chain sequence (SEQ ID NO:7) together with the JH1 minigene 10 (Kabat: AEYFQHWGQQGTLTVSS (SEQ ID NO:26)). The first six residues of the JH1 minigene residues fall within the CDR3 region and were replaced by the incoming CDR from the donor antibody.

Five humanised variants were generated on the basis of sequence comparison and possible impact on antibody function. Construct H0 was a straight graft of murine CDRs (using the 15 Kabat definition) into the human acceptor framework selected above. Construct H1 has additional back-mutations at residues 27 and 30. Constructs H2 and H3 were based on H1 with additional back-mutations at residues 2 (H2), and 48 and 67 (H3). Construct H4 was based on H3 with additional back-mutations at residues 69, 73 and 91. See Table 3.

The sequences of the humanised variable heavy domains of H0, H1, H2, H3 and H4 are given 20 below (SEQ ID NO:27, SEQ ID NO:28 SEQ ID NO:29, SEQ ID NO:30 and SEQ ID NO:31 respectively).

**Table 3: Summary of SAP-E humanised VH variants generated**

| <u>Construct</u>                | <u>Acceptor/template</u><br><u>Framework</u> | <u>Back-mutations@aa# (Kabat)</u> | <u>Total number of back-mutations</u> | <u>Human acceptor framework</u> | <u>Original mouse sequence</u> |
|---------------------------------|--|-----------------------------------|---------------------------------------|---------------------------------|--------------------------------|
| <u><b>H0 (SEQ ID NO:27)</b></u> | IGHV1-69 (SEQ ID NO:25)                      | -----                             | NONE                                  | ----                            | -----                          |
| <u><b>H1 (SEQ ID NO:28)</b></u> | H0   | 27<br>30                          | 2                                     | G<br>S                          | F<br>A                         |
| <u><b>H2 (SEQ ID NO:29)</b></u> | H1   | 2                                 | 3                                     | V                               | A                              |
| <u><b>H3 (SEQ ID NO:30)</b></u> | H1   | 48<br>67                          | 4                                     | M<br>V                          | I<br>A                         |
| <u><b>H4 (SEQ ID NO:31)</b></u> | H3   | 69<br>73<br>91                    | 7                                     | I<br>K<br>Y                     | L<br>T<br>F                    |

SAP-E Light chain humanisation

For the SAP-E mouse variable light chain sequence a human germ line acceptor framework was selected (IGKV1-39, SEQ ID NO:32) which had 68% identity (including CDRs) with the 5 mouse SAP-E variable light chain sequence (SEQ ID No:9) together with the J-region kappa 2 minigene (Kabat: YTFGQQGTKLEIK, SEQ ID NO:33) based on sequence similarity. The first two residues of the JK-2 minigene residues fall within the CDR3 region and were replaced by the incoming CDR from the donor antibody.

Three humanised variants were generated on the basis of sequence comparison and possible impact on antibody function. Construct L0 was a straight graft of murine CDRs (using the Kabat definition) into the human acceptor framework selected above. Construct L1 has a back-mutation at residue 49 and construct L2 has back mutations at positions 48 and 49. See Table 4.

The sequences of the humanised variable light domains of L0, L1 and L2 are given below (SEQ ID NO:34, SEQ ID NO:35 and SEQ ID NO:36 respectively).

**Table 4: Summary of SAP-E humanised VL variants generated**

| <u>Construct</u>         | <u>Acceptor/template</u><br><u>Framework</u> | <u>Back-mutations@aa# (Kabat)</u> | <u>Total number of back-mutations</u> | <u>Human acceptor framework</u> | <u>Original mouse sequence</u> |
|--------------------------|--|-----------------------------------|---------------------------------------|---------------------------------|--------------------------------|
| <u>L0 (SEQ ID NO:34)</u> | IGKV1-39 (SEQ ID NO:32)                      | -----                             | NONE                                  | ----                            | -----                          |
| <u>L1 (SEQ ID NO:35)</u> | L0   | 49                                | 1                                     | Y                               | H                              |
| <u>L2 (SEQ ID NO:36)</u> | L1   | 48<br>49                          | 2                                     | I<br>Y                          | V<br>H                         |

#### SAP-K Humanisation Strategy

10 SAP-K Heavy chain humanisation

For the SAP-K mouse variable heavy chain sequence a human germ line acceptor framework was selected (IGHV1-69, SEQ ID NO:25) which had 65% identity (including CDRs) with the mouse SAP-K variable heavy chain sequence (SEQ ID NO:17) together with the JH1 minigene (Kabat: AEYFQHWGQGTLVTVSS (SEQ ID NO:26)). The first six residues of the JH1 minigene

residues fall within the CDR3 region and were replaced by the incoming CDR from the donor antibody.

Four humanised variants were generated on the basis of sequence comparison and possible impact on antibody function. Construct H0 was a straight graft of murine CDRs (using the Kabat definition) into the human acceptor framework selected above. Construct H1 has additional back-mutations at residues 27 and 30. Construct H2 was based on H1 with additional back-mutations at residues 48 and 67. Construct H3 was based on H2 with additional back-mutations at residues 69 and 71. See Table 5.

The sequences of the humanised variable heavy domains of H0, H1, H2 and H3 are given below (SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 and SEQ ID NO:40 respectively).

**Table 5: Summary of SAP-K humanised VH variants generated**

| <u>Construct</u>                | <u>Acceptor/template</u><br><u>Framework</u> | <u>Back-mutations@aa# (Kabat)</u> | <u>Total number of back-mutations</u> | <u>Human acceptor framework</u> | <u>Original mouse sequence</u> |
|---------------------------------|--|-----------------------------------|---------------------------------------|---------------------------------|--------------------------------|
| <u><b>H0 (SEQ ID NO:37)</b></u> | IGHV1-69 (SEQ ID NO: 25)                     | -----                             | NONE                                  | ----                            | -----                          |
| <u><b>H1 (SEQ ID NO:38)</b></u> | H0   | 27<br>30                          | 2                                     | G<br>S                          | Y<br>T                         |
| <u><b>H2 (SEQ ID NO:39)</b></u> | H1   | 48<br>67                          | 4                                     | M<br>V                          | I<br>A                         |
| <u><b>H3 (SEQ ID NO:40)</b></u> | H2   | 69<br>71                          | 6                                     | I<br>A                          | L<br>V                         |

### SAP-K Light chain humanisation

For the SAP-K mouse variable light chain sequence a human germ line acceptor framework was selected (IGKV1-39, SEQ ID NO:32) which had 63% identity (including CDRs) with the mouse SAP-K variable light chain sequence (SEQ ID NO:19) together with the J-region kappa

5 2 minigene (Kabat: YTFGQGTKLEIK, SEQ ID NO:33) based on sequence similarity. The first two residues of the JK-2 minigene residues fall within the CDR3 region and were replaced by the incoming CDR from the donor antibody.

Two humanised variants were generated on the basis of sequence comparison and possible impact on antibody function. Construct L0 was a straight graft of murine CDRs (using the

10 Kabat definition) into the human acceptor framework selected above. Construct L1 has a back-mutation at residue 46.

The sequences of the humanised variable light domains of L0 and L1 are given below (SEQ ID NO:41 and SEQ ID NO:42 respectively).

**Table 6: Summary of SAP-K humanised VL variants generated**

| <u>Construct</u>         | <u>Acceptor/template</u><br><u>Framework</u> | <u>Back-mutations@aa# (Kabat)</u> | <u>Total number of back-mutations</u> | <u>Human acceptor framework</u> | <u>Original mouse sequence</u> |
|--------------------------|--|-----------------------------------|---------------------------------------|---------------------------------|--------------------------------|
| <u>L0</u> (SEQ ID NO:41) | IGKV1-39 (SEQ ID NO:32)                      | -----                             | NONE                                  | ----                            | -----                          |
| <u>L1</u> (SEQ ID NO:42) | L0   | 46                                | 1                                     | L                               | A                              |

15

### **Construction of humanised antibody vectors**

The humanised variable region DNA sequences were sequence optimised. DNA fragments encoding the humanised variable heavy and variable light regions were constructed de novo using a PCR-based strategy and overlapping oligonucleotides. The PCR product was cloned

into mammalian expression vectors containing the human gamma 1 constant region and the human kappa constant region respectively. This is the wild-type Fc region.

IGHV1-69 human variable heavy chain germline acceptor nucleotide sequence (SEQ ID NO:49)

5 CAGGTGCAGCTGGTGCAGTCTGGGCTGAGGTGAAGAAGCCTGGTCCTCGGTGAAGGTCTCCTG  
CAAGGCTTCTGGAGGCACCTCAGCAGCTATGCTATCAGCTGGTGCGACAGGCCCCTGGACAAGG  
GCTTGAGTGGATGGGAGGGATCATCCCTATCTTGGTACAGCAAACATACGCACAGAAGTTCCAGGG  
CAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATC  
TGAGGACACGGCCGTGTATTACTGTGCGAGA

10 IGHV1-69 human variable heavy chain germline acceptor amino acid sequence (SEQ ID NO:25)

QVQLVQSGAEVKPGSSVKVSCKASGGTFSSYAIWVRQAPGQGLEWMGGIIPFGTANYAQKFQGRV  
TITADKSTSTAYMELSSLRSEDTAVYYCAR

IGKV1-39 human variable heavy chain germline acceptor nucleotide sequence (SEQ ID NO:50)

15 GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCATCTGTAGGAGACAGAGTCACCATCACTTG  
CCGGGCAAGTCAGAGCATTAGCAGCTATTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAA  
GCTCCTGATCTATGCTGCATCCAGTTGCAAAGTGGGTCCCATCAAGGTTAGTGGCAGTGGATCT  
GGGACAGATTCACTCTACCACATCAGCAGTCTGCAACCTGAAGATTGCAACTACTACTGTCAACA  
20 GAGTTACAGTACCCCT

IGKV1-39 human variable heavy chain germline acceptor amino acid sequence (SEQ ID NO:32)

DIQMTQSPSSLSASVGDRVITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGBTDF  
TLTISSLQPEDFATYYCQQSYSTP

25 JH1 minigene (SEQ ID NO:26)

AEYFQHWGQGTLTVSS

Jκ2 minigene (SEQ ID NO:33)

YTFGQGTKLEIK

SAP-E humanised heavy chain V region variant H0 nucleotide sequence non-codon optimised (SEQ ID NO:51)

5 CAGGTGCAGCTGGTGCAGTCTGGGCTGAGGTGAAGAAGCCTGGTCCTCGGTGAAGGTCTCCTG  
CAAGGCTTCTGGAGGCACCTCAGCACTTACAATATGCACTGGGTGCGACAGGCCCTGGACAAGG  
GCTTGAGTGGATGGATATATTATCCTGGAGATGGTAATGCTAACTACAATCAGCAGTTCAAGGGC  
AGAGTCACGATTACCGCGAACAAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCT  
GAGGACACGGCCGTGTATTACTGTGCGAGAGGGACTTGATTACGACGGAGGGTACTACTTGAC  
10 TCCTGGGCCAGGGCACCTGGTACCGTCTCCTCA

SAP-E humanised light chain V region variant L0 nucleotide sequence non-codon optimised (SEQ ID NO:52)

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTG  
CCGAGCAAGTGAGAATATTACAGTTAGCATGGTATCAGCAGAAACCAGGGAAAGCCCCTAA  
15 GCTCCTGATCTATAATGCAAAAACCTTAGCAGAAGGGTCCCATCAAGGTTAGTGGCAGTGGATCT  
GGGACAGATTCACTCTACCACATCAGCAGTCTGCAACCTGAAGATTGCAACTTACTACTGTCAACA  
TCATTATGGTGCTCCGCTACGTTGGCCAGGGACCAAGCTGGAGATCAA

SAP-E humanised heavy chain V region variant H0 nucleotide sequence (codon optimised) (SEQ ID NO:53)

20 CAGGTGCAGCTGGTGCAGAGCGCGCCGAGGTGAAGAAACCCGGCAGCAGCGTGAAGGTGAGCT  
GCAAGGCTAGCGGGGGCACCTCTCACCTACAACATGCACTGGTCAGGCAGGCACCCGGCCAGG  
GCCTGGAGTGGATGGCTATATCTACCCCGCGACGGCAACGCCAACTACAACCAGCAGTTCAAGG  
GCAGGGTGACCATACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACGTGAGCAGCCTGAGG  
AGCGAGGATACCGCCGTGTACTACTGCGCCAGGGCGACTTCGACTACGACGGCGGCTACTACTTC  
25 GACAGCTGGGACAGGGCACACTAGTGACCGTGTCCAGC

SAP-E humanised heavy chain V region variant H0 amino acid sequence (SEQ ID NO:27)

QVQLVQSGAEVKKPGSSVKVSCKASGGTFSTYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFK  
GRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLTVSS

SAP-E humanised heavy chain V region variant H1 nucleotide sequence (codon optimised)

5 (SEQ ID NO:54)

CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAACCCGGCAGCAGCGTGAAGGTGAGCT  
GCAAGGCTAGCGGGTTCACCTCGCCACCTACAACATGCACTGGGTAGGCAGGCACCCGGCCAGG  
GCCTGGAGTGGATGGCTATATCTACCCCGGCACGGCAACGCCAACTACAACCAGCAGTTCAAGG  
GCAGGGTGACCATACCGCCGACAAGAGCACCAGCACCGCCTACATGGAAC TGAGCAGCCTGAGG  
10 AGCGAGGATAACGCCGTGTACTACTGCGCCAGGGCGACTTCGACTACGACGGCGGCTACTACTTC  
GACAGCTGGGGACAGGGCACACTAGTGACCGTGTCCAGC

SAP-E humanised heavy chain V region variant H1 amino acid sequence (SEQ ID NO:28)

QVQLVQSGAEVKKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFK  
GRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLTVSS

15 SAP-E humanised heavy chain V region variant H2 nucleotide sequence (codon optimised)  
(SEQ ID NO:55)

CAGGCGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAACCCGGCAGCAGCGTGAAGGTGAGCT  
GCAAGGCTAGCGGGTTCACCTCGCCACCTACAACATGCACTGGGTAGGCAGGCACCCGGCCAGG  
GCCTGGAGTGGATGGCTATATCTACCCCGGCACGGCAACGCCAACTACAACCAGCAGTTCAAGG  
20 GCAGGGTGACCATACCGCCGACAAGAGCACCAGCACCGCCTACATGGAAC TGAGCAGCCTGAGG  
AGCGAGGATAACGCCGTGTACTACTGCGCCAGGGCGACTTCGACTACGACGGCGGCTACTACTTC  
GACAGCTGGGGACAGGGCACACTAGTGACCGTGTCCAGC

SAP-E humanised heavy chain V region variant H2 amino acid sequence SEQ ID NO:29

QAQLVQSGAEVKKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFK  
25 GRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLTVSS

SAP-E humanised heavy chain V region variant H3 nucleotide sequence (codon optimised)(SEQ ID NO:56)

CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAACCCGGCAGCAGCGTGAAGGTGAGCT  
 GCAAGGCTAGCGGGTTCACCTCGCCACCTACAACATGCACTGGGTCAAGGCAGGCACCCGGCCAGG  
 5 GCCTGGAGTGGATCGGCTATATCTACCCCGGCACGGCAACGCCAACTACAACCAGCAGTTCAAGG  
 GCAGGGCCACCATACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGA  
 GCGAGGATACCGCCGTGTACTACTGCGCCAGGGCGACTTCGACTACGACGGCGCTACTACTCG  
 ACAGCTGGGGACAGGGCACACTAGTGACCGTGTCCAGC

SAP-E humanised heavy chain V region variant H3 amino acid sequence (SEQ ID NO:30)

10 QVQLVQSGAEVKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWIGYIYPGDGNANYNQQFKG  
 RATITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLVTVSS

SAP-E humanised heavy chain V region variant H4 nucleotide sequence (codon optimised)(SEQ ID NO:57)

CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAACCCGGCAGCAGCGTGAAGGTGAGCT  
 15 GCAAGGCTAGCGGGTTCACCTCGCCACCTACAACATGCACTGGGTCAAGGCAGGCACCCGGCCAGG  
 GCCTGGAGTGGATCGGCTATATCTACCCCGGCACGGCAACGCCAACTACAACCAGCAGTTCAAGG  
 GCAGGGCCACCTGACCGCCGACACCAGCACCGCACCGCCTACATGGAACTGAGCAGCCTGAGGA  
 GCGAGGATACCGCCGTGTACTTCTGCGCCAGGGCGACTTCGACTACGACGGCGCTACTACTCG  
 ACAGCTGGGGACAGGGCACACTAGTGACCGTGTCCAGC

SAP-E humanised heavy chain V region variant H4 amino acid sequence (SEQ ID NO:31)

QVQLVQSGAEVKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWIGYIYPGDGNANYNQQFKG  
 RATLTADTSTSTAYMELSSLRSEDTAVYFCARGDFDYDGGYYFDSWGQGTLVTVSS

SAP-E humanised light chain V region variant L0 nucleotide sequence (codon optimised)(SEQ ID NO:58)

25 GACATCCAGATGACCCAGAGCCCCAGCTCACTGAGGCCAGCGTGGCGACAGGGTACCATTACC  
 TGCAGGGCCTCCGAGAACATCTACAGCTACCTGGCCTGGTACCAGCAGAACGCCGGCAAGGCC  
 AAGCTGCTGATCTACACGCCAACGCCCTGCCAGGGCGTCCCTAGCAGGTTCTCTGGAAGCGGC

AGCGGCACCGACTTCACCCCTGACCATCAGCAGCCTGCAGCCCGAGGGACTTCGCCACCTATTACTGCC  
AGCACCACACTACGGCGCCCCCTGACCTTGGCCAGGGCACCAAACCTGGAGATCAAG

SAP-E humanised light chain V region variant L0 amino acid sequence SEQ ID NO:34

DIQMTQSPSSLSASVGDRVITCRASENIYSLAWYQQKPGKAPKLLIYNAKTLAEGVPSRSGSGSGTDF  
5 TLTSSLQPEDFATYYCQHHYGAPLTFGQGTKEIK

SAP-E humanised light chain V region variant L1 nucleotide sequence (codon optimised)  
(SEQ ID NO:59)

GACATCCAGATGACCCAGAGCCCCAGCTCACTGAGGCCAGCGTGGCGACAGGGTACCATTACC  
TGCAGGGCCTCCGAGAACATCTACAGCTACCTGGCCTGGTACCAGCAGAACGCCGGCAAGGCC  
10 AAGCTGCTGATCCACAACGCCAAGACCCCTGCCAGGGCGTCCCTAGCAGGTTCTCTGGAAGCGGC  
AGCGGCACCGACTTCACCCCTGACCATCAGCAGCCTGCAGCCCGAGGGACTTCGCCACCTATTACTGCC  
AGCACCACACTACGGCGCCCCCTGACCTTGGCCAGGGCACCAAACCTGGAGATCAAG

SAP-E humanised light chain V region variant L1 amino acid sequence (SEQ ID NO:35)

DIQMTQSPSSLSASVGDRVITCRASENIYSLAWYQQKPGKAPKLLIYNAKTLAEGVPSRSGSGSGTDF  
15 TLTSSLQPEDFATYYCQHHYGAPLTFGQGTKEIK

SAP-E humanised light chain V region variant L2 nucleotide sequence (codon optimised)  
(SEQ ID NO:60)

GACATCCAGATGACCCAGAGCCCCAGCTCACTGAGGCCAGCGTGGCGACAGGGTACCATTACC  
TGCAGGGCCTCCGAGAACATCTACAGCTACCTGGCCTGGTACCAGCAGAACGCCGGCAAGGCC  
20 AAGCTGCTGGTGCACAACGCCAAGACCCCTGCCAGGGCGTCCCTAGCAGGTTCTCTGGAAGCGGC  
AGCGGCACCGACTTCACCCCTGACCATCAGCAGCCTGCAGCCCGAGGGACTTCGCCACCTATTACTGCC  
AGCACCACACTACGGCGCCCCCTGACCTTGGCCAGGGCACCAAACCTGGAGATCAAG

SAP-E humanised light chain V region variant L2 amino acid sequence (SEQ ID NO:36)

DIQMTQSPSSLSASVGDRVITCRASENIYSLAWYQQKPGKAPKLLVHNAKTLAEGVPSRSGSGSGTDF  
25 FTLTSSLQPEDFATYYCQHHYGAPLTFGQGTKEIK

SAP-E humanised heavy chain H1 full mature nucleotide sequence (codon optimised) (SEQ ID NO:61)

CAGGTGCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAACCCGGCAGCAGCGTGAAGGTGAGCT  
 GCAAGGCTAGCGGGTTCACCTCGCCACCTACAACATGCACTGGGTAGGCAGGCACCCGGCCAGG  
 5 GCCTGGAGTGGATGGCTATATCTACCCCGGCACGGCAACGCCAACTACAACCAGCAGTTCAAGG  
 GCAGGGTACCATCACCGCCACAAGAGCACCAGCACCGCCTACATGGAAC TGAGCAGCCTGAGG  
 AGCGAGGATACGCCGTGTACTACTGCGCCAGGGCGACTCGACTACGACGGCGGCTACTACTTC  
 GACAGCTGGGACAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGT  
 10 CCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGCCGGCACAGCCGCCCTGGCTGCCTGGTGAAGG  
 ACTACTCCCCGAACCGGTGACCGTGTCTGGAACAGCGGAGCCCTGACCAGCGCGTGCACACCTT  
 CCCC CGCGTGTGACAGCAGCGGCCCTGACAGCCTGAGCAGCGTGGTACCGTGCCTGGCAGCAGCAG  
 CCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAA  
 GGTGGAGCCAAGAGCTGTGACAAGACCCACACCTGCCCTGCCCTGCCCTGAGCTGCTGGG  
 15 AGGCCCGAGCGTGTCCCTGTTCCCCCAAGCCTAAGGACACCCCTGATGATCAGCAGAACCCCCGAG  
 GTGACCTGTGTGGTGGATGTGAGCCACGAGGACCCCTGAGGTGAAGTTCAACTGGTACGTGGA  
 CGCGTGGAGGTGACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGG  
 TGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTAACGGCAAGGAGTACAAGTGTAAAGGTGT  
 CCAACAAGGCCCTGCCCTGCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGC  
 CCCAGGTGTACACCCCTGCCCTAGCAGAGATGAGCTGACCAAGAACAGGTGTCCCTGACCTGCCT  
 20 GGTGAAGGGCTTCTACCCAGCGACATGCCGTGGAGTGGAGAGAGCAACGCCAGCCCAGAACACA  
 ACTACAAGACCACCCCCCTGTGCTGGACAGCGATGGCAGCTTCTCCTGTACAGCAAGCTGACCGT  
 GGACAAGAGCAGATGGCAGCAGGGCAACGTGTTAGCTGCTCCGTATGCACGAGGCCCTGCACA  
 ATCACTACACCCAGAACAGAGCCTGAGCCTGTCCTGGCAAG

SAP-E humanised heavy chain H1 full mature amino acid sequence (SEQ ID NO:62)

25 QVQLVQSGAEVKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFK  
 GRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLTVSSASTKGPSVFPLAP  
 SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQTYICN  
 VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPE  
 VKFNWYVDGVEVHNNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTKAKG

QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFYSKTV  
DKSRWQQGNVFSCVMHEALHNHYTQKSLSPGK

SAP-E humanised light chain L1 full mature nucleotide sequence (codon optimised) (SEQ ID NO:63)

5 GACATCCAGATGACCCAGAGCCCCAGCTCACTGAGGCCAGCGTGGCGACAGGGTACCCATTACC  
TGCAGGGCCTCCGAGAACATCTACAGCTACCTGGCCTGGTACCAAGCAGAAGCCGGCAAGGCC  
AAGCTGCTGATCCACAACGCCAAGACCCCTGCCAGGGCGTCCCTAGCAGGTTCTGGAAAGCGGC  
AGCGGCACCGACTTCACCCCTGACCATCAGCAGCCTGCAGCCGAGGGACTTCGCCACCTATTACTGCC  
AGCACCACATCGCGCCCCCTGACCTTGGCCAGGGCACCAAACGGAGATCAAGCGTACGGTGG  
10 CCGCCCCCAGCGTGTTCATCTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGG  
TGTGTCTGCTGAACAACCTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAAGGTGGACAATGCCCTGC  
AGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGCAAGGACTCCACCTACAGCCTGAGC  
AGCACCCTGACCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCGTGAGGTGACCCAC  
CAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCAGGGCGAGTGC

15 SAP-E humanised light chain L1 full mature amino acid sequence (SEQ ID NO:64)

DIQMTQSPSSLSASVGDRVITCRASENIYSYLAWYQQKPGKAPKLLIHNNAKTLAEGVPSRFSGSGSGTDF  
TLTISSLQPEDFATYYCQHHYGAPLTFGQGTKEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNFYPREA  
KVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

20 SAP-K humanised heavy chain V region variant H0 nucleotide sequence non-codon optimised (SEQ ID NO:65)

CAGGTGCAGCTGGTCAGTCTGGGCTGAGGTGAAGAACGCTGGTCCTCGGTGAAGGTCTCCTG  
CAAGGCTTCTGGAGGCACCTCAGCAGCTACTGGATGCAGCTGGGTGCGACAGGCCCTGGACAAGG  
GCTTGAGTGGATGGGAATGATTCTACCTAATAGTGTAACTAACTACAATGAGAAGTTCAAGAGT  
AGAGTCACGATTACCGCGGACAAATCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCT  
25 GAGGACACGGCCGTGTATTACTGTGCGAGACGGAATGATTACTACTGGTACTCGATGTCTGGGC  
CAGGGCACCTGGTCACCGTCTCCTCA

SAP-K humanised light chain V region variant L0 nucleotide sequence non-codon optimised(SEQ ID NO:66)

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTG  
CAAGGCCAGTCAGAATGTGAACTCTAATGTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAA  
5 GCTCCTGATCTATTGGCTTCCCTACCGGTACAGTGGGTCCCATCAAGGTTAGTGGCAGTGGATCT  
GGGACAGATTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTGCAACTTACTACTGTCAGCA  
ATGTAACAACATCCATTACGTTGCCAGGGACCAAGCTGGAGATCAAA

SAP-K humanised heavy chain V region variant H0 nucleotide sequence (codon optimised)(SEQ IS NO:67)

10 CAGGTGCAGCTGGTGCAGAGCGGCCGAAGTGAAGAAGCCGGCAGCAGCGTAAAGTGAGCT  
GCAAGGCCAGCGGCCGAACCTTCAGCAGCTACTGGATGCACTGGTGAGGCAGGCACCCGGCCAG  
GGCCTGGAGTGGATGGCATGATCCACCCAACAGCGTAACACCAACTACAACGAGAAGTTCAAG  
AGCAGAGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTATATGGAGCTGAGCTCTGAGG  
15 AGCGAGGATACCGCCGTGTACTACTGCGCCAGGAGGAACGACTACTGGTACCGACGTCTGG  
GCCAGGGCACACTAGTGACCGTGTCCAGC

SAP-K humanised heavy chain V region variant H0 amino acid sequence (SEQ ID NO:37)

QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYWMHWVRQAPGQGLEWMGMIHPNSVNTNYNEKFK  
SRVTITADKSTSTAYMELSSLRSEDTAVYYCARRNDYYWYFDVWGQGTLTVSS

SAP-K humanised heavy chain V region variant H1 nucleotide sequence (codon optimised)(SEQ ID NO:68)

20 CAGGTGCAGCTGGTGCAGAGCGGCCGAAGTGAAGAAGCCGGCAGCAGCGTAAAGTGAGCT  
GCAAGGCCAGCGCTACACCTTACCCAGCTACTGGATGCACTGGTGAGGCAGGCACCCGGCCAG  
GGCCTGGAGTGGATGGCATGATCCACCCAACAGCGTAACACCAACTACAACGAGAAGTTCAAG  
AGCAGAGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTATATGGAGCTGAGCTCTGAGG  
25 AGCGAGGATACCGCCGTGTACTACTGCGCCAGGAGGAACGACTACTGGTACCGACGTCTGG  
GCCAGGGCACACTAGTGACCGTGTCCAGC

SAP-K humanised heavy chain V region variant H1 amino acid sequence (SEQ ID NO:38)

QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGMIHPNSVNTNYNEKFK  
SRVTITADKSTSTAYMELSSLRSEDTAVYYCARRNDYYWYFDVWGQGTLTVSS

SAP-K humanised heavy chain V region variant H2 nucleotide sequence (codon optimised)5 (SEQ ID NO:69)

CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCGGCAGCAGCGTAAAGTGAGCT  
GCAAGGCCAGCGGCTACACCTTACCCAGCTACTGGATGCACTGGGTGAGGCAGGCACCCGGCCAG  
GGCCTGGAGTGGATCGGCATGATCCACCCAACAGCGTAACACCAACTACAACGAGAAGTTCAAG  
AGCAGAGCCACCATCACCGCCGACAAGAGCACCAGCACCGCTATATGGAGCTGAGCTCTGAGG  
10 AGCGAGGATACCGCCGTGTACTACTGCGCCAGGAGGAACGACTACTGGTACCGTACGTCTGG  
GGCCAGGGCACACTAGTGACCGTGTCCAGC

SAP-K humanised heavy chain V region variant H2 amino acid sequence (SEQ ID NO:39)

QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGMIHPNSVNTNYNEKFKS  
RATITADKSTSTAYMELSSLRSEDTAVYYCARRNDYYWYFDVWGQGTLTVSS

15 SAP-K humanised heavy chain V region variant H3 nucleotide sequence (codon optimised)  
(SEQ ID NO:70)

CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCGGCAGCAGCGTAAAGTGAGCT  
GCAAGGCCAGCGGCTACACCTTACCCAGCTACTGGATGCACTGGGTGAGGCAGGCACCCGGCCAG  
GGCCTGGAGTGGATCGGCATGATCCACCCAACAGCGTAACACCAACTACAACGAGAAGTTCAAG  
20 AGCAGAGCCACCTGACCGTGGACAAGAGCACCAGCACCGCTATATGGAGCTGAGCTCTGAGG  
AGCGAGGATACCGCCGTGTACTACTGCGCCAGGAGGAACGACTACTGGTACCGTACGTCTGG  
GGCCAGGGCACACTAGTGACCGTGTCCAGC

SAP-K humanised heavy chain V region variant H3 amino acid sequence (SEQ ID NO:40)

QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGMIHPNSVNTNYNEKFKS  
25 RATLTVDKSTSTAYMELSSLRSEDTAVYYCARRNDYYWYFDVWGQGTLTVSS

SAP-K humanised light chain V region variant L0 nucleotide sequence (codon optimised) SEQID NO:71)

GACATCCAGATGACCCAGAGCCCCCTTCACTGAGCGCTAGCGTGGCGACAGGGTACCATCACC  
 TGCAAGGCCAGCCAGAACGTGAACAGCAACGTGGCTGGTACCAGCAGAACGCCGAAAGCCCC  
 5 CAAGCTCCTGATCTACAGCGCCAGCTACAGATATAGCGCGTGCCTAGCAGGTTAGCGGCAGCGG  
 AAGCGGGACCGATTCAACCTGACCATCAGCAGCCTGCAGCCGAGGACTTCGCCACTTACTACTGC  
 CAGCAGTGCAACAACTACCCCTCACCTCGGCCAGGGCACCAAGCTGGAGATCAAG

SAP-K humanised light chain V region variant L0 amino acid sequence (SEQ ID NO:41)

DIQMTQSPSSLSASVGDRVITCKASQNVNSNVAWYQQKPGKAPKLLIYSASYRYSVPSRSGSGSGTD  
 10 FTLTISSLQPEDFATYYCQQCNYPFTFGQGTKLEIK

SAP-K humanised light chain V region variant L1 nucleotide sequence (codon optimised) (SEQ ID NO:72)

GACATCCAGATGACCCAGAGCCCCCTTCACTGAGCGCTAGCGTGGCGACAGGGTACCATCACC  
 TGCAAGGCCAGCCAGAACGTGAACAGCAACGTGGCTGGTACCAGCAGAACGCCGAAAGCCCC  
 15 CAAGGCCCTGATCTACAGCGCCAGCTACAGATATAGCGCGTGCCTAGCAGGTTAGCGGCAGCGG  
 AAGCGGGACCGATTCAACCTGACCATCAGCAGCCTGCAGCCGAGGACTTCGCCACTTACTACTGC  
 CAGCAGTGCAACAACTACCCCTCACCTCGGCCAGGGCACCAAGCTGGAGATCAAG

SAP-K humanised light chain V region variant L1 amino acid sequence (SEQ ID NO:42)

DIQMTQSPSSLSASVGDRVITCKASQNVNSNVAWYQQKPGKAPKALIYSASYRYSVPSRSGSGSGT  
 20 DFTLTSSLQPEDFATYYCQQCNYPFTFGQGTKLEIK

SAP-K humanised H3 heavy chain nucleotide sequence (codon optimised) (SEQ ID NO:75)

CAGGTGCAGCTGGTGCAGAGCGGCCGAAGTGAAGAACGCCGGCAGCAGCGTAAAGTGAGCT  
 GCAAGGCCAGCGGCTACACCTTACCCAGCTACTGGATGCAGCTGGGTGAGGCAGGCACCCGGCCAG  
 GGCCTGGAGTGGATCGGCATGATCCACCCAACAGCGTAAACACCAACTAACGAGAAAGTTCAAG  
 25 AGCAGAGCCACCTGACCGTGGACAAGAGCACCAGCACCGCTATATGGAGCTGAGCTCTGAGG  
 AGCGAGGATACGCCGTGTACTACTGCGCCAGGAGGAACGACTACTGGTACTTCGACGTCTGG  
 GGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTCCCCCTGGCC

CCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGCTGCCTGGTGAAGGACTACTCCCC  
 GAACCGGTGACCGTGTCTGGAACAGCGGAGCCCTGACCAGCGCGTGCACACCTCCCCGCCGTG  
 CTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTACCCTGCCCAGCAGCAGCAGCCTGGGCAC  
 CCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCC  
 5 CAAGAGCTGTGACAAGACCCACACCTGCCCCCCTGCCCTGCCCCGAGCTGCTGGAGGCCCCAG  
 CGTGTCCCTGTTCCCCCAAGCCTAAGGACACCCCTGATGATCAGCAGAACCCCCGAGGTGACCTGT  
 GTGGTGGTGGATGTGAGCCACGAGGACCTGAGGTGAAGTTCACTGGTACGTGGACGGCGTGG  
 GGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACACAGCACCTACCGGGTGGTCCG  
 TGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAAGGTGTCCAACAAGG  
 10 CCCTGCCTGCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCAGAGAGCCCCAGGTGT  
 ACACCCCTGCCCTAGCAGAGATGAGCTGACCAAGAACCAAGGTGCTGCCCTGACCTGCCTGGTGAAGG  
 GCTTCTACCCAGCGACATGCCGTGGAGTGGAGAGCAACGCCAGCCAGAACAACTACAAGA  
 CCACCCCCCTGTGCTGGACAGCGATGGCAGCTCTCCTGTACAGCAAGCTGACCGTGGACAAGAG  
 CAGATGGCAGCAGGGCAACGTGTTAGCTGCTCCGTATGCACGAGGCCCTGCACAATCACTACAC  
 15 CCAGAAGAGCCTGAGCCTGCCCCGGCAAG

SAP-K humanised H3 heavy chain amino acid sequence (SEQ ID NO:76)

QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGMIHPNSVNTNYNEKF  
 RATLTVDKSTSTAYMELSSLRSEDTAVYYCARRNDYYWYFDVWGQGTLVTVSSASTKGPSVFLAPSSKS  
 TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSVVTVPSSSLGTQTYICNVNH  
 20 PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN  
 WYVDGVEVHNAKTKPREEQYNSTYRVVSVLVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE  
 PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR  
 WQQGNVFCSVNHEALHNHYTQKSLSLSPGK

SAP-K humanised L0 light chain nucleotide sequence (codon optimised) (SEQ ID NO:77)

25 GACATCCAGATGACCCAGAGGCCCTTCACTGAGCGTAGCGTGGCGACAGGGTACCATCACC  
 TGCAAGGCCAGCCAGAACGTGAACAGAACGCAACGTTGGCTGGTACCAGCAGAACGCCGAAAGCCCC  
 CAAGCTCCTGATCTACAGCGCCAGCTACAGATATAGCGCGTGCCTAGCAGGTTAGCGGCAGCGG  
 AAGCGGGACCGATTCAACCTGACCATCAGCAGCCTGCAGCCGAGGACTTCGCCACTTACTACTGC  
 CAGCAGTGCAACAACACTACCCCTCACCTCGGCCAGGGCACCAAGCTGGAGATCAAGCGTACGGTG  
 30 GCCGCCAGCGTGTTCATCTTCCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCCAGCGTG

GTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAAGGTGGACAATGCCCTG  
CAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAG  
CAGCACCCCTGACCCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCGTGAGGTGACCCA  
CCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCAGGGCGAGTGC

5 SAP-K humanised L0 light chain amino acid sequence (SEQ ID NO:78)

DIQMTQSPSSLSASVGDRVITCKASQNVNSNVAWYQQKPGKAPKLLIYSASYRSGVPSRSGSGSGTD  
FTLTISLQPEDFATYYCQQCNYPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVCLNNFYPRE  
AKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG  
EC

10 Leader sequence for immunoglobulin chains (SEQ ID: 79)

MGWSCIILFLVATATGVHS

Example 4: - Antibody expression

Recombinant antibody expression

15 Expression plasmids encoding the heavy and light chains respectively of chimeric or humanised antibodies were transiently co-transfected into HEK293E cells by lipid transfection using Fectin 293. Cells were grown in Freestyle expression media 293 with 10% pluronic F68 and 50mg/ml geneticin, 37 degrees C, 5% CO<sub>2</sub> for 72 – 120 hrs, supernatant was harvested by centrifugation. In some instances the supernatant material was used as  
20 the test article in binding assays. In other instances, the supernatant material was filter sterilised and the antibody recovered by affinity chromatography using Protein A MAbSelect SuRE column followed by dialysis into PBS.

Hybridoma antibody expression

25 The hybridoma cells were grown in shake flasks in Ex620 medium supplemented with 4mM glutamax and 10% low IgG FCS. The cells were passaged and weaned off serum until growing well in serum free medium. The cells were then used as a seed for a 10L wavebag. The cells were grown in the wavebag at 22 rocks/min, 37 degrees C, 5% CO<sub>2</sub> @ 0.1L/min

until viability dropped to 30%. The conditioned medium was collected by sterile filtration. Antibody was recovered by affinity chromatography using recombinant Protein A followed by dialysis into PBS.

5 Examples 5-7: Comparative data between hybridomas and/or chimeric mAbs and/or humanised Mabs

Example 5: Comparison of SAP-K and SAP-E hybridomas in human SAP binding ELISA

1  $\mu$ g/mL or 5  $\mu$ g/mL human SAP was directly immobilised onto an ELISA plate and blocked with 1%BSA/TBS plus 0.05% TWEEN20. Anti-SAP antibodies from purified material were titrated across the plate. Bound antibody was detected by treatment with a horse-radish peroxidase (HRP) -conjugated rabbit-anti-mouse IgG antibody (Dako, P0260). The ELISA was developed using O-phenylenediamine dihydrochloride (OPD) peroxidase substrate (Sigma, P9187).

Figure 1 shows the binding curves for murine antibodies SAP-E and SAP-K at a 1  $\mu$ g/mL coating concentration of human SAP.

Figure 2 shows the binding curves for murine antibodies SAP-E and SAP-K at a 5  $\mu$ g/mL coating concentration of human SAP.

At the 5  $\mu$ g/mL coating concentration, SAP-K and SAP-E showed similar binding to the immobilised human SAP, whereas at the 1  $\mu$ g/mL lower density coating SAP-K showed greater binding than the SAP-E. All subsequent human SAP binding ELISAs using this format used the lower density 1  $\mu$ g/mL coating concentration to distinguish between the binding properties of the two antibodies.

Example 6: Comparison of SAP-K and SAP-E chimeric/humanised mAbs in human SAP

25 binding ELISA

1 $\mu$ g/mL human SAP was directly immobilised onto an ELISA plate and blocked with 1%BSA/TBS plus 0.05% TWEEN20. Anti-SAP antibodies from the test supernatants or

purified material were titrated across the plate. Bound antibody was detected by treatment with goat anti-human Kappa Light Chains peroxidase conjugate (Sigma, A7164). The ELISA was developed using O-phenylenediamine dihydrochloride (OPD) peroxidase substrate (Sigma, P9187).

5 Figure 3 shows the binding curves for chimeric antibodies cSAP-E and cSAP-K. The profile of the curves for the chimeric antibodies is the same as that of the equivalent hybridomas.

Figure 4 shows the binding curves for SAP-K HOLO, SAP-K H1L0, SAP-K H2L0 and SAP-K H3L0 compared to the SAP-K chimera and the SAP-E H1L1 compared to the SAP-E chimera. An irrelevant human IgG1 kappa antibody was also tested as a negative control. The data shows

10 that humanisation of the SAP-K antibody resulted in a loss of human SAP binding activity of approximately 2-fold compared to the parental SAP-K chimera, whilst the humanised SAP-E antibody retained binding activity compared to the parental SAP-E chimera.

#### Example 7 - Competition ELISA

15 ELISA plates were coated with human SAP at either 1 $\mu$ g/mL (for competition with SAP-K chimera) or 5 $\mu$ g/mL (for competition with SAP-E chimera) and blocked with 1% BSA/PBS. A constant concentration of chimeric anti-SAP mAb was mixed with serial diluted (1:1) amounts of mouse anti-SAP mAbs. Plates were washed and the amount of chimeric antibody bound to the immobilised human SAP was detected using goat anti-human Kappa

20 Light chain peroxidase conjugate (Sigma, A7164). The ELISA was developed using O-phenylenediamine dihydrochloride (OPD) peroxidase substrate (Sigma, P9187).

Figure 5 shows purified SAP-K and SAP-E murine monoclonal antibodies in the competition ELISA with the SAP-E chimera.

25 Figure 6 shows purified SAP-K and SAP-E murine monoclonal antibodies in the competition ELISA with the SAP-K chimera.

In both figures 5 and 6 no competition is observed between the SAP-E and SAP-K antibodies showing that the two antibodies bind to distinct epitopes on the human SAP molecule.

Example 8: Determination of kinetics of bindingBiacore analysis of binding of humanised anti-SAP antibody variants to purified human and purified cynomologus monkey SAP.

Human and cynomologus monkey SAP were immobilised on a Biacore C1 chip by primary  
5 amine coupling in accordance with the manufacturer's instructions. Humanised anti-SAP antibody contained in culture supernatants and purified chimeric antibodies at 512nM were passed over both human and cynomologus monkey SAP surfaces and binding sensograms obtained.All runs were double referenced with a buffer injection for purified sample or media for the supernatant samples over the human and cyano SAP surfaces. Analysis was  
10 carried out at 25°C using HBS-EP buffer. Regeneration of surface was done in the presence of 3M MgCl<sub>2</sub> and did not affect the ability of antibodies to rebind to human SAP in a subsequent cycle. Data were analysed using the 1 to 1 dissociation model within the Biacore T100 evaluation software.

The data generated in Tables 6a and 6b show off-rates (kd) of the humanised SAP-E and  
15 SAP-K antibody supernatants respectively. The values were based on a single curve and used for ranking purposes between the different constructs for binding to human SAP. Humanised SAP-E antibodies showed better off-rates than the humanised SAP-K antibodies for binding human SAP. A number of the SAP-K humanised antibody variants showed binding to cynomologus monkey SAP (N.B. the SAP-K chimera bound cynomologus monkey  
20 SAP) whilst none of the humanised SAP-E antibody variants bound cynomologus monkey SAP (N.B. the SAP-E chimera likewise did not bind cynomologous monkey SAP). Humanised SAP-E variants which contained either the straight graft humanised heavy chain (H0) or the straight graft humanised light chain (L0) or a combination of both showed the poorest off-rates. The SAP-E humanised L1 light chain was the best light chain variant and combination  
25 of the L1 with the H1 heavy chain variant gave a humanised antibody with an acceptable off-rate whilst keeping the number of back mutations to a minimum. Off-rate ranking of the humanised SAP-K variants showed the L0 straight graft to be the best humanised light chain variant and the H0 straight graft to be the poorest humanised heavy chain variant.

**Table 6a**

| SAP-E Variant | Kd for human SAP (s <sup>-1</sup> ) |
|---------------|-------------------------------------|
| SAP-E chimera | 3.83E-03                            |
| SAP-E H1L1    | 4.80E-03                            |
| SAP-E H4L1    | 5.43E-03                            |
| SAP-E H1L2    | 5.51E-03                            |
| SAP-E H3L1    | 5.76E-03                            |
| SAP-E H4L2    | 5.80E-03                            |
| SAP-E H2L1    | 6.09E-03                            |
| SAP-E H3L2    | 6.31E-03                            |
| SAP-E H2L2    | 6.52E-03                            |
| SAP-E H1L0    | 8.09E-03                            |
| SAP-E H3L0    | 9.10E-03                            |
| SAP-E H2L0    | 9.79E-03                            |
| SAP-E H4L0    | 9.81E-03                            |
| SAP-E H0L1    | 4.02E-02                            |
| SAP-E H0L2    | 4.29E-02                            |
| SAP-E H0L0    | 5.35E-02                            |

**Table 6b**

N.B. Kd is for human SAP

|               | kd (s <sup>-1</sup> ) | Binding to cyno SAP |
|---------------|-----------------------|---------------------|
| SAP-K chimera | 6.64E-03              | Yes                 |
| SAP-K H1L0    | 1.71E-02              | poor                |
| SAP-K H3L0    | 1.84E-02              | Yes                 |
| SAP-K H2L0    | 2.04E-02              | Yes                 |
| SAP-K H3L1    | 2.36E-02              | yes                 |
| SAP-K HOLO    | 2.63E-02              | no                  |
| SAP-K H1L1    | 2.96E-02              | poor                |
| SAP-K H2L1    | 3.21E-02              | poor                |
| SAP-K HOL1    | 4.79E-02              | no                  |

Biacore analysis of binding of anti-SAP antibodies to purified human SAP directly5 immobilised on a solid phase support

Human SAP was immobilised on a Biacore CM3 chip by primary amine coupling in accordance with the manufacturer's instructions. Anti SAP antibodies were passed over this surface at 512, 128, 32, 8, 2, 0.5nM and binding sensorgrams obtained. All runs were double referenced with a buffer injection over the human SAP surface. Analysis was carried out at

10 25 °C using HBS-EP buffer. Regeneration of surface was done by allowing buffer to flow over the surface for several minutes and did not affect the ability of human SAP to rebind antibodies in a subsequent cycle. Data were analysed from the 128 – 0.5nM runs using the bivalent analyte model inherent to the Biacore T100 evaluation software.

The data generated and compiled in table 7 were meant for comparison between the

15 constructs and show that SAP-K antibodies have a better association rate in this assay while

SAP-E antibodies show better dissociation rates. Furthermore, humanization had not altered the binding kinetics of SAP-E antibody whilst for SAP-K a loss in association and dissociation rate was observed following humanisation.

**Table 7**

|               | Ka (M-1.s <sup>-1</sup> ) | Kd (s <sup>-1</sup> ) | KD (nM) |
|---------------|---------------------------|-----------------------|---------|
| SAP-K chimera | 4.06E+5                   | 7.59E-03              | 18.7    |
| SAP-K HOLO    | 6.08E+4                   | 4.49E-02              | 739     |
| SAP-K H1L0    | 1.15E+5                   | 1.78E-02              | 155     |
| SAP-K H2L0    | 1.15E+5                   | 2.20E-02              | 191     |
| SAP-K H3L0    | 1.50E+5                   | 1.92E-02              | 128     |
| SAP-E chimera | 2.64E+4                   | 2.18E-03              | 82.6    |
| SAP-E H1L1    | 2.64E+4                   | 2.07E-03              | 78.3    |

5

Biacore analysis of binding of anti-SAP antibodies to purified human SAP captured on immobilised O-phosphoethanolamine

O-phosphoethanolamine was immobilised on a Biacore CM5 chip by primary amine coupling in accordance with the manufacturer's instructions. Human SAP was then captured on the 10 surface in the presence of calcium chloride, in order to replicate in the Biacore system *in vitro*, the precise orientation of SAP molecules bound to amyloid fibrils *in vivo*. Anti SAP antibodies were then passed over this surface at 256, 64, 16, 4, 1nM and a binding sensorgrams obtained. Analysis was carried out at 25°C using 4% BSA, 10mM Tris, 140mM NaCl, 2mM CaCl<sub>2</sub>, 0.05% surfactant P20, 0.02% NaN<sub>3</sub>, pH 8.0 as running buffer. Regeneration 15 was achieved using two pulses of Tris-EDTA (10mM Tris, 140mM NaCl, 10mM EDTA, pH 8.0) which removed the bound human SAP but did not significantly affect subsequent binding of SAP to the immobilised phosphoethanolamine. Data generated were double referenced

with a buffer injection over the human SAP surface and analyzed using the bivalent analyte model in the Biacore T100 evaluation software.

The data generated, as shown in Table 8, are intended only for comparison between the constructs. They do not constitute accurate kinetic values, due to possible modification of binding by the avidity effect inherent in the assay format. Avidity is more likely to have affected antibody dissociation rates, leading to lower calculated KD values. Furthermore, for all the SAP-E antibodies, the dissociation rate (kd) obtained is outside the limit of the Biacore measurement range. Nevertheless, the results indicate tight binding of the anti-SAP antibodies to human SAP immobilised by interaction of the SAP with a solid phase ligand, just as it is in amyloid deposits *in vivo*, which is the therapeutic target of the present invention.

**Table 8**

|               | ka (M <sup>-1</sup> .s <sup>-1</sup> ) | kd (s <sup>-1</sup> ) | KD (nM)  |
|---------------|--|-----------------------|----------|
| SAP-K chimera | 3.32E+5                                | 2.97E-4               | 0.895    |
| SAP-E chimera | 2.03E+4                                | 9.12E-7               | 4.49E-11 |
| Mouse SAP-K   | 3.00E+5                                | 2.19E-4               | 0.730    |
| Mouse SAP-E   | 3.15E+4                                | 1.51E-8               | 4.79E-13 |
| SAP-K H3L0    | 1.36E+5                                | 5.01E-3               | 36.8     |
| SAP-E H1L1    | 1.94E+4                                | 1.58E-7               | 8.14E-12 |

15

Example 9: Amino acid scan at position 91 of SAP-K L0 humanised light chain

Site-directed saturation mutagenesis was used to generate a panel of variants where the cysteine residue at position 91 (Kabat numbering) was potentially substituted with all other

19 amino acids in a single reaction by using a mutagenesis primer encoding NNK at this position (where N codes for adenosine or cytidine or guanosine or thymidine and K codes for guanosine or thymidine). From Biacore off-rate ranking carried out on antibody supernatant for the variants generated, four were selected for scale up in the HEK2936E 5 cells and purification. Biacore kinetic analysis using the O-phosphoethanolamine method as detailed in Example 7 showed that the variant with alanine at position 91 (SEQ ID NO:43) had an improved affinity compared to the wild-type; KD values of 0.436 nM and 36.8 nM were measured respectively. N.B. all variants were tested in the same experiment used to produce the results shown in table 7.

10 Other variants, for example glycine, serine and valine improved binding with respect to H3L0, but to a lesser extent than alanine. In addition, the fact that these four variants had better binding properties than L0 was also observed in a binding ELISA and a Biacore off-rate ranking experiment when the light chains were paired with H1.

SAP-K humanised light chain V region variant L0 91A nucleotide sequence (codon optimised)  
15 (SEQ ID NO:73)

GACATCCAGATGACCCAGAGCCCCCTTCACTGAGCGCTAGCGTGGCGACAGGGTACCACCATCACC  
TGCAAGGCCAGCCAGAACGTGAACAGCAACGTGGCCTGGTACCAGCAGAACGCCGAAAGCCCC  
CAAGCTCCTGATCTACAGCGCCAGCTACAGATATAGCGGCGTGCCTAGCAGGTTAGCGGCAGCGG  
AAGCGGGACCGATTCAACCTGACCATCAGCAGCCTGCAGCCGAGGACTTCGCCACTTACTACTGC  
20 CAGCAGGCGAACAACTACCCCTCACCTCGGCCAGGGACCAAGCTGGAGATCAAG

SAP-K humanised light chain V region variant L0 91A amino acid sequence (SEQ ID NO:74)  
DIQMTQSPSSLSASVGDRVITCKASQNVNSNVAWYQQKPGKAPKLLIYSASYRSGVPSRSGSGSGTD  
FTLTSSLQPEDFATYYCQQANNYPFTFGQGTKLEIK

25 Example 10: Complement dependence of amyloid clearance by anti-SAP antibody.

The role of complement in amyloid clearance by anti-SAP antibody was investigated by comparing the efficiency of the treatment between mice with complement deficiency and normal, complement sufficient, animals. Targeted deletion of the gene for C1q blocks

activation of the classical complement pathway, which is initiated by binding of C1q to antibody-antigen complexes, but C3 activation, the pivotal functional step responsible for chemotaxis and opsonisation, the major biological functions of complement, can still proceed via the alternative and lectin pathways as well as by direct C3 cleavage by non-5 complement serine proteinases. Targeted deletion of the gene for C3 completely abrogates these functions.

#### Induction of AA amyloidosis

AA amyloidosis was induced and confirmed in two groups of complement deficient mice: C3 knockouts (n=14) and C1q knockouts (n=12), and in 15 wild-type mice. All mice were pure 10 line C57BL/6. Each mouse received a single dose of amyloid enhancing factor, an extract of amyloidotic tissue containing amyloid fibrils (Baltz et al, (1986) Plenum Press, New York, pp. 1 15-121), by intravenous injection followed 4 days later by 10 daily subcutaneous injections of 10% w/v casein in solution in 0.1M NaHCO<sub>3</sub> administered over a 12 day period (Botto et al, (1997) *Nature Med.*, 3: 855-859). Casein elicits persistent acute inflammation and a 15 sustained increase in serum amyloid A protein (SAA) production leading to AA amyloid deposition in all animals. Seven days after the last casein injection, KI was introduced into the drinking water of all mice and 3 days later each mouse received an intravenous injection of a standard dose of <sup>125</sup>I-labelled human SAP (Hawkins et al, (1990) *J. Clin. Invest.*, 86: 1862-20 1 869 and Hawkins et al, (1988) *J. Exp. Med.*, 167: 903-913). All mice underwent whole body counting 24h and 48h after the tracer injection to determine retention of radioactivity, a precise index of whole body amyloid load. Ten days after the <sup>125</sup>I-SAP tracer injection, all mice were 'loaded' with human SAP by a single intraperitoneal injection of 10 mg per mouse 25 of isolated pure human SAP. Human SAP injected into amyloidotic mice localises in the amyloid deposits and persists there with a half life of about 3-4 days whilst any human SAP not bound to amyloid is cleared from the circulation with a half life of about 3-4 hours (Hawkins et al, (1988) *J. Exp. Med.*, 167: 903-913 and Pepys et al, (2002) *Nature*, 41 7: 254-259).

30 Immunohistochemical staining with anti-human SAP antibody in spleen of an amyloidotic mouse after injection of isolated pure human SAP shows that there is strong positive staining of all the amyloid deposits in their typical marginal zone distribution. This bound

human SAP is the target of the therapeutic anti-SAP antibody according to the present invention.

#### Anti-SAP treatment

Three days after the human SAP injection, when human SAP was no longer detectable in the circulation, all mice except two in each of the complement knockout groups received a single intraperitoneal injection of 1 ml of the whole IgG fraction (batch no. 2866) of monospecific sheep anti-human SAP antiserum at 50 mg/ml in solution in phosphate buffered saline (PBS), containing 7 mg/ml of actual anti-SAP antibody. The antiserum was produced by The Binding Site Ltd, Birmingham, UK, using human SAP (rigorously purified to 100% in the University College London Centre for Amyloidosis and Acute Phase Proteins) and proprietary immunisation procedures. All animals were then killed 15 days after anti-SAP administration for histological estimation of amyloid load by alkaline alcoholic Congo red staining (Puchtler, H., Sweat, F. and Levine, M. (1962) On the binding of Congo red by amyloid. *J. Histochem. Cytochem.*, **10**: 355-364). Congo red sections of spleen and liver of all animals were independently examined by one or more expert observers, blinded to the treatment each mouse had received, and scored for the amount of amyloid present as previously reported (Botto et al, (1997) *Nature Med.*, 3 : 855-859). The scores of 1-5 represent an approximately log base 10 ranking scale from 1, corresponding to one or two tiny specks of amyloid among several sections of a particular organ, to 5, corresponding to 20 abundant widespread deposits comprising about 10,000 times more amyloid than grade 1 (Botto et al, (1997) *Nature Med.*, 3: 855-859). The scores of the different observers were always highly concordant although some observers also used intermediate integer.5 scores. The arithmetic mean of the scores of all observers for each organ in each animal were used for statistical analysis.

#### Results

In marked contrast to the effective clearance of amyloid deposits in the complement sufficient wild-type mice, there was still abundant amyloid present in both groups of complement deficient animals although it tended to have a more fragmented appearance than in the two control complement deficient mice of each type. The median, range, spleen 30 amyloid scores were: wild type, 1.17, 0.0-1.5, n=15; C3 knockout, 1.92, 1.17-4.33, n=12; C1q

knockout, 1.25, 1.17-3.5, n=10 (Kruskal-Wallis non-parametric ANOVA, P<0.001). The differences between the wild type controls and both complement deficient groups were significant, P<0.001 for the C3 knockouts and P=0.036 (with Bonferroni correction for multiple comparisons) for the C1q knockouts, but the difference between the C3 and C1q 5 knockouts was not significant, P=0.314 (Mann-Whitney U tests).

### Discussion

In mice lacking either C1q or C3, anti-SAP treatment did not clear amyloid deposits as effectively as in complement sufficient wild-type mice. The therapeutic efficacy of anti-SAP is thus very substantially complement dependent and is not mediated by IgG antibody 10 binding alone which could, in theory, engage phagocytic cells via their Fc( $\gamma$ ) receptors. Nevertheless the more fragmented appearance of the persistent amyloid deposits in the complement deficient mice suggested at least some effect of antibody alone. Also the trend to more clearance in C1q deficient compared to C3 deficient animals suggested that C3 activation is critical and that some complement activation may be taking place in the 15 absence of C1q.

### Example 11: Requirement for intact IgG anti-SAP antibody

Complement activation by IgG antibody requires the whole intact molecule, including the Fc region, and proceeds via the classical pathway initiated by binding of C1q. However, in 20 some antibody-antigen systems, complement activation via the alternative pathway can be mediated by the F(ab)<sub>2</sub> fragment. In order to confirm the complement dependence of amyloid clearing by anti-SAP antibody and to investigate the potential requirement for the Fc region of the antibody, the effect was tested of F(ab)<sub>2</sub> anti-SAP antibody which was produced by pepsin cleavage at pH 4.0 of the IgG fraction of the sheep polyclonal anti- 25 human SAP antiserum (batch 2866) and purified by standard methods.

### Induction and treatment of AA amyloidosis

AA amyloidosis was induced and confirmed in wild-type C57BL/6 mice as detailed in Example 10 above. After loading the amyloid deposits with human SAP also as detailed in

Example 10, groups of mice were treated with whole IgG fraction of the sheep polyclonal anti-human SAP antiserum, with buffer vehicle alone or with the F(ab)<sub>2</sub> fragment of the IgG fraction. The dose of anti-SAP antibody activity injected was 7.28 mg per mouse receiving F(ab)<sub>2</sub> and 7 mg (50 mg of total IgG as usual) per mouse receiving whole IgG. All mice were 5 killed 14 days later for estimation of amyloid load by Congo red staining.

### Results

Clearance of amyloid deposits was almost complete in mice receiving IgG anti-SAP antibody compared to the massive amyloid deposits in the control mice receiving vehicle alone. The mice receiving F(ab)<sub>2</sub> had less amyloid than untreated controls, but still substantially more 10 than the mice treated with whole IgG anti-SAP antibody (Table 9).

**Table 9. Reduced efficacy of F(ab)<sub>2</sub> anti-SAP compared to intact IgG antibody in clearing amyloid deposits.**

| Group<br>(treatment, group size)              | Amyloid score<br>median, range |                 |
|---|--------------------------------|-----------------|
|   | Spleen                         | Liver           |
| 1 (no antibody, n=10)                         | 4.0, 4.0-4.33                  | 3.5, 2.67-4.67  |
| 2 (IgG anti-SAP antibody, n=8)                | 1.0, 1.0-3.67*                 | 1.25, 1.0-1.5   |
| 3 (F(ab) <sub>2</sub> anti-SAP antibody, n=5) | 2.17, 1.33-3.0                 | 1.67, 1.33-1.67 |

Kruskal-Wallis test: spleen, P<0.001; liver P<0.001

15 Mann-Whitney tests\*\*: 1 vs 2, spleen & liver both, P<0.001; 1 vs 3, spleen & liver both, P=0.001; 2 vs 3, spleen, P=0.284; liver, P=0.019

\*Single outlier in group 2 with heavy spleen amyloid despite IgG anti-SAP treatment. Excluding this animal gives a highly significant difference between efficacy of IgG and F(ab)<sub>2</sub> anti-SAP antibody treatment. \*\*Due to the multiple comparisons, a P value of 0.01 or less is 20 required for significance

## Discussion

The molar dose of F(ab)<sub>2</sub> anti-SAP antibody used in this study was about one third greater than that of IgG antibody, due to the smaller molecular weight of the F(ab)<sub>2</sub> fragment compared to whole IgG. For optimal effect on amyloid clearance the Fc is required. This is

5 not because of direct involvement of cellular recognition by Fc( $\gamma$ ) receptors since the whole IgG was even less effective in complement deficient mice than was F(ab)<sub>2</sub> in complement sufficient mice. It is likely that the high dose of F(ab)<sub>2</sub> that was administered was able to activate some complement via the alternative pathway.

10 Example 12: Requirement for macrophages

The histological and histochemical studies described in US 2009/0191196 show that the cells which infiltrate, surround and phagocytose the amyloid deposits in mice treated with anti-SAP antibody are macrophages. In order to confirm that macrophages are indeed responsible for the clearance of the amyloid, the effect of treatment with the whole IgG

15 fraction of the sheep polyclonal anti-human SAP antiserum (batch 2866) was tested in mice in which all macrophage activity had been inhibited by administration of liposomal clodronate. The reagents, experimental protocol and effects on macrophage function of liposomal clodronate are well established and extensively documented (Van Rooijen et al, (2002) *J. Liposome Research*. Vol. 12. Pp, 81-94).

20 Induction and treatment of AA amyloidosis

After induction and confirmation of AA amyloidosis in wild-type mice, using the protocol detailed in Example 10 above, all animals received a single intraperitoneal dose of 10 mg of isolated pure human SAP to load their deposits with human SAP. The test group then received 0.3 ml of liposomal clodronate intraperitoneally immediately and on days 2, 7 and

25 14 thereafter. One control group and the test group received a single intraperitoneal dose of 50 mg of the IgG fraction of sheep anti-human SAP antiserum on day 3 after the human SAP injection. A second control group received no anti-SAP and no other additional treatment. All mice were killed for estimation of amyloid load by Congo red staining 14 days after administration of the anti-SAP to the test and antibody control groups.

## Results

Treatment with anti-SAP produced almost complete clearance of amyloid deposits compared to the group which received no antibody. In contrast, in mice which received the liposomal clodronate in a regime known to completely ablate macrophage function, there 5 was no clearance of amyloid deposits (Table 10).

**Table 10. Macrophage depletion inhibits clearance of amyloid deposits by anti-SAP antibody.**

| Group<br>(treatment, group size)   | Amyloid score<br>median, range |                |
|------------------------------------|--------------------------------|----------------|
|                                    | Spleen                         | Liver          |
| 1 (clodronate plus anti-SAP, n=13) | 4.83, 2.0-5.0                  | 3.17, 2.0-3.5  |
| 2 (anti-SAP only, n=12)            | 1.33, 0.67-3.5                 | 1.0, 0.67-2.5  |
| 3 (none, n=12)                     | 4.0, 3.5-4.5                   | 2.83, 1.0-3.17 |

Kruskal-Wallis test: spleen, P<0.001; liver P<0.001

10 Mann-Whitney tests with Bonferroni correction: 1 vs 2: spleen & liver both, P<0.003; 1 vs 3: spleen, P=0.078; liver, P=0.411; 2 vs 3, spleen & liver both, P<0.003.

## Discussion

The result in this particular experiment confirmed that macrophage function is required for clearance of amyloid deposits by anti-human SAP antibody.

Example 13: Efficacy of mouse monoclonal anti-human SAP antibody, SAP-E, in clearing mouse systemic AA amyloid deposits.

The capacity of various monoclonal antibodies to mediate clearance of murine AA amyloid deposits containing human SAP was sought in comparison with the standard sheep polyclonal anti-human SAP antibody as a positive control.

Induction of AA amyloidosis and treatment

SAP knockout C57BL/6 mice transgenic for human SAP were created by crossing pure line C57BL/6 animals in which the mouse SAP gene has been deleted (Botto et al, (1997) *Nature Med.*, 3: 855-859) with C57BL/6 mice bearing a human SAP transgene (Yamamura et al, (1993) *Mol. Reprod. Dev.*, 36: 248-250 and Gillmore et al, (2004) *Immunology*, 112: 255-264). These mice thus lack mouse SAP but express human SAP at concentrations significantly greater than those seen in man. Systemic AA amyloidosis was induced in the human SAP transgenic mouse SAP knockout mice as described in Example 10, and 9 days after the final injection of casein into the mice, the presence and extent of amyloid deposition were confirmed as usual by whole body counting of amyloid after injection of a tracer dose of <sup>125</sup>I-labelled human SAP. All mice had substantial and comparable amounts of amyloid, and were allocated into closely matched groups to receive the different treatments. One week after the tracer injection, each mouse received a single dose of 5 mg CPHPC by intraperitoneal injection, to deplete their circulating human SAP, followed 5h later via the same route by either the standard sheep polyclonal anti-human SAP IgG fraction (batch 2866, 1 ml at 50 mg/ml total protein containing 7 mg/ml anti-human SAP antibody) or 5 mg of one of nine different isolated pure monoclonal anti-human SAP antibodies (Table 11). All mice were killed 21 days after the antibody injection and amyloid load was determined by Congo red histology of their spleens.

**Table 11. The presence of amyloid in spleen of mice with systemic AA amyloidosis after treatment with CPHPC and various anti-human SAP antibodies.**

| Antibody treatment      | Antibody isotype | Amyloid score<br>median, range |
|-------------------------|------------------|--------------------------------|
| none                    |                  | <b>3, 3-5</b>                  |
|                         |                  |                                |
| <b>polyclonal</b>       | <b>NA</b>        | <b>1, 1-1</b>                  |
|                         |                  |                                |
| monoclonal SAP-A        | IgG1             | 3, 2-4                         |
| monoclonal SAP-B        | IgG2a            | 3, 2-4                         |
| monoclonal SAP-C        | IgG1             | 4, 2-4                         |
| monoclonal SAP-D (n=1)  | IgG1             | 4                              |
|                         |                  |                                |
| <b>monoclonal SAP-E</b> | <b>IgG2a</b>     | <b>1, 1-1</b>                  |
|                         |                  |                                |
| monoclonal SAP-F (n=1)  | IgG1             | 2                              |
| monoclonal SAP-G        | IgG1             | 3, 2-4                         |

Among the monoclonal antibodies tested, only SAP-E produced clearance of the amyloid deposits but its effect was the same as the highly reproducible and dramatic action of the sheep polyclonal antibody. Importantly SAP-E is of the mouse IgG2a isotype which is known to activate mouse complement while all the other monoclonals except SAP-B were mouse IgG1 isotype which is not complement activating. Although SAP-B is a mouse IgG2a isotype, its binding to SAP *in vitro* was notably less than that of SAP-E and evidently was not sufficient *in vivo* to be effective.

## Discussion

These results demonstrate that a sufficiently avid, complement activating, IgG2a mouse monoclonal anti-human SAP antibody mediates amyloid clearance *in vivo* as effectively as sheep polyclonal anti-human SAP antibody.

5

### Example 14: Comparative characterisation of monoclonal mouse anti-human SAP antibodies, SAP-K and SAP-E, *in vitro*.

SAP-K was selected from among the 6 different, most avidly binding, mouse IgG2a monoclonals, derived by standard techniques from immunization with purified human SAP 10 and a conventional fusion to produce hybridomas which were cloned by routine methods. Among these IgG2a antibodies, SAP-K showed the greatest binding to immobilised human SAP. This was the case regardless of whether the human SAP had been directly immobilised 15 on plastic surfaces by non-specific adherence or by covalent attachment, or by the specific calcium dependent binding of SAP to immobilised ligands, whether amyloid fibrils or the small molecule ligand, phosphoethanolamine. SAP-K also bound well to directly immobilised SAP in the presence or absence of calcium, and if the SAP had previously been complexed with CPHPC and then covalently 'fixed' in the decameric SAP-CPHPC complex (Pepys, M.B. *et al* (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. *Nature*, 417: 254-259; Kolstoe, S.E. *et al* 20 (2009) Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. *Proc. Natl. Acad. Sci. USA*, 106: 7619-7623). SAP-E also bound well to human SAP in all these different configurations. However the two antibodies differ significantly in that much more SAP-K than SAP-E became bound when human SAP was only sparsely available, for example when plates were exposed to just 1 µg/ml of human SAP for 25 coating, whereas when there was more abundant immobilised SAP, for example when the coating solution contained 100 µg/ml of SAP, then there was more binding of SAP-E than SAP-K. This difference suggest that SAP-E binds optimally when more than one SAP molecule lies closely associated with another whilst SAP-K binds avidly to single isolated SAP molecules. This mechanism is supported by the finding that when human SAP was 30 immobilised by capture on plates coated with polyclonal sheep anti-human SAP (batch

2866), which provides pairs of SAP molecules held closely together in the two arms of each sheep IgG antibody molecule, SAP-E bound better than SAP-K at all levels of human SAP input (Figure 7).

Figure 7 shows immunoradiometric assay for binding of monoclonal mouse antibodies to 5 human SAP captured by immobilised sheep polyclonal anti-human SAP antibody. Substantially more SAP-E than SAP-K bound at all concentrations of human SAP offered. Each point is the mean of 3 replicates.

Very importantly, both SAP-E and SAP-K bound apparently equally well to native human SAP, shown by the similar immunoprecipitation of both antibodies in double 10 immunodiffusion in agarose gel against both isolated pure human SAP and whole human serum. The similar binding of these two mouse monoclonal antibodies was reflected in the similar parameters measured in the Biacore instrument (BIAcoreX, Pharmacia Biosensor AB, Uppsala, Sweden) using human SAP covalently immobilised on the chip (Table 12).

15 **Table 12. Affinity of monoclonal antibodies for human SAP determined by Biacore**

|       | $k_a (M^{-1} sec^{-1})$  | $k_d (sec^{-1})$             | $K_D (M)$                  |
|-------|--------------------------|------------------------------|----------------------------|
| SAP-E | $2 \pm 5 \times 10^4$    | $6 \pm 4 \times 10^{-5}$     | $5 \pm 4 \times 10^{-9}$   |
| SAP-K | $3.18 \pm 5 \times 10^4$ | $1.7 \pm 0.9 \times 10^{-5}$ | $1 \pm 1.7 \times 10^{-9}$ |

Values shown are mean and SD of 3 replicate measurements

In contrast, although both antibodies bound to native human SAP in western blotting after agarose gel electrophoresis in physiological buffers, only SAP-E bound to human SAP in western blotting from reduced SDS-PAGE. SAP-E thus recognises denatured human SAP 20 while SAP-K only recognises native human SAP and must be binding to a conformational epitope.

CNBr digestion of human SAP results in cleavage between 159M and 160W resulting in a new peptide where position 159 has been converted from methionine to homoserine lactone (termed 150-158-homoserine lactone). In western blotting from SDS-PAGE, SAP-E

bound to the *N*-terminal 1-158-homoserine lactone polypeptide released by CNBr cleavage of SAP at residue Met159, but scarcely reacted with the 1-140 fragment released by chymotrypsin digestion in the absence of calcium (Figure 8). The epitope recognised by SAP-E must therefore be in the region 140-158 which evidently comprises some 5 denaturation resistant secondary structure since SAP-E binding is not potently inhibited by the peptides 136-147, 138-149, 140-151 and 112-119 in solution. This is consistent with the kinetic stability and resistance to denaturation of SAP (Manning, M. and Colón, W. (2004) *Biochemistry*, 43: 11248-11254).

Figure 8 shows epitope mapping for monoclonal anti-human SAP antibody, SAP-E. **A**, complete amino acid sequence of human SAP showing the points at which it is cleaved by CNBr in 70%TFA (residue 159M) and by chymotrypsin, without reduction/carbamidomethylation, in ammonium bicarbonate in the absence of calcium, (residues 140Y and 144F). **B**, SDS-PAGE analysis of SAP cleaved with CNBr. Left panel: Coomassie blue stain; lane 1, untreated control SAP; lane 2, SAP after CNBr cleavage, showing trace residual uncleaved intact protomer and the expected fragments at approximately 20kD (residues 1-158-homoserine-lactone) and 5kD (160-204) respectively. These were precisely confirmed by mass spectrometry. Right panel: Western blot with SAP-5 showing intense staining of intact untreated SAP in lanes 1 (100 ng loaded) and 2 (10 ng), and also residual intact SAP and the larger residue 1-158-homoserine-lactone fragment in CNBr cleaved SAP in lanes 3 (600 ng), 4 (130 ng) and 5 (64 ng). Lane 6 contained isolated pure human CRP with which the SAP-5 did not react at all. **C**, SDS-PAGE analysis of SAP digested with chymotrypsin. Left panel: Coomassie blue stain; lane 1, untreated control SAP; lane 2, SAP after chymotrypsin digestion, showing the expected major fragments corresponding to residues 1-140 and 145-204. These were precisely confirmed by mass spectrometry. Right panel: Western blot with SAP-E showing intense staining of intact untreated SAP in lanes 1 (500 ng loaded) and 2 (100 ng), and also residual intact SAP in lanes 3 and 4 which contained the chymotrypsin digested SAP at different loadings. Very weak binding of SAP-E to the residue 1-140 fragment is seen only in lane 3 which was most heavily loaded. Lanes 5 (500 ng) and 6 (100 ng) contained isolated pure human CRP with which the SAP-E did not react at all. **D**, Sequence comparison between human SAP (h) and mouse SAP (m) for residues 136-147. Top panel, differences indicated above by residues shown in black

in the murine sequence. Bottom panel, position of this extended loop with 140Y at its apex shown in white in the 3D subunit structure of human SAP. The different residues in the murine sequence are shown in black. The grey spheres represent the calcium atoms bound in the ligand binding pocket.

The conformational epitope recognised by SAP-K was identified by CLIPS® technology epitope mapping (Pepscan Presto BV) as the exposed peripheral loop, residues 121-131, at the circumference of the disc like pentameric native SAP molecule.

5 Figure 9 shows the location of the epitopes on human SAP recognised by SAP-K (A, highlighted in black, as determined by CLIPS® technology) and SAP-E (B, shown in white, 140-158 as determined by binding results with the CNBr cleavage product of SAP and the fragment released by chymotrypsin digestion in the absence of calcium).

10 Example 15: Efficacy of SAP-K mouse monoclonal anti-human SAP antibody in clearing amyloid deposits *in vivo* in the mouse AA amyloidosis model.

The potency of SAP-K was compared with the action of the standard sheep polyclonal antibody in clearing established systemic AA amyloid deposits in mice.

#### Induction of AA amyloidosis and treatment

15 AA amyloidosis was induced and confirmed in wild-type C57BL/6 mice as detailed in Example 10 above. After loading the amyloid deposits with human SAP also detailed in Example 10, groups of mice were treated with 50 mg per mouse of total IgG as the whole IgG fraction (batch 2866) of the sheep polyclonal anti-human SAP antiserum providing a dose of 7 mg of actual anti-SAP antibody, isolated purified SAP-K at a dose of 5 mg per 20 mouse, isolated purified SAP-K at a dose of 1 mg per mouse, and, as a negative control, isolated purified monoclonal mouse IgG2a antibody specific for an unrelated human antigen and unreactive with either human SAP or any murine antigen. All mice were killed 17 days later for estimation of amyloid load by Congo red staining.

## Results

The mice treated with 5 mg of SAP-K showed the same remarkable clearance of splenic and hepatic amyloid deposits as seen with the 7 mg dose of sheep polyclonal antibody. Only trace specks of amyloid remained in the spleens of the treated mice and none at all was 5 detected in many of the livers, contrasting sharply with the extensive splenic and hepatic amyloid deposits in all animals which received the irrelevant control mouse IgG2a antibody (Table 13). At the lower doses of 1 mg, 0.5 mg and 0.1 mg (data not shown for 0.5 mg and 0.1 mg) of SAP-K per mouse, there was no significant effect.

10 **Table 13. Effect of monoclonal mouse IgG2a anti-human SAP antibody SAP-K on visceral amyloid deposits in mice with systemic AA amyloidosis.**

| Group (treatment, group size)  | Amyloid score  |                |
|--|----------------|----------------|
|  | median, range  |                |
| 1 (negative control mouse IgG2a, n=8)                                | 4.08, 1.5-4.50 | 2.42, 2.0-2.67 |
| 2 (7 mg sheep polyclonal IgG anti-human SAP antibody, n=5)           | 1.17, 1.0-1.5  | 1.0, 0.67-1.17 |
| 3 (1 mg monoclonal mouse IgG2a anti-human SAP antibody, SAP-K, n=10) | 3.5, 2.83-4.5  | 1.83, 1.0-2.83 |
| 4 (5 mg monoclonal mouse IgG2a anti-human SAP antibody, SAP-K, n=10) | 1.25, 1.0-2.0  | 1.0, 1.0-1.33  |

Kruskal-Wallis test: spleen, P<0.001; liver P<0.001

Mann-Whitney tests\*: 1 vs 2, spleen, P=0.002; liver, P=0.002; 1 vs 3, spleen, P=0.173; liver, 15 P=0.083; 1 vs 4, spleen, P<0.001; liver, P<0.001; 2 vs 3, spleen, P=0.0001; liver, P=0.019; 2 vs

4, spleen, P=0.513; liver, P=0.768; 3 vs 4, spleen, P<0.001; liver, P=0.004. \*Due to the multiple comparisons, a P value of 0.01 or less is required for significance.

### Discussion

These results demonstrate the efficacy in clearing amyloid deposits *in vivo* of a monoclonal 5 anti-human SAP antibody, of the complement activating mouse IgG2a isotype, which specifically recognizes a conformational epitope. Thus monoclonal anti-human SAP antibodies for use according to the present invention can be directed at either predominantly sequence epitopes, such as antibody SAP-E, or at entirely conformational epitopes, such as SAP-K.

10

### Example 16: Comparison of efficacy of SAP-E and SAP-K in clearing systemic AA amyloid deposits in mice, and estimation of plasma anti-SAP antibody concentrations.

#### Induction of AA amyloidosis and treatment

AA amyloidosis was induced and confirmed in wild-type C57BL/6 mice as detailed in 15 Example 10 above. After loading the amyloid deposits with human SAP also detailed in Example 10, groups of mice were treated with 3 mg and 1 mg per mouse of the two different antibodies. A control group, in which amyloid was also induced, received just PBS instead of antibody and two further groups were given the known effective dose of 20 5 mg/mouse of each antibody. All mice were bled for assay of circulating anti-SAP antibody at days 1, 5 and 15 after dosing with antibody, and all were killed on day 21 for estimation of amyloid load by Congo red staining. All sera were assayed for anti-SAP activity using a robust immunoradiometric assay standardised with purified SAP-E and SAP-K respectively, spiked at known concentrations into normal mouse serum.

#### Results

25 Amyloid load was scored by four independent expert observers all blinded to the identity of each tissue examined. The scores of all observers were, as usual highly concordant and for statistical analysis, the total scores of all observers for both spleen and liver for each mouse were summed. Both antibodies were efficacious, as previously demonstrated, and there

was a clear dose dependent effect but SAP-E was apparently more potent than SAP-K at the lower doses.

**Table 14. Comparison of potency between SAP-E and SAP-K in clearing visceral AA**

5 **amyloid deposits**

| Group<br>(treatment, no. of mice) | Spleen plus liver amyloid score<br>median, range |
|-----------------------------------|--|
| C (negative control, PBS only)    | 6.81, 4.25-8.0                                   |
| K5 (SAP-K 5 mg, n=5)              | 2.25, 2.25-2.5                                   |
| K3 (SAP-K 3 mg, n=10)             | 2.81, 2.0-4.25                                   |
| K1 (SAP-K 1 mg, n=10)             | 5.63, 4.0-6.5                                    |
| E5 (SAP-E 5 mg, n=5)              | 2.0, 1.5-2.38                                    |
| E3 (SAP-E 3 mg, n=10)             | 2.5, 2.0-5.0                                     |
| E1 (SAP-E 1 mg, n=10)             | 3.38, 2.5-5.63                                   |

Kruskal-Wallis test: P<0.001

Mann-Whitney tests\*: K5 vs E5, P=0.095; K3 vs E3, P=0.684; K1 vs E1, P=0.001; K5 vs K3,

P=0.594; K5 vs K1, P=0.001; K3 vs K1, P<0.001; E5 vs E3, P=0.008; E5 vs E1, P=0.001; E3 vs

10 E1, P=0.004; K5 vs C, P=0.001; E5 vs C, P=0.001; K3 vs C, P<0.001; E3 vs C, P<0.001; K1 vs C,

P=0.043; E1 vs C, P<0.001. \*Due to the multiple comparisons, a P value of 0.01 or less is

required for significance.

The concentrations of circulating anti-SAP antibody activity were strongly and consistently

15 dose dependent after the single dose administered to all animals, apart from a single

outlying individual in each of the lower dose groups. After the 1 mg per mouse dose,

nothing above background was generally detectable even at day 1 in most mice. In

contrast, after the 5 mg dose abundant antibody was still present at 15 days, and after 3 mg most mice had circulating antibody at day 5 but few after 15 days (Table 15). There was no significant difference between the patterns for SAP-E and SAP-K.

5 **Table 15. Serum concentration of anti-SAP antibody after single intraperitoneal doses.**

| Group<br>(dose of<br>anti-SAP<br>antibody) | anti-SAP concentration after dosing<br>median, range (µg/ml)* |              |            |
|--|---|--------------|------------|
|  | 1 day   | 5 days       | 15 days    |
| K5<br>(SAP-K 5 mg)                         | 950, 840-1200   | 400, 300-480 | 45, 25-90  |
| E5<br>(SAP-E 5 mg)                         | 1000, 800-1500  | 600, 360-700 | 80, 15-113 |
| K3<br>(SAP-K 3 mg)                         | 240, 50-600   | 40, 8-280    | 8, 6-30    |
| E3<br>(SAP-E 3 mg)                         | 275, 4-480  | 48, 0-240    | 4, 2-68    |
| K1<br>(SAP-K 1mg)                          | 7, 7-90   | 6, 5-38      | 4, 2-9     |
| E1<br>(SAP-E 1mg)                          | 7, 6-280  | 7, 6-120     | 5, 3-12    |
| C<br>(PBS only)                            | 5, 5-7  | 5, 5-13      | 5, 5-16    |

\*Apparent anti-SAP antibody concentrations below 17 µg/ml are background for the assay and represent no genuine activity.

10 Discussion

In direct head to head comparison there was consistent evidence that SAP-E was slightly but significantly more potent than SAP-K. After administration of 1 mg per mouse no circulating anti-SAP antibody activity was detectable one day later, having evidently all localised to human SAP within the amyloid deposits. After the 3 mg dose abundant anti-SAP was 15 present in the circulation at day 1 and was still present at day 5. After 5 mg per mouse there was still a significant concentration of anti-SAP in the blood after 15 days. These

observations suggest that repeated small doses of anti-SAP antibody may be sufficient to trigger amyloid clearance.

Example 17: Comparison of efficacy of low dose SAP-E and SAP-K in clearing systemic AA

5 amyloid deposits in mice.

Induction of AA amyloidosis and treatment

AA amyloidosis was induced and confirmed in wild-type C57BL/6 mice as detailed in Example 10 above. After loading the amyloid deposits with human SAP as also detailed in Example 10, groups of mice (n=10 each) were treated with single doses of either 0.5 mg and 10 1 mg per mouse of the two different antibodies, or 6 repeated doses of 0.15 mg, given at 3 or 4 day intervals. A control group (n=9), in which amyloid was also induced, received just PBS instead of antibody and two further groups (n=3 each) were given the known effective dose of 5 mg/mouse of each antibody. All were killed on day 29 for estimation of amyloid load by Congo red staining.

15 Results

The low doses, including the repeated very low dose, showed significant efficacy in reducing amyloid load, especially in the liver. SAP-E was again apparently more potent than SAP-K.

20 **Table 16. Comparison of potency between low doses of SAP-E and SAP-K in clearing visceral AA amyloid deposits**

| Group                        | Amyloid score, (median, range) |                |
|------------------------------|--------------------------------|----------------|
|                              | Spleen                         | Liver          |
| C, negative control PBS only | 4.5, 4.0-4.75                  | 3.25, 2.0-4.0  |
| E1, SAP-E 1 mg               | 1.25, 1.0-4.25                 | 1.0, 0.5-1.25  |
| E0.5, SAP-E 0.5 mg           | 4.75, 1.0-5.0                  | 1.0, 0.5-3.5   |
| Erep, SAP-E 6x 0.15 mg       | 3.5, 2.0-4.5                   | 0.5, 0.0-3.25  |
| K1, SAP-K 1 mg               | 4.13, 1.0-5.0                  | 1.0, 0.0-4.0   |
| K0.5, SAP-K 0.5 mg           | 4.25, 1.75-4.5                 | 1.13, 0.0-2.75 |

|                        |                |               |
|------------------------|----------------|---------------|
| Krep, SAP-K 6x 0.15 mg | 4.38, 1.5-4.75 | 1.0, 0.0-2.25 |
|------------------------|----------------|---------------|

Kruskal-Wallis test: spleen, P<0.001; liver, P=0.001

Mann-Whitney tests\*: E1 vs C: spleen, P<0.001; liver P<0.001; E0.5 vs C: spleen, P=0.604; liver P=0.004; Erep vs C: spleen, P0.002; liver, P<0.001; K1 vs C: spleen, P=0.065; liver, P=0.001; K0.5 vs C: spleen, P=0.022; liver, P=0.001; Krep vs C: spleen, P=0.079; liver, P<0.001; E1 vs E0.5: spleen, P=0.005; liver P=0.143; E1 vs Erep: spleen, P=0.043; liver, P=0.280; E0.5 vs Erep: spleen, P=0.019; liver, P=0.043; K1 vs K0.5: no significant differences; K1 vs Krep: no significant differences; K0.5 vs Krep: no significant differences; E1 vs K1: spleen, P=0.015; liver, P=0.353; E0.5 vs K0.5: no significant differences; Erep vs Krep: no significant differences. \*Due to the multiple comparisons, a P value of 0.01 or less is required for significance.

### Discussion

The significantly greater potency of SAP-E than SAP-K appears to be reproducible. The efficacy of even very low doses when administered repeatedly and the suggestion of greater effects on liver than spleen amyloid deposits are of interest and potential clinical significance.

### Example 18: Activation of complement by humanised monoclonal anti-human SAP antibodies *in vitro*.

Complement activation is essential for efficacy of amyloid clearing by anti-human SAP antibodies according to the present invention. The capacity of the humanised monoclonal antibodies, SAP-E H1L1 and SAP-K H3L0, to activate C3 in human and mouse serum was compared *in vitro* by adding different amounts of the isolated pure antibodies to either whole human serum containing a SAP concentration of 30 mg/l, or to whole mouse serum which had been spiked with isolated pure human SAP to this same concentration. In both cases the serum was fresh and complement sufficient and experimental conditions were optimal for complement activation with complement fixation test buffer (CFT) as the diluent.

The following mixtures were made (Table 17):

| Tube no. | Serum             | Monoclonal<br>anti-SAP antibody | Final concentrations (µg/ml) |           |
|----------|-------------------|---------------------------------|------------------------------|-----------|
|          |                   |                                 | Anti-SAP                     | Human SAP |
| M1       | Mouse + human SAP | SAP-E H1L1                      | 15                           | 30        |
| M2       | Mouse + human SAP | SAP-E H1L1                      | 30                           | 30        |
| M3       | Mouse + human SAP | SAP-E H1L1                      | 60                           | 30        |
| M4       | Mouse + human SAP | SAP-E H1L1                      | 120                          | 30        |
| M5       | Mouse + human SAP | SAP-K H3L0                      | 15                           | 30        |
| M6       | Mouse + human SAP | SAP-K H3L0                      | 30                           | 30        |
| M7       | Mouse + human SAP | SAP-K H3L0                      | 60                           | 30        |
| M8       | Mouse + human SAP | SAP-K H3L0                      | 120                          | 30        |
| M9       | Mouse + human SAP | None                            | 0                            | 30        |
|          |                   |                                 |                              |           |
| H1       | Human             | SAP-E H1L1                      | 15                           | 30        |
| H2       | Human             | SAP-E H1L1                      | 30                           | 30        |
| H3       | Human             | SAP-E H1L1                      | 60                           | 30        |
| H4       | Human             | SAP-E H1L1                      | 120                          | 30        |
| H5       | Human             | SAP-K H3L0                      | 15                           | 30        |
| H6       | Human             | SAP-K H3L0                      | 30                           | 30        |
| H7       | Human             | SAP-K H3L0                      | 60                           | 30        |
| H8       | Human             | SAP-K H3L0                      | 120                          | 30        |
| H9       | Human             | None                            | 0                            | 30        |

5 All tubes were incubated at 37°C for 2 hours to enable complement activation to proceed. Since slow spontaneous activation always occurs in serum, two additional controls were provided, replicates of M9 and H9, designated M10 and H10, which were not incubated but were frozen at -80°C immediately after mixing and then thawed just before assaying for C3

cleavage. Comparison between M/H9 and M/H10 enables distinction between spontaneous C3 cleavage and any additional activation produced by the anti-SAP antibody, as well as any effect of addition of human SAP alone t mouse serum.

5 C3 cleavage in human serum was assayed by two dimensional electroimmunophoresis using monospecific antibody against human C3. This method is of low sensitivity for mouse C3 cleavage because the different electrophoretic mobilities of mouse C3 are more difficult to distinguish reliable than is the case with human C3. Mouse C3 cleavage was therefore assayed by agarose gel electrophoresis followed by immunoblotting with monospecific anti-10 mouse C3 antibody.

### Results

Both humanised antibodies efficiently activated human complement, evidenced by major dose dependent cleavage of C3, producing reduction in the size of the slower mobility 15 native C3 immunoprecipitation peak and increase in the size of the faster cleaved C3c peak (Figure 10).

Figure 10 shows C3 activation by humanised monoclonal anti-human SAP antibodies in whole human serum.

In an assay including the control for baseline C3 cleavage in sample H10, it is clear that even 20 the lowest dose of both anti-SAP antibodies produces more C3 cleavage than seen in the no antibody, spontaneous cleavage, control (Figure 11).

Figure 11 shows C3 activation by low dose humanised monoclonal anti-human SAP antibodies in whole human serum.

Very similar results were obtained for cleavage of mouse C3 in whole mouse serum 25 supplemented with human SAP. Both antibodies showed dose dependent cleavage of native mouse C3 leading to decreased intensity of the slow mobility native C3 band and increased intensity of the faster mobility activated form. Also even the lowest dose of each antibody produced more C3 cleavage than was seen in the no antibody, spontaneous activation, control (Figure 12).

Figure 12 shows C3 activation by humanised monoclonal anti-human SAP antibodies in whole mouse serum supplemented with pure human SAP.

### Discussion

Both humanised monoclonal anti-human SAP antibodies efficiently activate complement in 5 the presence of human SAP and are thus suitable candidates for use in treatment of systemic amyloidosis, and any other disease caused by extracellular amyloid deposits in the tissues, according to the present invention.

## SEQUENCE CONCORDANCE

| SEQ ID NO | Sequence description  |
|-----------|---|
| 1         | SAP-E CDRH1 amino acid sequence   |
| 2         | SAP-E CDRH2 amino acid sequence   |
| 3         | SAP-E CDRH3 amino acid sequence   |
| 4         | SAP-E CDRL1 amino acid sequence   |
| 5         | SAP-E CDRL2 amino acid sequence   |
| 6         | SAP-E CDRL3 amino acid sequence   |
| 7         | SAP-E V <sub>H</sub> amino acid sequence                                  |
| 8         | SAP-E V <sub>H</sub> DNA sequence   |
| 9         | SAP-E V <sub>L</sub> amino acid sequence                                  |
| 10        | SAP-E V <sub>L</sub> DNA sequence   |
| 11        | SAP-K CDRH1 amino acid sequence   |
| 12        | SAP-K CDRH2 amino acid sequence   |
| 13        | SAP-K CDRH3 amino acid sequence   |
| 14        | SAP-K CDRL1 amino acid sequence   |
| 15        | SAP-K CDRL2 amino acid sequence   |
| 16        | SAP-K CDRL3 amino acid sequence   |
| 17        | SAP-K V <sub>H</sub> amino acid sequence                                  |
| 18        | SAP-K V <sub>H</sub> DNA sequence   |
| 19        | SAP-K V <sub>L</sub> amino acid sequence                                  |
| 20        | SAP-K V <sub>L</sub> DNA sequence   |
| 21        | SAP-E V <sub>H</sub> chimera amino acid sequence                          |
| 22        | SAP-E V <sub>L</sub> chimera amino acid sequence                          |
| 23        | SAP-K V <sub>H</sub> chimera amino acid sequence                          |
| 24        | SAP-K V <sub>L</sub> chimera amino acid sequence                          |
| 25        | IGHV1-69 human variable heavy chain germline acceptor amino acid sequence |
| 26        | JH1 minigene  |
| 27        | SAP-E humanised V <sub>H</sub> variant H0 amino acid sequence             |
| 28        | SAP-E humanised V <sub>H</sub> variant H1 amino acid sequence             |
| 29        | SAP-E humanised V <sub>H</sub> variant H2 amino acid sequence             |
| 30        | SAP-E humanised V <sub>H</sub> variant H3 amino acid sequence             |
| 31        | SAP-E humanised V <sub>H</sub> variant H4 amino acid sequence             |
| 32        | IGKV1-39 human variable light chain germline acceptor amino acid sequence |
| 33        | JK2 minigene  |
| 34        | SAP-E humanised V <sub>L</sub> variant L0 amino acid sequence             |
| 35        | SAP-E humanised V <sub>L</sub> variant L1 amino acid sequence             |

|    |  |
|----|--|
| 36 | SAP-E humanised V <sub>L</sub> variant L2 amino acid sequence                              |
| 37 | SAP-K humanised V <sub>H</sub> variant H0 amino acid sequence                              |
| 38 | SAP-K humanised V <sub>H</sub> variant H1 amino acid sequence                              |
| 39 | SAP-K humanised V <sub>H</sub> variant H2 amino acid sequence                              |
| 40 | SAP-K humanised V <sub>H</sub> variant H3 amino acid sequence                              |
| 41 | SAP-K humanised V <sub>L</sub> variant L0 amino acid sequence                              |
| 42 | SAP-K humanised V <sub>L</sub> variant L1 amino acid sequence                              |
| 43 | Homo sapiens SAP amino acid sequence   |
| 44 | Mus musculus SAP amino acid sequence   |
| 45 | SAP-E VH chimera nucleotide sequence   |
| 46 | SAP-E VL chimera nucleotide sequence   |
| 47 | SAP-K VH chimera nucleotide sequence   |
| 48 | SAP-K VL chimera nucleotide sequence   |
| 49 | IGHV1-69 human variable heavy chain germline acceptor nucleotide sequence                  |
| 50 | IGHV1-39 human variable heavy chain germline acceptor nucleotide sequence                  |
| 51 | SAP-E humanised heavy chain V region variant H0 nucleotide sequence<br>non-codon optimised |
| 52 | SAP-E humanised light chain V region variant L0 nucleotide sequence<br>non-codon optimised |
| 53 | SAP-E humanised heavy chain V region variant H0 nucleotide sequence<br>(codon optimised)   |
| 54 | SAP-E humanised heavy chain V region variant H1 nucleotide sequence<br>(codon optimised)   |
| 55 | SAP-E humanised heavy chain V region variant H2 nucleotide sequence<br>(codon optimised)   |
| 56 | SAP-E humanised heavy chain V region variant H3 nucleotide sequence<br>(codon optimised)   |
| 57 | SAP-E humanised heavy chain V region variant H4 nucleotide sequence<br>(codon optimised)   |
| 58 | SAP-E humanised light chain V region variant L0 nucleotide sequence<br>(codon optimised)   |
| 59 | SAP-E humanised light chain V region variant L1 nucleotide sequence<br>(codon optimised)   |
| 60 | SAP-E humanised light chain V region variant L2 nucleotide sequence<br>(codon optimised)   |
| 61 | SAP-E humanised heavy chain H1 full mature nucleotide sequence<br>(codon optimised)        |
| 62 | SAP-E humanised heavy chain H1 full mature amino acid sequence                             |

|    |   |
|----|---|
| 63 | SAP-E humanised light chain L1 full mature nucleotide sequence (codon optimised)          |
| 64 | SAP-E humanised light chain L1 full mature amino acid sequence                            |
| 65 | SAP-K humanised heavy chain V region variant H0 nucleotide sequence non-codon optimised   |
| 66 | SAP-K humanised light chain V region variant L0 nucleotide sequence non-codon optimised   |
| 67 | SAP-K humanised heavy chain V region variant H0 nucleotide sequence (codon optimised)     |
| 68 | SAP-K humanised heavy chain V region variant H1 nucleotide sequence (codon optimised)     |
| 69 | SAP-K humanised heavy chain V region variant H2 nucleotide sequence (codon optimised)     |
| 70 | SAP-K humanised heavy chain V region variant H3 nucleotide sequence (codon optimised)     |
| 71 | SAP-K humanised light chain V region variant L0 nucleotide sequence (codon optimised)     |
| 72 | SAP-K humanised light chain V region variant L1 nucleotide sequence (codon optimised)     |
| 73 | SAP-K humanised light chain V region variant L0 91A nucleotide sequence (codon optimised) |
| 74 | SAP-K humanised light chain V region variant L0 91A amino acid sequence                   |
| 75 | SAP-K humanised H3 heavy chain nucleotide sequence (codon optimised)                      |
| 76 | SAP-K humanised H3 heavy chain amino acid sequence  |
| 77 | SAP-K humanised L0 light chain nucleotide sequence (codon optimised)                      |
| 78 | SAP-K humanised L0 light chain amino acid sequence  |
| 79 | Signal sequence for immunoglobulin chains   |

**CLAIMS**

1. A non-murine antigen binding protein which specifically binds to SAP and competes for binding to SAP with a reference antibody which comprises a heavy chain variable region sequence of SEQ ID NO:7, and a light chain variable region sequence of SEQ ID NO:9.
- 5
2. A non-murine antigen binding protein which binds to SAP and comprises CDRH3 set forth in SEQ ID NO: 3 or a functional variant of CDRH3.
- 10
3. An antigen binding protein according to claim 2, which further comprises one or more or all CDRs selected from: CDRH1 (SEQ ID NO:1), CDRH2 (SEQ ID NO:12, CDRL1 (SEQ ID NO:4), CDRL2 (SEQ ID NO:5), and CDRL3 (SEQ ID NO:6); or a functional variant of CDRH1, CDRH2, CDRL1, CDRL2 or CDRL3.
- 15
4. An antigen binding protein according to claim 2 or 3, wherein the CDRH3 functional variant is a variant of SEQ ID NO:3 wherein Ser 102 is substituted for Tyr, His, Val, Ile, Asp or Gly.
- 20
5. An antigen binding protein according to claim 3 or 4, wherein:
  - (a) the CDRH1 functional variant is a variant of SEQ ID NO:1 wherein Tyr 32 is substituted for Ile, His, Phe, Thr, Asn, Cys, Glu or Asp; Asn 33 is substituted for Tyr, Ala, Trp, Gly, Thr, Leu or Val; Met 34 is substituted for Ile, Val or Trp; and/or His 35 is substituted for Glu, Asn, Gln, Ser, Tyr or Thr;
  - 25
  - (b) the CDRH2 functional variant is a variant of SEQ ID NO:2 wherein Tyr 50 is substituted for Arg, Glu, Trp, Gly, Gln, Val, Leu, Asn, Lys or Ala; Ile51 is substituted for Leu, Val, Thr, Ser or Asn; Tyr 52 is substituted for Asp, Leu, Asn or Ser, Gly 53 is substituted for Ala, Tyr, Ser, Lys, Thr or Asn, Asp 54 is substituted for Asn, Ser, Thr, Lys or Gly; Asn 56 is substituted for Tyr, Arg, Glu, Asp, Gly, Val, Ser or Ala; and/or Asn 58 is substituted for Lys, Thr, Ser, Asp, Arg, Gly, Phe or Tyr;
  - 30
  - (c) the CDRL1 functional variant is a variant of SEQ ID NO:4 wherein Asn 28 is substituted for Ser, Asp, Thr or Glu; Ile 29 is substituted for Val; Tyr 30 is substituted for Asp, Leu, Val, Ile, Ser, Asn, Phe, His, Gly or Thr; Ser 31 is substituted for Asn, Thr, Lys or Gly; Tyr

32 is substituted for Phe, Asn, Ala, His, Ser or Arg; Leu 33 is substituted for Met, Val, Ile or Phe; and/or Ala 34 is substituted for Gly, Asn, Ser, His, Val or Phe;

(d) the CDRL2 functional variant is a variant of SEQ ID NO:5 wherein Ala 51 is substituted for Thr, Gly or Val; and/or

5 (e) the CDRL3 functional variant is a variant of SEQ ID NO:6 wherein Gln 89 is substituted for Ser, Gly, Phe or Leu; His 90 is substituted for Gln or Asn; His 91 is substituted for Asn, Phe, Gly, Ser, Arg, Asp, Thr, Tyr or Val; Tyr 92 is substituted for Asn, Trp, Thr, Ser, Arg, Gln, His, Ala or Asp; Gly 93 is substituted for Glu, Asn, His, Thr, Ser, Arg or Ala; Ala 94 is substituted for Asp, Tyr, Thr, Val, Leu, His, Asn, Ile, Trp, Pro or Ser; and/or Leu 96 is 10 substituted for Pro, Tyr, Arg, Ile, Trp or Phe.

6. An antigen binding protein which specifically binds to SAP, wherein the antigen binding protein is a chimeric or a humanised antibody comprising the corresponding CDRH3 of the variable domain sequence of SEQ ID NO:7, or a functional variant of CDRH3.

15

7. An antigen binding protein according to claim 6, which further comprises one or more or all of corresponding CDRs selected from CDRH1 or CDRH2 of the variable domain sequence of SEQ ID NO:7; or CDRL1, CDRL2, CDRL3 of the variable domain sequence of SEQ ID NO:9; or a functional variant of CDRH1, CDRH2, CDRL1, CDRL2 or CDRL3.

20

8. An antigen binding protein which specifically binds to SAP, and comprises a binding unit H3 comprising Kabat residues 95-101 of SEQ ID NO:7, or a functional variant of binding unit H3.

25

9. An antigen binding protein according to claim 8, which further comprises one or more or all binding units selected from: H1 comprising Kabat residues 31-32 of SEQ ID NO:7, H2 comprising Kabat residues 52-56 of SEQ ID NO:7, L1 comprising Kabat residues 30-34 of SEQ ID NO:9, L2 comprising Kabat residues 50-55 of SEQ ID NO:9; and L3 comprising Kabat residues 89-96 of SEQ ID NO:9; or a functional variant of binding unit H1, H2, L1, L2 or L3.

30

10. An antigen binding protein according to any one of claims 1-9, wherein the antigen binding protein comprises a heavy chain and/or a light chain wherein:

(a) the heavy chain framework comprises the following residues: Val, Ile or Gly at position 2; Leu or Val at position 4; Leu, Ile, Met or Val at position 20; Cys at position 22; Thr, Ala, Val, Gly or Ser at position 24; Gly at position 26; Ile, Phe, Leu or Ser at position 29; Trp at position 36; Trp or Tyr at position 47; Ile, Met, Val or Leu at position 48; Ile, Leu, Phe, Met or

5 Val at position 69; Val, Ala or Leu at position 71; Ala, Leu, Val, Tyr or Phe at position 78; Leu or Met at position 80; Tyr or Phe at position 90; Cys at position 92; and/or Arg, Lys, Gly, Ser, His or Asn at position 94; and/or

(b) the light chain framework comprises the following residues: Ile, Leu or Val at position 2; Val, Gln, Leu or Glu at position 3; Met or Leu at position 4; Cys at position 23; Trp at position 35; Tyr, Leu or Phe at position 36; Leu, Arg or Val at position 46; Tyr, His, Phe or Lys at position 49; Tyr or Phe at position 71; Cys at position 88; and/or Phe at position 98.

11. An antigen binding protein according to any one of claims 1-10, wherein: the heavy chain framework comprises the following residues: Val at position 2, Leu at position 4, Val at

15 position 20, Cys at position 22, Ala at position 24, Gly at position 26, Phe at position 29, Trp at position 36, Trp at position 47, Met at position 48, Ile at position 69, Ala at position 71, Ala at position 78, Met at position 80, Tyr at position 90, Cys at position 92, and Arg at position 94, and/or the light chain framework comprises the following residues: Ile at position 2, Gln at position 3, Met at position 4, Cys at position 23, Trp at position 35, Tyr at 20 position 36, Leu at position 46, His at position 49, Phe at position 71, Cys at position 88, and Phe at position 98.

12. An antigen binding protein according to any one of claims 1-11, which further comprises a heavy chain variable domain antibody framework having 75% or greater

25 sequence identity to the framework regions as shown in SEQ ID NO:25; and/or a light chain variable domain antibody framework having 75% or greater sequence identity to the framework regions as shown in SEQ ID NO:32.

13. An antigen binding protein which specifically binds to SAP and comprises a heavy

30 chain variable region selected from SEQ ID NO:27-31; and/or a light chain variable region selected from SEQ ID NO:34-36; or a variant heavy chain variable region or light chain variable region with 75% or greater sequence identity.

14. An antigen binding protein which specifically binds to SAP and comprises a heavy chain of SEQ ID NO:62; and/or a light chain of SEQ ID NO:64; or a variant heavy chain or light chain with 75% or greater sequence identity.

5

15. An antigen binding protein as claimed in any one of claims 1-14, wherein the SAP is human SAP which is bound to amyloid fibrils *in vivo*.

16. An antigen binding protein as claimed in any one of claims 1-15, wherein the antigen 10 binding protein binds to the A face of human SAP.

17. An antigen binding protein as claimed in any one of claims 1-16, wherein the antigen binding protein activates the human complement system.

15 18. An antigen binding protein according to any one of claims 1-5, 8, 9 or 15-17, which is chimeric, humanised, or human.

19. An antigen binding protein according to any one of the previous claims, wherein the antigen binding protein comprises a human IgG1 or IgG3 human constant domain.

20

20. A nucleic acid molecule which encodes an antigen binding protein as defined in any one of claims 1-19.

21. A nucleic acid molecule as claimed in claim 20, wherein the nucleic acid sequence 25 comprises SEQ ID NO:54 and/or SEQ ID NO:59.

22. A nucleic acid molecule as claimed in claim 21, wherein the nucleic acid sequence comprises SEQ ID NO:61 and/or SEQ ID NO:63.

30 23. An expression vector comprising a nucleic acid molecule as defined in any one of claims 20-22.

24. A recombinant host cell comprising an expression vector as defined in claim 23.

25. A method for the production of an antigen binding protein as defined in any one of claims 1-19, which method comprises the step of culturing a host cell as defined in claim 24

5 and recovering the antigen binding protein.

26. A pharmaceutical composition comprising an antigen binding protein as defined in any one of claims 1-19 and a pharmaceutically acceptable carrier.

10 27. A method of treating a subject afflicted with a disease associated with amyloid deposition, which method comprises the step of administering to said subject a therapeutically effective amount of an antigen binding protein as defined in any one of claims 1-19 or the composition of claim 26.

15 28. A method of preventing a disease associated with amyloid deposition in a subject, which method comprises the step of administering to said subject a prophylactically effective amount of an antigen binding protein as defined in any one of claims 1-19 or the composition of claim 26.

20 29. A method according to claim 27 or 28, wherein the antigen binding protein is to be administered with a SAP depleting compound.

30. An antigen binding protein as defined in any one of claims 1-19 for use in treating or preventing a disease associated with amyloid deposition, wherein said antigen binding protein is to be administered with a SAP depleting compound.

31. A SAP depleting compound for use in treating or preventing a disease associated with amyloid deposition, wherein said SAP depleting compound is to be administered with an antigen binding protein as defined in any one of claims 1-19.

32. A method according to claim 27, 28 or 29, an antigen binding protein according to claim 29, or a SAP depleting compound according to claim 31, wherein the administration of the antigen binding protein and SAP depleting compound is sequential.

5 33. A method, an antigen binding protein, or a SAP depleting compound according to claim 32, wherein the SAP depleting compound is to be administered first.

10 34. A method, an antigen binding protein, or a SAP depleting compound according to claim 33, wherein the antigen binding protein is to be administered when substantially all of the SAP circulating in the subject has been cleared.

15 35. A method according to claim 27, 28, 29, 31, 33, or 34, an antigen binding protein according to claim 30, 32, 33, or 34, or a SAP antagonist compound according to claim 31, 32, 33, or 34, wherein the disease is selected from the group consisting of: systemic amyloidosis, local amyloidosis, Alzheimer's disease, type 2 diabetes, dialysis-related amyloidosis, monoclonal immunoglobulin chain (AL) amyloidosis and cerebral amyloid angiopathy.

20 36. A method according to claim 27, 28, 29, 32, 33, 34, or 35, an antigen binding protein according to claim 30, 32, 33, 34, or 35, or a SAP depleting compound according to claim 31, 32, 33, 34, or 35, wherein the SAP depleting compound is a D-proline derivative or a glycerol cyclic pyruvate derivative.

25 37. A method, antigen binding protein or SAP depleting compound according to claim 36, wherein the D-proline derivative is CPHPC.

## FIGURES

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6






Figure 7









FIG. 8 Cont'd

(D)


136 140 147  
h EQDSYGGKFDRS  
m EQDNYGGGFQRS




FIG. 8 Cont'd



Figure 9

(A)



(B)





(A)

-ve

| M5 | M6 | M7 | M8 | M9 | M10 |
|----|----|----|----|----|-----|
|    |    |    |    |    |     |

+ve

(B) Immunoblot probed with anti-mouse C3 at 1:5000

-ve

| M5 | M6 | M7 | M8 | M9 | M10 |
|----|----|----|----|----|-----|
|    |    |    |    |    |     |

+ve

(C) Immunoblot probed with anti-mouse C3 at 1:10000

-ve

| M5 | M6 | M7 | M8 | M9 | M10 |
|----|----|----|----|----|-----|
|    |    |    |    |    |     |

+ve

FIG. 12

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2011/053038

#### A. CLASSIFICATION OF SUBJECT MATTER

1. **SEARCHED** **INDEXED** **MAILED**  
INV. A61K39/395 A61P25/28 C07K16/18  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K C07K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

#### C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|-----------|---|-----------------------|
| X         | WO 2009/155962 A1 (PENTRAXIN THERAPEUTICS LTD [GB]; PEPYS MARK BRIAN [GB])<br>30 December 2009 (2009-12-30)<br>examples 1-11<br>-----       | 1-37                  |
| X         | WO 2009/000926 A1 (PENTRAXIN THERAPEUTICS LTD [GB]; PEPYS MARK BRIAN [GB])<br>31 December 2008 (2008-12-31)<br>examples 1-8<br>-----        | 1-37                  |
| X         | WO 95/05394 A1 (ROYAL POSTGRAD MED SCHOOL [GB]; BIRKBECK COLLEGE [GB]; PEPYS MARK BRIA) 23 February 1995 (1995-02-23)<br>example 3<br>----- | 1-37                  |
|           |   | -/-                   |

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

|  |  |
|--|--|
| Date of the actual completion of the international search  | Date of mailing of the international search report |
| 28 April 2011  | 09/05/2011   |
| Name and mailing address of the ISA/<br>European Patent Office, P.B. 5818 Patentlaan 2<br>NL - 2280 HV Rijswijk<br>Tel. (+31-70) 340-2040,<br>Fax: (+31-70) 340-3016 | Authorized officer<br><br>Cilensek, Zoran          |

## INTERNATIONAL SEARCH REPORT

|                              |
|------------------------------|
| International application No |
| PCT/EP2011/053038            |

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|-----------|---|-----------------------|
| X, P      | KARL BODIN ET AL: "Antibodies to human serum amyloid P component eliminate visceral amyloid deposits", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 468, 4 November 2010 (2010-11-04), pages 93-97, XP007918427, ISSN: 0028-0836, DOI: DOI:10.1038/NATURE09494 [retrieved on 2010-10-20] the whole document<br>-----   | 1-37                  |
| A         | PEPYS M B ET AL: "Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 417, no. 6886, 1 January 2002 (2002-01-01), pages 254-259, XP002219442, ISSN: 0028-0836, DOI: DOI:10.1038/417254A the whole document<br>-----  | 1-37                  |
| A         | JULIAN D GILMORE ET AL: "Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis", BRITISH JOURNAL OF HAEMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 148, 1 January 2010 (2010-01-01), pages 760-767, XP007918426, ISSN: 0007-1048, DOI: DOI:10.1111/J.1365-2141.2009.08036.X [retrieved on 2010-01-08] the whole document<br>-----                                     | 1-37                  |
| A         | SIMON E KOLSTOE ET AL: "Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 106, no. 18, 5 May 2009 (2009-05-05), pages 7619-7623, XP007918428, ISSN: 0027-8424, DOI: DOI:10.1073/PNAS.0902640106 [retrieved on 2009-04-16] the whole document<br>----- | 1-37                  |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

|   |
|---|
| International application No<br>PCT/EP2011/053038 |
|---|

| Patent document cited in search report | Publication date | Patent family member(s) |                  |  | Publication date |
|--|------------------|-------------------------|------------------|--|------------------|
| WO 2009155962                          | A1<br>30-12-2009 | AU<br>2008358292        | A1<br>30-12-2009 |  |                  |
| WO 2009000926                          | A1<br>31-12-2008 | AU<br>2008267148        | A1<br>31-12-2008 |  |                  |
|  |                  | CA<br>2691054           | A1<br>31-12-2008 |  |                  |
|  |                  | CA<br>2729034           | A1<br>30-12-2009 |  |                  |
|  |                  | CN<br>101801372         | A<br>11-08-2010  |  |                  |
|  |                  | EA<br>201070063         | A1<br>30-06-2010 |  |                  |
|  |                  | EP<br>2173341           | A1<br>14-04-2010 |  |                  |
|  |                  | JP<br>2010531338        | T<br>24-09-2010  |  |                  |
|  |                  | KR<br>20100050495       | A<br>13-05-2010  |  |                  |
|  |                  | US<br>2009191196        | A1<br>30-07-2009 |  |                  |
| WO 9505394                             | A1<br>23-02-1995 | AU<br>7389894           | A<br>14-03-1995  |  |                  |
|  |                  | DE<br>69435088          | T2<br>02-04-2009 |  |                  |
|  |                  | EP<br>0714405           | A1<br>05-06-1996 |  |                  |
|  |                  | US<br>6126918           | A<br>03-10-2000  |  |                  |